<table>
<thead>
<tr>
<th>No.</th>
<th>NCT Number</th>
<th>Title</th>
<th>Enrollment</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NCT0295076</td>
<td>A Study</td>
<td>20</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02950766">https://ClinicalTrials.gov/show/NCT02950766</a></td>
</tr>
<tr>
<td>2</td>
<td>NCT0272949</td>
<td>Study Evalua…</td>
<td>25</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02729493">https://ClinicalTrials.gov/show/NCT02729493</a></td>
</tr>
<tr>
<td>3</td>
<td>NCT0272512</td>
<td>Study Evalua…</td>
<td>19</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02725125">https://ClinicalTrials.gov/show/NCT02725125</a></td>
</tr>
<tr>
<td>4</td>
<td>NCT0291544</td>
<td>EpCAM CAR-…</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02915445">https://ClinicalTrials.gov/show/NCT02915445</a></td>
</tr>
<tr>
<td>5</td>
<td>NCT0298031</td>
<td>A New EBV R</td>
<td>20</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02980315">https://ClinicalTrials.gov/show/NCT02980315</a></td>
</tr>
<tr>
<td>6</td>
<td>NCT0312210</td>
<td>Neoantigen I</td>
<td>15</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03122106">https://ClinicalTrials.gov/show/NCT03122106</a></td>
</tr>
<tr>
<td>7</td>
<td>NCT0321945</td>
<td>A Pilot Study</td>
<td>10</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03219450">https://ClinicalTrials.gov/show/NCT03219450</a></td>
</tr>
<tr>
<td>8</td>
<td>NCT0319805</td>
<td>PSCA/MUC1/…</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03198052">https://ClinicalTrials.gov/show/NCT03198052</a></td>
</tr>
<tr>
<td>9</td>
<td>NCT031904</td>
<td>Neoantigen I</td>
<td>24</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03190400">https://ClinicalTrials.gov/show/NCT03190400</a></td>
</tr>
<tr>
<td>10</td>
<td>NCT0303589</td>
<td>Hypofraction</td>
<td>33</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03035890">https://ClinicalTrials.gov/show/NCT03035890</a></td>
</tr>
<tr>
<td>11</td>
<td>NCT0314146</td>
<td>Vvax001 Can</td>
<td>12</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03141463">https://ClinicalTrials.gov/show/NCT03141463</a></td>
</tr>
<tr>
<td>12</td>
<td>NCT0273529</td>
<td>Study Evalua…</td>
<td>24</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02735291">https://ClinicalTrials.gov/show/NCT02735291</a></td>
</tr>
<tr>
<td>13</td>
<td>NCT0279496</td>
<td>CD22 Targeti</td>
<td>10</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02794961">https://ClinicalTrials.gov/show/NCT02794961</a></td>
</tr>
<tr>
<td>14</td>
<td>NCT0326717</td>
<td>Evaluate the</td>
<td>10</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03267173">https://ClinicalTrials.gov/show/NCT03267173</a></td>
</tr>
<tr>
<td>15</td>
<td>NCT0295838</td>
<td>A Clinical Res</td>
<td>45</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02958384">https://ClinicalTrials.gov/show/NCT02958384</a></td>
</tr>
<tr>
<td>16</td>
<td>NCT0295839</td>
<td>A Clinical Res</td>
<td>45</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02958397">https://ClinicalTrials.gov/show/NCT02958397</a></td>
</tr>
<tr>
<td>17</td>
<td>NCT0332924</td>
<td>QUILT-3.060:</td>
<td>80</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03329248">https://ClinicalTrials.gov/show/NCT03329248</a></td>
</tr>
<tr>
<td>18</td>
<td>NCT0315243</td>
<td>EGFR CART C</td>
<td>20</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03152435">https://ClinicalTrials.gov/show/NCT03152435</a></td>
</tr>
<tr>
<td>19</td>
<td>NCT0278235</td>
<td>Humanized C</td>
<td>50</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02782351">https://ClinicalTrials.gov/show/NCT02782351</a></td>
</tr>
<tr>
<td>20</td>
<td>NCT0319758</td>
<td>QUILT-3.051:</td>
<td>67</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03197584">https://ClinicalTrials.gov/show/NCT03197584</a></td>
</tr>
<tr>
<td>21</td>
<td>NCT0181832</td>
<td>Phase I Trial:</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01818323">https://ClinicalTrials.gov/show/NCT01818323</a></td>
</tr>
<tr>
<td>22</td>
<td>NCT0313640</td>
<td>QUILT-3.039:</td>
<td>80</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03136406">https://ClinicalTrials.gov/show/NCT03136406</a></td>
</tr>
<tr>
<td>23</td>
<td>NCT0324430</td>
<td>A Phase 1 Stu</td>
<td>33</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03244306">https://ClinicalTrials.gov/show/NCT03244306</a></td>
</tr>
<tr>
<td>24</td>
<td>NCT0270429</td>
<td>The Study of</td>
<td>36</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02704299">https://ClinicalTrials.gov/show/NCT02704299</a></td>
</tr>
<tr>
<td>25</td>
<td>NCT0294169</td>
<td>Immunother:</td>
<td>400</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02941697">https://ClinicalTrials.gov/show/NCT02941697</a></td>
</tr>
<tr>
<td>26</td>
<td>NCT0072744</td>
<td>Vaccine Ther</td>
<td>87</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00727441">https://ClinicalTrials.gov/show/NCT00727441</a></td>
</tr>
<tr>
<td>27</td>
<td>NCT0267250</td>
<td>A Study to As</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02672501">https://ClinicalTrials.gov/show/NCT02672501</a></td>
</tr>
<tr>
<td>28</td>
<td>NCT0271398</td>
<td>A Clinical Res</td>
<td>60</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02713984">https://ClinicalTrials.gov/show/NCT02713984</a></td>
</tr>
<tr>
<td>29</td>
<td>NCT0318281</td>
<td>CTLA-4 and P</td>
<td>40</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03182816">https://ClinicalTrials.gov/show/NCT03182816</a></td>
</tr>
<tr>
<td>30</td>
<td>NCT0317900</td>
<td>CTLA-4 and P</td>
<td>40</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03179007">https://ClinicalTrials.gov/show/NCT03179007</a></td>
</tr>
<tr>
<td>31</td>
<td>NCT0244383</td>
<td>CARPALL: Im</td>
<td>18</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02443831">https://ClinicalTrials.gov/show/NCT02443831</a></td>
</tr>
<tr>
<td>32</td>
<td>NCT0282232</td>
<td>Phase I Study</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02822326">https://ClinicalTrials.gov/show/NCT02822326</a></td>
</tr>
<tr>
<td>33</td>
<td>NCT0301371</td>
<td>A Clinical Res</td>
<td>60</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03013712">https://ClinicalTrials.gov/show/NCT03013712</a></td>
</tr>
<tr>
<td>34</td>
<td>NCT0318611</td>
<td>Pilot Study of</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03186118">https://ClinicalTrials.gov/show/NCT03186118</a></td>
</tr>
<tr>
<td>35</td>
<td>NCT0295915</td>
<td>A Study of Ch</td>
<td>20</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02959151">https://ClinicalTrials.gov/show/NCT02959151</a></td>
</tr>
<tr>
<td>36</td>
<td>NCT0293099</td>
<td>Anti-mesothi</td>
<td>20</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02930993">https://ClinicalTrials.gov/show/NCT02930993</a></td>
</tr>
<tr>
<td>37</td>
<td>NCT0317122</td>
<td>Neoantigen F</td>
<td>40</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03171220">https://ClinicalTrials.gov/show/NCT03171220</a></td>
</tr>
<tr>
<td>38</td>
<td>NCT0303000</td>
<td>PD-1 Antiboc</td>
<td>40</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03030001">https://ClinicalTrials.gov/show/NCT03030001</a></td>
</tr>
<tr>
<td>39</td>
<td>NCT0308596</td>
<td>Autologous I</td>
<td>30</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03085966">https://ClinicalTrials.gov/show/NCT03085966</a></td>
</tr>
<tr>
<td>40</td>
<td>NCT0312686</td>
<td>Study of Ado</td>
<td>39</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03126864">https://ClinicalTrials.gov/show/NCT03126864</a></td>
</tr>
<tr>
<td>41</td>
<td>NCT0306426</td>
<td>CAR-T Therap</td>
<td>10</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03064269">https://ClinicalTrials.gov/show/NCT03064269</a></td>
</tr>
</tbody>
</table>
NCT0255364 Relationship
NCT0296509 CD19 Chimeric Ant
NCT0218686 Chimeric Ant
NCT0169166 Adaptive Cell
NCT0246598 Pilot Study of
NCT0317617 Radical-Dose
NCT0306841 CD19-targeted
NCT0290381 Combination
NCT0330084 Ability of a D.
NCT0295655 Neoantigen-β
NCT0296303 CAR T Cells for
NCT0203535 Immunotherapy:
NCT0293525 Immunotherapy:
NCT0284358 Combination
NCT0186490 Treatment of
NCT0279955 Allogeneic C
NCT0284433 Combination
NCT0332394 CAR T Cell Im
NCT0214099 Safety Study
NCT0312557 Combination
NCT0281383 Chimeric Ant
NCT0214692 Cellular Immuno
NCT0211365 T-Cell Respor
NCT0293710 A Clinical Res
NCT0284937 Combination
NCT0183643 Immunotherap:
NCT0284935 Combination
NCT0284931 Combination
NCT0284932 Combination
NCT0284934 Combination
NCT0284380 Combination
NCT0177457 Immunotherap:
NCT0284312 Combination
NCT0318280 CTLA-4 and P
NCT0284658 a Clinical Res
NCT0278658 Plasmodium
NCT0312162 CAR-T Therapy
NCT0326229 Anti-CD22 Cα
NCT0253797 CD19-directe
NCT0313103 Intratumoral
NCT0297568 CD19 CAR T C
NCT0318546 Intervention
84 NCT0287352 Precision Cell 40 https://ClinicalTrials.gov/show/NCT02873520
85 NCT0066010 Trial of Autol 34 https://ClinicalTrials.gov/show/NCT00660101
86 NCT0234972 A Clinical Res 75 https://ClinicalTrials.gov/show/NCT02349724
87 NCT0228027 Cytokine-indi 550 https://ClinicalTrials.gov/show/NCT02280278
88 NCT0271014 A Clinical Res 45 https://ClinicalTrials.gov/show/NCT02710149
89 NCT0245198 Neoadjuvant 50 https://ClinicalTrials.gov/show/NCT02451982
90 NCT0322987 Universal CD 20 https://ClinicalTrials.gov/show/NCT03229876
91 NCT0284381 Combination 30 https://ClinicalTrials.gov/show/NCT02843815
92 NCT0252993 An Explorato 36 https://ClinicalTrials.gov/show/NCT02529930
93 NCT0238044 Increased Fre 18 https://ClinicalTrials.gov/show/NCT02380443
94 NCT0323415 Neoadjuvant 68 https://ClinicalTrials.gov/show/NCT03234153
95 NCT0331220 CAR-T Cells f 50 https://ClinicalTrials.gov/show/NCT03312205
96 NCT0288265 Dendritic Killi 18 https://ClinicalTrials.gov/show/NCT02882659
97 NCT0270678 A Study of M 30 https://ClinicalTrials.gov/show/NCT02706782
98 NCT0311301 Autologous A 26 https://ClinicalTrials.gov/show/NCT03113019
99 NCT0284901 Combination 10 https://ClinicalTrials.gov/show/NCT02849015
100 NCT0202845 A Pediatric ar 80 https://ClinicalTrials.gov/show/NCT02028455
101 NCT0186916 Treatment of 60 https://ClinicalTrials.gov/show/NCT01869166
102 NCT0293515 A Clinical Res 45 https://ClinicalTrials.gov/show/NCT02935153
103 NCT0126536 A Clinical Stu 24 https://ClinicalTrials.gov/show/NCT01265368
104 NCT0319177 A Study of Ar 100 https://ClinicalTrials.gov/show/NCT03191773
105 NCT0284585 Combination 30 https://ClinicalTrials.gov/show/NCT02845856
106 NCT0243157 A Pilot Study 40 https://ClinicalTrials.gov/show/NCT02431572
107 NCT0295841 A Clinical Res 45 https://ClinicalTrials.gov/show/NCT02958410
108 NCT0308517 A Trial of "Ar 30 https://ClinicalTrials.gov/show/NCT03085173
109 NCT0261713 CAR-T Cell Irr 20 https://ClinicalTrials.gov/show/NCT02617134
110 NCT0231511 Pilot Study of 18 https://ClinicalTrials.gov/show/NCT02315118
111 NCT0293554 CART19 in Pa 24 https://ClinicalTrials.gov/show/NCT02935543
112 NCT0169162 Concurrent C 50 https://ClinicalTrials.gov/show/NCT01691625
113 NCT0331587 Combination 34 https://ClinicalTrials.gov/show/NCT03315871
114 NCT0292475 The Safety ar 20 https://ClinicalTrials.gov/show/NCT02924753
115 NCT0295444 A Clinical Res 45 https://ClinicalTrials.gov/show/NCT02954445
116 NCT0285390 Comparison i 200 https://ClinicalTrials.gov/show/NCT02853903
117 NCT0246036 Immunothera. 115 https://ClinicalTrials.gov/show/NCT02460367
118 NCT0264020 Pilot Trial Of 15 https://ClinicalTrials.gov/show/NCT02640209
119 NCT0258768 Phase I/II Stu 20 https://ClinicalTrials.gov/show/NCT02587689
120 NCT0283926 FLT3 Ligand I 29 https://ClinicalTrials.gov/show/NCT02839265
121 NCT0321493 Autologous A 30 https://ClinicalTrials.gov/show/NCT03214939
122 NCT0284360 Combination 30 https://ClinicalTrials.gov/show/NCT02843607
123 NCT0234674 Phase 2 Trial 89 https://ClinicalTrials.gov/show/NCT02346747
124 NCT0162649 Phase I/IIA St 76 https://ClinicalTrials.gov/show/NCT01626495
125 NCT0327549 Humanized C 40 https://ClinicalTrials.gov/show/NCT03275493
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naive Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

CAR T in the Treatment of AML

Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+B-cell Acute Lymphoblastic Leukemia/B-cell Lymphoma

Combination of Bevacizumab and NK Immunotherapy for Recurrent Solid Tumors

Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

Safety and Tolerability Study of AutoSynVax Vaccine in Subjects With Advanced Cancer

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer

Proteome-based Immunotherapy of Brain Metastases From Breast Cancer

Investigation of a Therapeutic Vaccine (ACIT-1) in Late Stage Cancer

Proteome-based Immunotherapy of Lung Cancer Brain Metastases

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

CART-19 Cells For MRD Positive CD19+ ALL

MB-CART19.1 in Patients With R/R ALL

Efficacy of C4

126 NCT02810222 Efficacy of C4

127 NCT0308920 CART-PSMA-2

128 NCT03321112 MB-CART19.1

129 NCT03193566 Study of High

130 NCT02862566 Precision Cell

131 NCT03027736 CART-19 Cell

132 NCT0197035 A Phase I Stu

133 NCT0287339 PD-1 Antiboc

134 NCT0311064 Anti-CD19 C4

135 NCT0228742 Ph I Personal

136 NCT0178228 Proteome-ba

137 NCT0309609 Investigation

138 NCT0248596 A Pilot Study

139 NCT01436966 Phase 3 Stud

140 NCT0178227 Proteome-ba

141 NCT0275051 An Investigat

142 NCT0326320 CD19 CAR-T (I

143 NCT0189021 Immunotherap:

144 NCT0297614 The Efficacy o

145 NCT0229769 Phase II Trial

146 NCT0299297 Safety and Tc

147 NCT0242758 Safety and In

148 NCT0252981 CD19+ CAR T

149 NCT0298152 Phase 2 Stud

150 NCT0311463 Dendritic Cel

151 NCT0269297 Natural Denc

152 NCT0196628 SGI-110 in Cc

153 NCT0327151 Immunotherap:

154 NCT0285792 Combination

155 NCT0328155 Efficacy and 

156 NCT0284320 Combination

157 NCT0328261 Dendritic Cel

158 NCT0322267 CAR T in the

159 NCT0264828 Study With C

160 NCT0190663 Gene Express:

161 NCT0215949 Genetically M

162 NCT0332692 HA-1 T TCR T

163 NCT0241569 DC-CIK Immum

164 NCT0249652 Dendritic Cel

165 NCT0199854 Safety and Tc

166 NCT0319081 Anti-PD-1 Alc

167 NCT0168849 Combining Ip
209 NCT01968109
208 NCT02886897
207 NCT02759588
206 NCT02862028
205 NCT02759588
204 NCT02616184
203 NCT0269788 An Investigative
202 NCT01935843
201 NCT03165591
200 NCT02316457
199 NCT03241940
198 NCT03165591
197 NCT03018405
196 NCT0317566
195 NCT03241940
194 NCT03165591
193 NCT0323423 Phase II Trial
192 NCT01570036
191 NCT02169600
190 NCT0320244 Randomized
189 NCT02873411 Precision Cell
188 NCT02873442
187 NCT03197571
186 NCT03197571
185 NCT01837602
184 NCT02448173
183 NCT03183232
182 NCT02843165
181 NCT0213307 Immunotherapy
180 NCT00470574
179 NCT03183241 Safety and Ef
178 NCT03183206
177 NCT0213307 Immunotherapy
176 NCT03114671 The Study of
175 NCT03047811
174 NCT0276391 A Multicenter
173 NCT03098355
172 NCT03323424
171 NCT02579000 Radio-Immuno
terapy
170 NCT03296137
169 NCT035429 CAR T Cells in
168 NCT0169687 A Neoadjuvanta

https://ClinicalTrials.gov/show/NCT01968109
https://ClinicalTrials.gov/show/NCT02886897
https://ClinicalTrials.gov/show/NCT02759588
https://ClinicalTrials.gov/show/NCT02862028
https://ClinicalTrials.gov/show/NCT02759588
https://ClinicalTrials.gov/show/NCT03165591
https://ClinicalTrials.gov/show/NCT03018405
https://ClinicalTrials.gov/show/NCT03241940
https://ClinicalTrials.gov/show/NCT02906371
https://ClinicalTrials.gov/show/NCT03018405
https://ClinicalTrials.gov/show/NCT0317566
https://ClinicalTrials.gov/show/NCT00405327
https://ClinicalTrials.gov/show/NCT02316457
https://ClinicalTrials.gov/show/NCT01935843
https://ClinicalTrials.gov/show/NCT02616184
https://ClinicalTrials.gov/show/NCT0269788 An Investigatiga
https://ClinicalTrials.gov/show/NCT0269788 An Investigatiga
https://ClinicalTrials.gov/show/NCT02616185
https://ClinicalTrials.gov/show/NCT02862028
https://ClinicalTrials.gov/show/NCT02759588
https://ClinicalTrials.gov/show/NCT02466900
https://ClinicalTrials.gov/show/NCT02886897
https://ClinicalTrials.gov/show/NCT01968109
Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR

Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread

CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

T Cell Immunotherapy for Advanced Ovarian Cancer

PD-L1 Inhibition as Checkpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

CD22 Redirected Autologous T Cells for ALL

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240535 Phase 1 Study  211 NCT02650414 CD22 Redirected Autologous T Cell Immunotherapy in Patients With Relapsed/Refractory CD19 Positive B Acute Lymphoblastic Leukemia

NCT03169738

NCT02650414 https://ClinicalTrials.gov/show/NCT02650414

NCT01227772 https://ClinicalTrials.gov/show/NCT01227772

NCT00317603 https://ClinicalTrials.gov/show/NCT00317603

NCT00799110 https://ClinicalTrials.gov/show/NCT00799110

NCT03180437 https://ClinicalTrials.gov/show/NCT03180437

NCT02060188 https://ClinicalTrials.gov/show/NCT02060188

NCT01519817 https://ClinicalTrials.gov/show/NCT01519817

NCT02652455 https://ClinicalTrials.gov/show/NCT02652455

NCT01146262 https://ClinicalTrials.gov/show/NCT01146262

NCT03179410 https://ClinicalTrials.gov/show/NCT03179410

NCT02685670 https://ClinicalTrials.gov/show/NCT02685670

NCT02617589 https://ClinicalTrials.gov/show/NCT02617589

NCT03101475 https://ClinicalTrials.gov/show/NCT03101475

NCT02666254 https://ClinicalTrials.gov/show/NCT02666254

NCT01326104 https://ClinicalTrials.gov/show/NCT01326104

NCT02757391 https://ClinicalTrials.gov/show/NCT02757391

NCT03206073 https://ClinicalTrials.gov/show/NCT03206073

NCT03166254 https://ClinicalTrials.gov/show/NCT03166254

NCT02477826 https://ClinicalTrials.gov/show/NCT02477826

NCT03179410 https://ClinicalTrials.gov/show/NCT03179410

NCT02317471 https://ClinicalTrials.gov/show/NCT02317471

NCT03318043 https://ClinicalTrials.gov/show/NCT03318043

NCT01883518 https://ClinicalTrials.gov/show/NCT01883518

NCT03110978 https://ClinicalTrials.gov/show/NCT03110978

NCT00799110 https://ClinicalTrials.gov/show/NCT00799110

NCT03016377 https://ClinicalTrials.gov/show/NCT03016377

NCT02858232 https://ClinicalTrials.gov/show/NCT02858232

NCT00317603 https://ClinicalTrials.gov/show/NCT00317603

NCT01227772 https://ClinicalTrials.gov/show/NCT01227772

NCT02897765 https://ClinicalTrials.gov/show/NCT02897765

NCT02818426 https://ClinicalTrials.gov/show/NCT02818426
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

A Study of PVX-410, a Cancer Vaccine, and Durvalumab +/- Lenalidomide for Smoldering MM

T-Cell Therapy for Advanced Breast Cancer

Glypican 3-specific Chimeric Antigen ReceptorExpressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

CD19/22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non-Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Neo-Adjuvant Immunotherapy With Nivolumab for Non-Small Cell Lung Cancer Patients

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Immunotherapy by Nivolumab for HIV+ Patients

Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prevention in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia

Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Safety and Efficacy Evaluation of IM19 CAR-T Cells

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

294 NCT0240952 An Individual... 30 https://ClinicalTrials.gov/show/NCT02409524
295 NCT0259896 An Investigat... 310 https://ClinicalTrials.gov/show/NCT02598960
296 NCT0275414 An Investigat... 216 https://ClinicalTrials.gov/show/NCT02754141
297 NCT0265889 An Investigat... 907 https://ClinicalTrials.gov/show/NCT02658890
298 NCT0212812 Study of the... 100 https://ClinicalTrials.gov/show/NCT02128126
299 NCT0314264 Safety and Ef... 20 https://ClinicalTrials.gov/show/NCT03142646
300 NCT0291331 An Investigat... 170 https://ClinicalTrials.gov/show/NCT02913313
301 NCT0328996 A Study of RC... 572 https://ClinicalTrials.gov/show/NCT03289962
302 NCT0254137 Treatment of... 20 https://ClinicalTrials.gov/show/NCT02541370
303 NCT0271885 Combination... 60 https://ClinicalTrials.gov/show/NCT02718859
304 NCT0231046 Trial of Acti... 58 https://ClinicalTrials.gov/show/NCT02310464
305 NCT0308191 Autologous T... 21 https://ClinicalTrials.gov/show/NCT03081910
306 NCT0277219 T-cells Expre... 40 https://ClinicalTrials.gov/show/NCT02772198
307 NCT0323612 Allogeneic Im... 52 https://ClinicalTrials.gov/show/NCT03236129
308 NCT0276836 Randomized... 156 https://ClinicalTrials.gov/show/NCT02768363
309 NCT0329144 CAR-T Cells C... 30 https://ClinicalTrials.gov/show/NCT03291444
310 NCT0316477 Phase 1/2 Sti... 56 https://ClinicalTrials.gov/show/NCT03164772
311 NCT0307643 Anti-CD19 Ch... 36 https://ClinicalTrials.gov/show/NCT03076437
312 NCT0203084 Study of Redi... 30 https://ClinicalTrials.gov/show/NCT02030847
313 NCT0255481 A Study Of Av... 671 https://ClinicalTrials.gov/show/NCT02554812
314 NCT0331167 T-Cell PET Im... 20 https://ClinicalTrials.gov/show/NCT03311672
316 NCT0167835 Imiquimod ai... 27 https://ClinicalTrials.gov/show/NCT01678352
317 NCT0225399 An Investigat... 200 https://ClinicalTrials.gov/show/NCT02253992
318 NCT0317341 Safety and Ef... 300 https://ClinicalTrials.gov/show/NCT03173417
319 NCT0234261 Adoptive Immr... 27 https://ClinicalTrials.gov/show/NCT02342613
320 NCT0271025 Trial of Salva... 150 https://ClinicalTrials.gov/show/NCT02710253
321 NCT0292979 Immunotherap... 72 https://ClinicalTrials.gov/show/NCT02929797
322 NCT0283995 CAR-pNK Cell... 10 https://ClinicalTrials.gov/show/NCT02839954
323 NCT0258074 Treatment of... 20 https://ClinicalTrials.gov/show/NCT02580747
324 NCT0254673 Immunotherap... 100 https://ClinicalTrials.gov/show/NCT02546739
325 NCT0101344 CD3/CD28 Be... 20 https://ClinicalTrials.gov/show/NCT01013441
326 NCT0322310 Safety and In... 20 https://ClinicalTrials.gov/show/NCT03223103
327 NCT0315958 To Evaluate t... 20 https://ClinicalTrials.gov/show/NCT03159585
328 NCT0210743 Phase II Stud... 62 https://ClinicalTrials.gov/show/NCT02107430
329 NCT0309816 Immunotherap... 69 https://ClinicalTrials.gov/show/NCT03098160
330 NCT0298896 A Study of Aë... 180 https://ClinicalTrials.gov/show/NCT02988960
331 NCT0321977 Tailored Imm... 250 https://ClinicalTrials.gov/show/NCT03219775
332 NCT0311044 Cancer/Testis... 15 https://ClinicalTrials.gov/show/NCT03110445
333 NCT0330409 Immunotherap... 30 https://ClinicalTrials.gov/show/NCT03304093
334 NCT0211185 T Cell Recept... 107 https://ClinicalTrials.gov/show/NCT02111850
335 NCT0222926 Randomised... 56 https://ClinicalTrials.gov/show/NCT02229266
336 NCT0285158 Study Evaluating CAR-T Hepatitis A Nodes 10 https://ClinicalTrials.gov/show/NCT02851589
337 NCT0201845 Safety Study 20 https://ClinicalTrials.gov/show/NCT02018458
338 NCT0241073 Evaluation of Combination Vaccination / Treatment 39 https://ClinicalTrials.gov/show/NCT02410733
339 NCT0316687 A Study Evaluating Combination Vaccination / Treatment 80 https://ClinicalTrials.gov/show/NCT03166878
340 NCT0143317 Combination Vaccination / Treatment 73 https://ClinicalTrials.gov/show/NCT01433172
341 NCT0323261 CD19-CART T Cells for Treatment of Relapsed and Refractory B-cell Malignancies 20 https://ClinicalTrials.gov/show/NCT03232619
342 NCT0291964 Vaccination / Treatment of Relapsed and Refractory B-cell Malignancies 19 https://ClinicalTrials.gov/show/NCT02919644
343 NCT0285053 CAR-T Hepatitis A Nodes 5 https://ClinicalTrials.gov/show/NCT02850536
344 NCT0262102 A Prospective Study of TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 170 https://ClinicalTrials.gov/show/NCT02621021
345 NCT0218736 Safety & Efficacy of TBI-1501 in Combination with Carboplatin and Paclitaxel for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 418 https://ClinicalTrials.gov/show/NCT02187367
346 NCT0263240 An Investigational Study of TBI-1501 in Combination with Carboplatin and Paclitaxel for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 640 https://ClinicalTrials.gov/show/NCT02632409
347 NCT0296059 hTERT Immune Therapy 54 https://ClinicalTrials.gov/show/NCT02960594
348 NCT0218578 Phase I Study of TBI-1501 in Combination with Carboplatin and Paclitaxel for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 6 https://ClinicalTrials.gov/show/NCT02185781
349 NCT0299722 Combination Vaccination / Treatment of Relapsed and Refractory B-cell Malignancies 439 https://ClinicalTrials.gov/show/NCT02997228
350 NCT0131956 Prospective Study Evaluating TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 102 https://ClinicalTrials.gov/show/NCT01319565
351 NCT0294416 CAR-pNK Cell Therapy for Treatment of Relapsed and Refractory Acute Lymphoblastic Leukemia 10 https://ClinicalTrials.gov/show/NCT02944162
352 NCT0270999 Consolidation Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia 23 https://ClinicalTrials.gov/show/NCT02709993
353 NCT0222331 Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia 23 https://ClinicalTrials.gov/show/NCT02223312
354 NCT0315519 Study of TBI-1501 in Combination with Carboplatin and Paclitaxel for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 21 https://ClinicalTrials.gov/show/NCT03155191
355 NCT0068429 Phase I Trial of TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 50 https://ClinicalTrials.gov/show/NCT00684294
356 NCT0306883 Personalized Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 10 https://ClinicalTrials.gov/show/NCT03068832
357 NCT0231839 A Phase 1 Study of TBI-1501 in Combination with Carboplatin and Paclitaxel for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 56 https://ClinicalTrials.gov/show/NCT02318394
358 NCT0286270 A Study of Molecules and Technologies for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 20 https://ClinicalTrials.gov/show/NCT02862704
359 NCT0241646 CAR-T Hepatitis A Nodes 4 https://ClinicalTrials.gov/show/NCT02416466
360 NCT0040859 Recombinant Safety Study 37 https://ClinicalTrials.gov/show/NCT00408590
361 NCT0329882 CD19 CAR an tibody Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 30 https://ClinicalTrials.gov/show/NCT03298828
362 NCT0300833 High-activity CAR an tibody Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 20 https://ClinicalTrials.gov/show/NCT03008330
363 NCT0280841 Personalized Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 30 https://ClinicalTrials.gov/show/NCT02808416
364 NCT0274428 Prostate Ster eotactic Radiotherapy for Treatment of Metastatic Prostate Cancer 30 https://ClinicalTrials.gov/show/NCT02744287
365 NCT0274272 CAR-pNK Cell Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 10 https://ClinicalTrials.gov/show/NCT02742727
366 NCT0186488 Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 12 https://ClinicalTrials.gov/show/NCT01864889
367 NCT0266971 Cellular Immunity Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 70 https://ClinicalTrials.gov/show/NCT02669719
368 NCT0300849 High-activity CAR an tibody Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 20 https://ClinicalTrials.gov/show/NCT03008499
369 NCT0300783 High-activity CAR an tibody Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 20 https://ClinicalTrials.gov/show/NCT03007836
370 NCT0325280 Phase I Study of TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 6 https://ClinicalTrials.gov/show/NCT03252808
371 NCT0250832 IPA Targeted Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 40 https://ClinicalTrials.gov/show/NCT02508324
372 NCT0222459 Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 23 https://ClinicalTrials.gov/show/NCT02224599
373 NCT0309777 Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 20 https://ClinicalTrials.gov/show/NCT03097770
374 NCT0066973 Vaccine Therapy for Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 18 https://ClinicalTrials.gov/show/NCT00669734
375 NCT0234969 A Clinical Research Study Evaluating TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 45 https://ClinicalTrials.gov/show/NCT02349698
376 NCT0305019 A Phase I/II Study of TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 200 https://ClinicalTrials.gov/show/NCT03050190
377 NCT0266168 Safety Study of TBI-1501 and Chemotherapy Combination for Relapsed or Refractory Acute Lymphoblastic Leukemia 9 https://ClinicalTrials.gov/show/NCT02661685
<table>
<thead>
<tr>
<th>Clinical Trial ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Status</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0213086 A Pilot Study</td>
<td>Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT02130866">https://ClinicalTrials.gov/show/NCT02130866</a></td>
</tr>
<tr>
<td>NCT0300787 High-activity</td>
<td>Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT03007875">https://ClinicalTrials.gov/show/NCT03007875</a></td>
</tr>
<tr>
<td>NCT0328742 MYPHISMO: Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)</td>
<td></td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0328742">https://ClinicalTrials.gov/show/NCT0328742</a></td>
</tr>
<tr>
<td>NCT0211841 Donor Cellul</td>
<td>Immunotherapy for Recurrent Ependymomas in Children</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0211841">https://ClinicalTrials.gov/show/NCT0211841</a></td>
</tr>
<tr>
<td>NCT0330050 ARRx Follow-up</td>
<td>Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0330050">https://ClinicalTrials.gov/show/NCT0330050</a></td>
</tr>
<tr>
<td>NCT0038399 Immunotherapy</td>
<td>E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0038399">https://ClinicalTrials.gov/show/NCT0038399</a></td>
</tr>
<tr>
<td>NCT0137650 Vaccine Therapy</td>
<td>Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0137650">https://ClinicalTrials.gov/show/NCT0137650</a></td>
</tr>
<tr>
<td>NCT0328532 Unresectable</td>
<td>CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0328532">https://ClinicalTrials.gov/show/NCT0328532</a></td>
</tr>
<tr>
<td>NCT01174121 Immunotherapy</td>
<td>Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT01174121">https://ClinicalTrials.gov/show/NCT01174121</a></td>
</tr>
<tr>
<td>NCT03162562 Immunotherapy</td>
<td>A Phase II Study Of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT03162562">https://ClinicalTrials.gov/show/NCT03162562</a></td>
</tr>
<tr>
<td>NCT01795313 Immunotherapy</td>
<td>A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT01795313">https://ClinicalTrials.gov/show/NCT01795313</a></td>
</tr>
<tr>
<td>NCT01795313 Immunotherapy</td>
<td>Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT01795313">https://ClinicalTrials.gov/show/NCT01795313</a></td>
</tr>
<tr>
<td>NCT03083050 Immunotherapy</td>
<td>Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Vaccine Therapy in Treating Patients With Metastatic Solid Tumors</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT03083050">https://ClinicalTrials.gov/show/NCT03083050</a></td>
</tr>
<tr>
<td>NCT00626483 Immunotherapy</td>
<td>Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT00626483">https://ClinicalTrials.gov/show/NCT00626483</a></td>
</tr>
<tr>
<td>NCT02423928 Immunotherapy</td>
<td>MK-3475 Immunotherapy in Endometrial Carcinoma</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT02423928">https://ClinicalTrials.gov/show/NCT02423928</a></td>
</tr>
<tr>
<td>NCT02968472 Immunotherapy</td>
<td>Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT02968472">https://ClinicalTrials.gov/show/NCT02968472</a></td>
</tr>
<tr>
<td>NCT03419821 Immunotherapy</td>
<td>MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT03419821">https://ClinicalTrials.gov/show/NCT03419821</a></td>
</tr>
<tr>
<td>NCT0263082 MK-3475 Imr</td>
<td>High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0263082">https://ClinicalTrials.gov/show/NCT0263082</a></td>
</tr>
<tr>
<td>NCT00458536 Immunotherapy</td>
<td>A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT00458536">https://ClinicalTrials.gov/show/NCT00458536</a></td>
</tr>
<tr>
<td>NCT0286513 Trial To Test Efficacy of Ado</td>
<td>Immunotherapy for Recurrent Ependymomas in Children</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0286513">https://ClinicalTrials.gov/show/NCT0286513</a></td>
</tr>
<tr>
<td>NCT0145459 CAR T Cell Receptor</td>
<td>Immunotherapy for Recurrent Ependymomas in Children</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0145459">https://ClinicalTrials.gov/show/NCT0145459</a></td>
</tr>
<tr>
<td>NCT0219350 MVX-ONCO-095</td>
<td>Immunotherapy for Recurrent Ependymomas in Children</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0219350">https://ClinicalTrials.gov/show/NCT0219350</a></td>
</tr>
<tr>
<td>NCT0306862 Study of Cells</td>
<td>Immunotherapy for Recurrent Ependymomas in Children</td>
<td></td>
<td></td>
<td><a href="https://ClinicalTrials.gov/show/NCT0306862">https://ClinicalTrials.gov/show/NCT0306862</a></td>
</tr>
</tbody>
</table>
420 NCT0280905 A Randomize 308 https://ClinicalTrials.gov/show/NCT02809053
421 NCT0174103 AlloStimâ"û In 450 https://ClinicalTrials.gov/show/NCT01741038
422 NCT0178909 A Phase I/IIa 18 https://ClinicalTrials.gov/show/NCT01789099
423 NCT0223249 Liver Cancer 120 https://ClinicalTrials.gov/show/NCT02232490
424 NCT0331380 Priming Imm 57 https://ClinicalTrials.gov/show/NCT03313804
425 NCT0328849 P-BCMA-101 40 https://ClinicalTrials.gov/show/NCT03288493
426 NCT008264 Vaccine Ther 24 https://ClinicalTrials.gov/show/NCT00826419
427 NCT0050506 Prospective 1 75 https://ClinicalTrials.gov/show/NCT00505063
428 NCT0254816 Dendritic Cel 20 https://ClinicalTrials.gov/show/NCT02548169
429 NCT0226171 Antigen-spec 32 https://ClinicalTrials.gov/show/NCT02261714
430 NCT0206142 HER-2 Pulsed 7 https://ClinicalTrials.gov/show/NCT02061423
431 NCT0305966 Immunother: 70 https://ClinicalTrials.gov/show/NCT03059667
432 NCT0195967 Combination 66 https://ClinicalTrials.gov/show/NCT01959672
433 NCT0262499 Study Compa 100 https://ClinicalTrials.gov/show/NCT02624999
434 NCT0330240 Clinical Study 48 https://ClinicalTrials.gov/show/NCT03302403
435 NCT0271437 Safety and Ef 36 https://ClinicalTrials.gov/show/NCT02714374
436 NCT0331377 Safety, Toler: 90 https://ClinicalTrials.gov/show/NCT03313778
437 NCT0178491 A Phase I/IIa 21 https://ClinicalTrials.gov/show/NCT01784913
438 NCT0264838 Stem Cell Ther 34 https://ClinicalTrials.gov/show/NCT02648386
439 NCT0068203 The Effect of 300 https://ClinicalTrials.gov/show/NCT00682032
440 NCT0247046 Evaluation of 105 https://ClinicalTrials.gov/show/NCT02470468
441 NCT0327163 Multi- CAR T 20 https://ClinicalTrials.gov/show/NCT03271632
442 NCT0236581 Safety and Ef 66 https://ClinicalTrials.gov/show/NCT02365818
443 NCT0332273 Study of BCM 10 https://ClinicalTrials.gov/show/NCT03322735
444 NCT0289541 Infection and 20 https://ClinicalTrials.gov/show/NCT02895412
445 NCT0259296 Safety & Imrn 42 https://ClinicalTrials.gov/show/NCT02592967
446 NCT0277134 Study Evaluat: 10 https://ClinicalTrials.gov/show/NCT02771340
447 NCT0186310 Safety Study 15 https://ClinicalTrials.gov/show/NCT01863108
448 NCT0321509 RAI Plus Imrn 11 https://ClinicalTrials.gov/show/NCT03215095
449 NCT0208193 CART-19 Imrn 2 https://ClinicalTrials.gov/show/NCT02081937
450 NCT0060109 Vaccine Ther 21 https://ClinicalTrials.gov/show/NCT00601094
451 NCT0266418 Pharmacolog 60 https://ClinicalTrials.gov/show/NCT02664181
452 NCT0293563 A Study to Te 300 https://ClinicalTrials.gov/show/NCT02935634
453 NCT0330049 Expanded Na 10 https://ClinicalTrials.gov/show/NCT03300492
454 NCT0019471 Vaccine Ther 20 https://ClinicalTrials.gov/show/NCT00194714
455 NCT0284488 Study of Apa: 60 https://ClinicalTrials.gov/show/NCT02844881
456 NCT0277209 Dendritic Cel 50 https://ClinicalTrials.gov/show/NCT02772094
457 NCT0220292 Adoptive Cell 60 https://ClinicalTrials.gov/show/NCT02202928
458 NCT0284005 Interest of Ar 120 https://ClinicalTrials.gov/show/NCT02840058
459 NCT0275152 QUILT-3.013: 30 https://ClinicalTrials.gov/show/NCT02751528
460 NCT0328767 TIL Therapy ii 12 https://ClinicalTrials.gov/show/NCT03287674
461 NCT0307352 Trial of Atezc 25 https://ClinicalTrials.gov/show/NCT03073525
Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-cell Surface Antigen Mesothelin

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors

Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Safety and Efficacy of T Cell Against Gastric Cancer

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

A Study in Adult Subjects With Select Advanced Solid Tumors

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Immunization of Patients With Non-small Cell Lung Cancer (NSCLC)

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Immunotherapy With Neo-adjuvant Chemotherapy for Ovarian Cancer
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Study Title</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0223990</td>
<td>Ipilimumab</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02239900">https://ClinicalTrials.gov/show/NCT02239900</a></td>
</tr>
<tr>
<td>NCT0173813</td>
<td>Ipilimumab Combination</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01738139">https://ClinicalTrials.gov/show/NCT01738139</a></td>
</tr>
<tr>
<td>NCT0219334</td>
<td>IDH1 Peptide</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02193347">https://ClinicalTrials.gov/show/NCT02193347</a></td>
</tr>
<tr>
<td>NCT0254616</td>
<td>CART-BCMA</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02546167">https://ClinicalTrials.gov/show/NCT02546167</a></td>
</tr>
<tr>
<td>NCT0186561</td>
<td>Laboratory Tl</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01865617">https://ClinicalTrials.gov/show/NCT01865617</a></td>
</tr>
<tr>
<td>NCT0272104</td>
<td>Safety and In</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02721043">https://ClinicalTrials.gov/show/NCT02721043</a></td>
</tr>
<tr>
<td>NCT0199371</td>
<td>Immunotherapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01993719">https://ClinicalTrials.gov/show/NCT01993719</a></td>
</tr>
<tr>
<td>NCT0314458</td>
<td>Pilot Study of</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03144583">https://ClinicalTrials.gov/show/NCT03144583</a></td>
</tr>
<tr>
<td>NCT0300410</td>
<td>MEDI4736 W</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03004105">https://ClinicalTrials.gov/show/NCT03004105</a></td>
</tr>
<tr>
<td>NCT0010110</td>
<td>Universal Gra</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00101101">https://ClinicalTrials.gov/show/NCT00101101</a></td>
</tr>
<tr>
<td>NCT0310000</td>
<td>Phase Ib/Ila Tl</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03100006">https://ClinicalTrials.gov/show/NCT03100006</a></td>
</tr>
<tr>
<td>NCT0310397</td>
<td>huJCAR014 C</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03103971">https://ClinicalTrials.gov/show/NCT03103971</a></td>
</tr>
<tr>
<td>NCT0307032</td>
<td>BCMA Target</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03070327">https://ClinicalTrials.gov/show/NCT03070327</a></td>
</tr>
<tr>
<td>NCT0287622</td>
<td>Study of Cobi</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02876224">https://ClinicalTrials.gov/show/NCT02876224</a></td>
</tr>
<tr>
<td>NCT0113201</td>
<td>Autologous C</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01132014">https://ClinicalTrials.gov/show/NCT01132014</a></td>
</tr>
<tr>
<td>NCT0236688</td>
<td>Clinical Eval</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02366884">https://ClinicalTrials.gov/show/NCT02366884</a></td>
</tr>
<tr>
<td>NCT0293844</td>
<td>Vaccination of</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02938442">https://ClinicalTrials.gov/show/NCT02938442</a></td>
</tr>
<tr>
<td>NCT0229668</td>
<td>Immunotherapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02296684">https://ClinicalTrials.gov/show/NCT02296684</a></td>
</tr>
<tr>
<td>NCT0240522</td>
<td>Safety and Fe</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02405221">https://ClinicalTrials.gov/show/NCT02405221</a></td>
</tr>
<tr>
<td>NCT0182397</td>
<td>Safety Study</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01823978">https://ClinicalTrials.gov/show/NCT01823978</a></td>
</tr>
<tr>
<td>NCT0260868</td>
<td>A Study of Pe</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02608684">https://ClinicalTrials.gov/show/NCT02608684</a></td>
</tr>
<tr>
<td>NCT0213319</td>
<td>T Cell Recept</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02133196">https://ClinicalTrials.gov/show/NCT02133196</a></td>
</tr>
<tr>
<td>NCT0305734</td>
<td>The Treatment</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03057340">https://ClinicalTrials.gov/show/NCT03057340</a></td>
</tr>
<tr>
<td>NCT0120468</td>
<td>Dendritic Cel</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01204684">https://ClinicalTrials.gov/show/NCT01204684</a></td>
</tr>
<tr>
<td>NCT0309065</td>
<td>LCAR-B38M-I</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03090659">https://ClinicalTrials.gov/show/NCT03090659</a></td>
</tr>
<tr>
<td>NCT0272548</td>
<td>Pilot Study of</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02725489">https://ClinicalTrials.gov/show/NCT02725489</a></td>
</tr>
<tr>
<td>NCT0202811</td>
<td>Phase I / Dos</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02028117">https://ClinicalTrials.gov/show/NCT02028117</a></td>
</tr>
<tr>
<td>NCT0228052</td>
<td>Cord Blood N</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02280525">https://ClinicalTrials.gov/show/NCT02280525</a></td>
</tr>
<tr>
<td>NCT0161630</td>
<td>A Controlled</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01616303">https://ClinicalTrials.gov/show/NCT01616303</a></td>
</tr>
<tr>
<td>NCT0251113</td>
<td>A Two-part P</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02511132">https://ClinicalTrials.gov/show/NCT02511132</a></td>
</tr>
<tr>
<td>NCT0299611</td>
<td>A Study to Te</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02996110">https://ClinicalTrials.gov/show/NCT02996110</a></td>
</tr>
<tr>
<td>NCT0316846</td>
<td>Radiation and</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03168464">https://ClinicalTrials.gov/show/NCT03168464</a></td>
</tr>
<tr>
<td>NCT0202844</td>
<td>Phase I / Il St</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02028442">https://ClinicalTrials.gov/show/NCT02028442</a></td>
</tr>
<tr>
<td>NCT0213540</td>
<td>CART-19 for I</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02135406">https://ClinicalTrials.gov/show/NCT02135406</a></td>
</tr>
<tr>
<td>NCT0184057</td>
<td>Study of Pem</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01840579">https://ClinicalTrials.gov/show/NCT01840579</a></td>
</tr>
<tr>
<td>NCT0309316</td>
<td>BCMA Chime</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03093168">https://ClinicalTrials.gov/show/NCT03093168</a></td>
</tr>
<tr>
<td>NCT0306715</td>
<td>CMV Specific</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03067155">https://ClinicalTrials.gov/show/NCT03067155</a></td>
</tr>
<tr>
<td>NCT0132280</td>
<td>Vaccine Ther</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01322802">https://ClinicalTrials.gov/show/NCT01322802</a></td>
</tr>
<tr>
<td>NCT0171168</td>
<td>Treatment of</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01711684">https://ClinicalTrials.gov/show/NCT01711684</a></td>
</tr>
<tr>
<td>NCT025032</td>
<td>Safety and Ef</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0250326">https://ClinicalTrials.gov/show/NCT0250326</a></td>
</tr>
<tr>
<td>NCT ID</td>
<td>Clinical Trial Title</td>
<td>Phase</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>NCT00524277</td>
<td>Vaccine Therapy TIB31322-01 and TIB31322-02</td>
<td>600</td>
</tr>
<tr>
<td>NCT0186733</td>
<td>Enzalutamide in combination with abiraterone for the treatment of prostate cancer</td>
<td>57</td>
</tr>
<tr>
<td>NCT0236245</td>
<td>Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer</td>
<td>50</td>
</tr>
<tr>
<td>NCT0316137</td>
<td>Phase 2 GVA: Study of Nivolumab in patients with advanced cancer</td>
<td>20</td>
</tr>
<tr>
<td>NCT0136936</td>
<td>Treatment of Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer</td>
<td>18</td>
</tr>
<tr>
<td>NCT0090080</td>
<td>QUILT-3018: Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)</td>
<td>100</td>
</tr>
<tr>
<td>NCT0045865</td>
<td>Vaccination \ of \ APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma</td>
<td>24</td>
</tr>
<tr>
<td>NCT01590273</td>
<td>Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer</td>
<td>44</td>
</tr>
<tr>
<td>NCT01213472</td>
<td>Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ESO-1</td>
<td>30</td>
</tr>
<tr>
<td>NCT00789776</td>
<td>REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors</td>
<td>42</td>
</tr>
<tr>
<td>NCT01814046</td>
<td>Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma</td>
<td>27</td>
</tr>
<tr>
<td>NCT01658878</td>
<td>Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer</td>
<td>12</td>
</tr>
<tr>
<td>NCT02955251</td>
<td>Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung</td>
<td>80</td>
</tr>
<tr>
<td>NCT0186733</td>
<td>Treatment of Acute Leukemia Relapse After Allotransplantation</td>
<td>44</td>
</tr>
<tr>
<td>NCT01877804</td>
<td>Study of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer</td>
<td>6</td>
</tr>
<tr>
<td>NCT0236245</td>
<td>Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer</td>
<td>6</td>
</tr>
<tr>
<td>NCT02649439</td>
<td>Prostvac in Patients With Biochemically Recurrent Prostate Cancer</td>
<td>80</td>
</tr>
<tr>
<td>NCT0173430</td>
<td>DC Vaccination \ of \ CD3 x Ar</td>
<td>30</td>
</tr>
<tr>
<td>NCT02466568</td>
<td>Fludarabine \ of \ APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma</td>
<td>40</td>
</tr>
<tr>
<td>NCT02948426</td>
<td>Intrapерitoneal Intraperitoneal \ of \ Nivolumab in Patients With Advanced Cancer</td>
<td>30</td>
</tr>
<tr>
<td>NCT01213472</td>
<td>Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ESO-1</td>
<td>34</td>
</tr>
<tr>
<td>NCT00789776</td>
<td>REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors</td>
<td>20</td>
</tr>
<tr>
<td>NCT01814046</td>
<td>Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma</td>
<td>50</td>
</tr>
<tr>
<td>NCT01877804</td>
<td>Study of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer</td>
<td>54</td>
</tr>
<tr>
<td>NCT02459067</td>
<td>Anti-PD-L1 in Treating Patients With Advanced Cancer</td>
<td>68</td>
</tr>
<tr>
<td>NCT00970203</td>
<td>Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer</td>
<td>12</td>
</tr>
<tr>
<td>NCT01683279</td>
<td>A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia</td>
<td>18</td>
</tr>
</tbody>
</table>

**ClinicalTrials.gov**

- [NCT00524277](https://ClinicalTrials.gov/show/NCT00524277)
- [NCT0186733](https://ClinicalTrials.gov/show/NCT01867333)
- [NCT0236245](https://ClinicalTrials.gov/show/NCT02362451)
- [NCT0316137](https://ClinicalTrials.gov/show/NCT03161379)
- [NCT0136936](https://ClinicalTrials.gov/show/NCT01369368)
- [NCT0090080](https://ClinicalTrials.gov/show/NCT00900809)
- [NCT02466568](https://ClinicalTrials.gov/show/NCT02466568)
- [NCT0045865](https://ClinicalTrials.gov/show/NCT00458653)
- [NCT0302927](https://ClinicalTrials.gov/show/NCT03029273)
- [NCT01814046](https://ClinicalTrials.gov/show/NCT01814046)
- [NCT01042535](https://ClinicalTrials.gov/show/NCT01042535)
- [NCT0159237](https://ClinicalTrials.gov/show/NCT01592370)
- [NCT0265098](https://ClinicalTrials.gov/show/NCT02650986)
- [NCT0290114](https://ClinicalTrials.gov/show/NCT02901145)
- [NCT00789776](https://ClinicalTrials.gov/show/NCT00789776)
- [NCT01827579](https://ClinicalTrials.gov/show/NCT01827579)
- [NCT01369368](https://ClinicalTrials.gov/show/NCT01369368)
- [NCT02362451](https://ClinicalTrials.gov/show/NCT02362451)
- [NCT01213472](https://ClinicalTrials.gov/show/NCT01213472)
- [NCT01658878](https://ClinicalTrials.gov/show/NCT01658878)
- [NCT02948426](https://ClinicalTrials.gov/show/NCT02948426)
- [NCT01213472](https://ClinicalTrials.gov/show/NCT01213472)
- [NCT0317327](https://ClinicalTrials.gov/show/NCT0317327)
- [NCT01807065](https://ClinicalTrials.gov/show/NCT01807065)
- [NCT03127007](https://ClinicalTrials.gov/show/NCT03127007)
- [NCT02459067](https://ClinicalTrials.gov/show/NCT02459067)
- [NCT01312389](https://ClinicalTrials.gov/show/NCT01312389)
- [NCT0287976](https://ClinicalTrials.gov/show/NCT0287976)
- [NCT03287804](https://ClinicalTrials.gov/show/NCT03287804)
- [NCT02572843](https://ClinicalTrials.gov/show/NCT02572843)
- [NCT00970203](https://ClinicalTrials.gov/show/NCT00970203)
- [NCT01683279](https://ClinicalTrials.gov/show/NCT01683279)
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>Phase</th>
<th>ClinicalTrials.gov Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03110322</td>
<td>Study of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>3</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03110322">https://ClinicalTrials.gov/show/NCT03110322</a></td>
</tr>
<tr>
<td>NCT0273778</td>
<td>A Study of Wx-100 Carboplatin in Combination With Pembrolizumab</td>
<td>1/2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0273778">https://ClinicalTrials.gov/show/NCT0273778</a></td>
</tr>
<tr>
<td>NCT0265821</td>
<td>Durvalumab in the Treatment of Patients With NSCLC</td>
<td>3</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0265821">https://ClinicalTrials.gov/show/NCT0265821</a></td>
</tr>
<tr>
<td>NCT00343109</td>
<td>IP-10 Inhibitor in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00343109">https://ClinicalTrials.gov/show/NCT00343109</a></td>
</tr>
<tr>
<td>NCT0240801</td>
<td>Genetically Modified Lymphocytes in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0240801">https://ClinicalTrials.gov/show/NCT0240801</a></td>
</tr>
<tr>
<td>NCT0149749</td>
<td>Ofatumumab in the Treatment of Patients With CD20 Positive DLBCL</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0149749">https://ClinicalTrials.gov/show/NCT0149749</a></td>
</tr>
<tr>
<td>NCT0240533</td>
<td>DC Vaccination in the Treatment of Patients With Melanoma</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0240533">https://ClinicalTrials.gov/show/NCT0240533</a></td>
</tr>
<tr>
<td>NCT006517</td>
<td>Trial of SBRT in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT006517">https://ClinicalTrials.gov/show/NCT006517</a></td>
</tr>
<tr>
<td>NCT0259586</td>
<td>Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0259586">https://ClinicalTrials.gov/show/NCT0259586</a></td>
</tr>
<tr>
<td>NCT0313193</td>
<td>Immunotherapy in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0313193">https://ClinicalTrials.gov/show/NCT0313193</a></td>
</tr>
<tr>
<td>NCT0259322</td>
<td>Folate Receptor Alpha Peptide Vaccine in the Treatment of Patients With Triple Negative Breast Cancer</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0259322">https://ClinicalTrials.gov/show/NCT0259322</a></td>
</tr>
<tr>
<td>NCT0135539</td>
<td>Vaccine Therapy in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0135539">https://ClinicalTrials.gov/show/NCT0135539</a></td>
</tr>
<tr>
<td>NCT0034310</td>
<td>Vaccine Therapy in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0034310">https://ClinicalTrials.gov/show/NCT0034310</a></td>
</tr>
<tr>
<td>NCT0109440</td>
<td>Efficacy of Ruxolitinib in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0109440">https://ClinicalTrials.gov/show/NCT0109440</a></td>
</tr>
<tr>
<td>NCT0215705</td>
<td>Vaccine Therapy in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0215705">https://ClinicalTrials.gov/show/NCT0215705</a></td>
</tr>
<tr>
<td>NCT0219716</td>
<td>DNX-2401 W in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0219716">https://ClinicalTrials.gov/show/NCT0219716</a></td>
</tr>
<tr>
<td>NCT0205868</td>
<td>Phase 1A/1B Study of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>1/2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0205868">https://ClinicalTrials.gov/show/NCT0205868</a></td>
</tr>
<tr>
<td>NCT0320786</td>
<td>A Phase 2 Study of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0320786">https://ClinicalTrials.gov/show/NCT0320786</a></td>
</tr>
<tr>
<td>NCT0325772</td>
<td>Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0325772">https://ClinicalTrials.gov/show/NCT0325772</a></td>
</tr>
<tr>
<td>NCT0259312</td>
<td>Allogeneic Stem Cell Transplantation in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0259312">https://ClinicalTrials.gov/show/NCT0259312</a></td>
</tr>
<tr>
<td>NCT0289075</td>
<td>Phase I Trial of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0289075">https://ClinicalTrials.gov/show/NCT0289075</a></td>
</tr>
<tr>
<td>NCT0175981</td>
<td>Proteome-based Immunotherapy in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0175981">https://ClinicalTrials.gov/show/NCT0175981</a></td>
</tr>
<tr>
<td>NCT0257864</td>
<td>Multicentre, Open Label Trial of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>3</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0257864">https://ClinicalTrials.gov/show/NCT0257864</a></td>
</tr>
<tr>
<td>NCT0225651</td>
<td>Open Label Trial of Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>3</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0225651">https://ClinicalTrials.gov/show/NCT0225651</a></td>
</tr>
<tr>
<td>NCT0211194</td>
<td>Vaccine Therapy in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0211194">https://ClinicalTrials.gov/show/NCT0211194</a></td>
</tr>
<tr>
<td>NCT0174748</td>
<td>CD19 Redirected T Cells in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0174748">https://ClinicalTrials.gov/show/NCT0174748</a></td>
</tr>
<tr>
<td>NCT0231696</td>
<td>Decitabine, Epirubicin, and Cisplatin in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0231696">https://ClinicalTrials.gov/show/NCT0231696</a></td>
</tr>
<tr>
<td>NCT0306576</td>
<td>89Zr-labeled Pembrolizumab in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0306576">https://ClinicalTrials.gov/show/NCT0306576</a></td>
</tr>
<tr>
<td>NCT0282656</td>
<td>Trial of Stereotactic Radiosurgery in the Treatment of Patients With NSCLC</td>
<td>2</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0282656">https://ClinicalTrials.gov/show/NCT0282656</a></td>
</tr>
<tr>
<td>NCT0300319</td>
<td>Vaccination Therapy in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0300319">https://ClinicalTrials.gov/show/NCT0300319</a></td>
</tr>
<tr>
<td>NCT0241538</td>
<td>Typhoid Vaccine in the Treatment of Patients With NSCLC</td>
<td>1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0241538">https://ClinicalTrials.gov/show/NCT0241538</a></td>
</tr>
</tbody>
</table>
Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Consolidation Therapy in Patients With Metastatic Solid Malignancies

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

TCR-engineered T Cells in NSCLC and HNSCC Patients (ACTengine)

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

https://ClinicalTrials.gov/show/NCT02715882
https://ClinicalTrials.gov/show/NCT03152565
https://ClinicalTrials.gov/show/NCT01245673
https://ClinicalTrials.gov/show/NCT02030561
https://ClinicalTrials.gov/show/NCT03015922
https://ClinicalTrials.gov/show/NCT02030561
https://ClinicalTrials.gov/show/NCT01245673
https://ClinicalTrials.gov/show/NCT02499835
https://ClinicalTrials.gov/show/NCT03152565
https://ClinicalTrials.gov/show/NCT03262103
https://ClinicalTrials.gov/show/NCT00439465
https://ClinicalTrials.gov/show/NCT01536054
https://ClinicalTrials.gov/show/NCT03012100
https://ClinicalTrials.gov/show/NCT02705703
https://ClinicalTrials.gov/show/NCT02715882
713 NCT02770820 Combination
30 https://ClinicalTrials.gov/show/NCT02770820

712 NCT0273416 A Study of Ge:
37 https://ClinicalTrials.gov/show/NCT02734160

711 NCT0211716 SAFIR02_Lun
650 https://ClinicalTrials.gov/show/NCT02117167

710 NCT0180718 Tumor-Infiltr
13 https://ClinicalTrials.gov/show/NCT01807182

709 NCT0323688 Nonmyeloab
30 https://ClinicalTrials.gov/show/NCT03236883

708 NCT0173560 Genetically E
50 https://ClinicalTrials.gov/show/NCT01735604

707 NCT0069455 PSMA and TA
29 https://ClinicalTrials.gov/show/NCT00694551

706 NCT008841 PANVAC-V ar
51 https://ClinicalTrials.gov/show/NCT0088413

705 NCT0319205 Study of Pem
43 https://ClinicalTrials.gov/show/NCT03192059

704 NCT0262115 Pembrolizum
54 https://ClinicalTrials.gov/show/NCT02621151

703 NCT0126646 Vaccine Ther
67 https://ClinicalTrials.gov/show/NCT01266460

702 NCT0284012 Safety Study
10 https://ClinicalTrials.gov/show/NCT02840123

701 NCT0223693 Parenteral Ni
154 https://ClinicalTrials.gov/show/NCT02236936

700 NCT034086 Genetically E
12 https://ClinicalTrials.gov/show/NCT0340861

699 NCT0298987 Sorafenib and ni
18 https://ClinicalTrials.gov/show/NCT02989870

698 NCT0178395 Study of S-1 l
30 https://ClinicalTrials.gov/show/NCT01783951

697 NCT0248216 Study of the l
50 https://ClinicalTrials.gov/show/NCT02482168

696 NCT0178152 Study of S-1 l
30 https://ClinicalTrials.gov/show/NCT01781520

695 NCT0242386 In Situ, Autol
100 https://ClinicalTrials.gov/show/NCT02423863

694 NCT0229370 A Phase II Ra
120 https://ClinicalTrials.gov/show/NCT02293707

693 NCT0273848 A Study to Ev
36 https://ClinicalTrials.gov/show/NCT02738489

692 NCT0180104 Donor Stem l
35 https://ClinicalTrials.gov/show/NCT01801046

691 NCT0325634 A Safety Stuc
36 https://ClinicalTrials.gov/show/NCT03256344

690 NCT0249278 A Trial to Eva
24 https://ClinicalTrials.gov/show/NCT02492789

689 NCT0223763 Phase I Study
15 https://ClinicalTrials.gov/show/NCT02237638

688 NCT009662 Vaccine Ther
15 https://ClinicalTrials.gov/show/NCT0096629

687 NCT0236449 A Phase I Stu
30 https://ClinicalTrials.gov/show/NCT02364492

686 NCT0232389 Study of Kine
30 https://ClinicalTrials.gov/show/NCT02323893

685 NCT0242164 Phase II Trial
116 https://ClinicalTrials.gov/show/NCT02421640

684 NCT009378 Xenogeneic l
12 https://ClinicalTrials.gov/show/NCT0093783

683 NCT0308744 Ceritinib + Tr
69 https://ClinicalTrials.gov/show/NCT03087448

682 NCT0180007 A Phase Ib Tr
22 https://ClinicalTrials.gov/show/NCT01800071

681 NCT0215391 Vaccine Plus
27 https://ClinicalTrials.gov/show/NCT02153918

680 NCT000266 Biological Thc
84 https://ClinicalTrials.gov/show/NCT0002663

679 NCT0300630 Epacadostat,
70 https://ClinicalTrials.gov/show/NCT03006302

678 NCT0220836 Genetically N
100 https://ClinicalTrials.gov/show/NCT02208362

677 NCT0275436 A Toll-like Re
30 https://ClinicalTrials.gov/show/NCT02754362

676 NCT0319026 Study of CRS-
63 https://ClinicalTrials.gov/show/NCT03190265

675 NCT0316976 QUILT-3.047:
113 https://ClinicalTrials.gov/show/NCT03169764

674 NCT0261483 IMP321 as Ac
241 https://ClinicalTrials.gov/show/NCT02614833

673 NCT0166052 Multi-peptide
12 https://ClinicalTrials.gov/show/NCT01660529

672 NCT0284936 Combination
35 https://ClinicalTrials.gov/show/NCT02849366
174 NCT0267874 Multi-center 45 https://ClinicalTrials.gov/show/NCT0267874
175 NCT0217309 Activated T C 40 https://ClinicalTrials.gov/show/NCT0217309
176 NCT0271839 Complement 120 https://ClinicalTrials.gov/show/NCT0271839
177 NCT0311348 P53MVA and 28 https://ClinicalTrials.gov/show/NCT0311348
178 NCT0208738 HPV (Human 125 https://ClinicalTrials.gov/show/NCT0208738
179 NCT0322623 Vaccination \ 37 https://ClinicalTrials.gov/show/NCT0322623
180 NCT0306642 Study to Eval 23 https://ClinicalTrials.gov/show/NCT0306642
181 NCT0156789 CT Antigen Ti 10 https://ClinicalTrials.gov/show/NCT0156789
182 NCT0215144 ε±DC1 Vaccir 168 https://ClinicalTrials.gov/show/NCT0215144
183 NCT0134825 Study With D 58 https://ClinicalTrials.gov/show/NCT0134825
184 NCT030081 MUC1 Vaccir 50 https://ClinicalTrials.gov/show/NCT030081
185 NCT0242689 Nivolumab ai 34 https://ClinicalTrials.gov/show/NCT0242689
186 NCT0245784 HSV G207 Ak 18 https://ClinicalTrials.gov/show/NCT0245784
187 NCT0199719 Intrapleural / 19 https://ClinicalTrials.gov/show/NCT0199719
188 NCT0119255 Allogeneic T. 11 https://ClinicalTrials.gov/show/NCT0119255
189 NCT0235173 Study of the i 75 https://ClinicalTrials.gov/show/NCT0235173
190 NCT0029996 Gene Therap 18 https://ClinicalTrials.gov/show/NCT0029996
191 NCT0158267 Phase 3 Trial 450 https://ClinicalTrials.gov/show/NCT0158267
192 NCT0243945 A Study of Cc 100 https://ClinicalTrials.gov/show/NCT0243945
193 NCT0273325 Cellular Imm 70 https://ClinicalTrials.gov/show/NCT0273325
194 NCT0301782 VSV-hIFNbet 24 https://ClinicalTrials.gov/show/NCT0301782
195 NCT0302940 Phase 1 Stud 42 https://ClinicalTrials.gov/show/NCT0302940
196 NCT0303609 Study of Nivc 897 https://ClinicalTrials.gov/show/NCT0303609
197 NCT0308387 Study of LN-1 47 https://ClinicalTrials.gov/show/NCT0308387
198 NCT0283350 Sirolimus anc 12 https://ClinicalTrials.gov/show/NCT0283350
199 NCT0314832 Astra Zeneca 105 https://ClinicalTrials.gov/show/NCT0314832
200 NCT0167576 Safety and Ef 60 https://ClinicalTrials.gov/show/NCT0167576
201 NCT0169752 Gene and Vac 22 https://ClinicalTrials.gov/show/NCT0169752
202 NCT0303533 Dendritic Cel 44 https://ClinicalTrials.gov/show/NCT0303533
203 NCT0297715 Immunization 60 https://ClinicalTrials.gov/show/NCT0297715
204 NCT0043698 Vaccine Ther 66 https://ClinicalTrials.gov/show/NCT0043698
205 NCT0131101 Toll-like Rece 55 https://ClinicalTrials.gov/show/NCT0131101
206 NCT0245277 Autologous C 12 https://ClinicalTrials.gov/show/NCT0245277
207 NCT0316652 Neoadjuvant 35 https://ClinicalTrials.gov/show/NCT0316652
208 NCT0298906 MAGE-A10‡ 22 https://ClinicalTrials.gov/show/NCT0298906
209 NCT0283792 Comparing H 300 https://ClinicalTrials.gov/show/NCT0283792
210 NCT0050402 Topical Imiq 8 https://ClinicalTrials.gov/show/NCT0050402
211 NCT0244993 ZOSTAVAX in 60 https://ClinicalTrials.gov/show/NCT0244993
212 NCT0137329 Oral Lenalide 17 https://ClinicalTrials.gov/show/NCT0137329
213 NCT0283968 Anti-Mesoth 55 https://ClinicalTrials.gov/show/NCT0283968
214 NCT0291341 Yttrium90, Ip 18 https://ClinicalTrials.gov/show/NCT0291341
215 NCT0313279 AFP‡|ï ċ |à à à à 30 https://ClinicalTrials.gov/show/NCT0313279
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With ... eleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
MAGE A10‡¦Ï‰ á‰¦T for Advanced NSCLC
Vaccination of High Risk Breast Cancer Patients
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Anti-OX40 Antibody in Head and Neck Cancer Patients
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
HER2-Peptide Vaccination of Patients With Solid Tumors
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non-Muscle Invasive Bladder Cancer
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
ImmunoTEP α 68-Ga-IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Pembrolizumab in Advanced BRCA-mutated Breast Cancer
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
NY-ESO-1 T Cells in OG Cancer
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours
Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
<table>
<thead>
<tr>
<th>Trial Code</th>
<th>Title</th>
<th>Study URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02229084</td>
<td>Vaccination of High Risk Breast Cancer Patients</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02229084">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02798406</td>
<td>Phase 1 Trial of PAN-301-1 in Cancer Patients</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02798406">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02503150</td>
<td>Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02503150">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02535286</td>
<td>Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02535286">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT00960752</td>
<td>Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00960752">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02812524</td>
<td>FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02812524">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02876978</td>
<td>Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02876978">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01923116</td>
<td>Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01923116">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03274219</td>
<td>Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03274219">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02916979</td>
<td>Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02916979">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03328026</td>
<td>Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03328026">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03319459</td>
<td>Study of bb21217 in Multiple Myeloma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03319459">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02933255</td>
<td>Rollover Study of BriaVax in Combination With Ipilimumab or Pembrolizumab</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02933255">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01957956</td>
<td>Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01957956">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03190941</td>
<td>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03190941">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02937675</td>
<td>Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02937675">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03258008</td>
<td>Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03258008">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03275597</td>
<td>A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03275597">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03071923</td>
<td>Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03071923">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01983748</td>
<td>A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01983748">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02229084</td>
<td>BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02229084">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02799095</td>
<td>PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced pre-treated Malignant Pleural Mesothelioma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02799095">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03225664</td>
<td>Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03225664">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01342224</td>
<td>A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non-small Cell Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01342224">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02808363</td>
<td>Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02808363">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01876212</td>
<td>MAGE-A4‡¦Ïå_å¼å_å_T for Multi-Tumor</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01876212">ClinicalTrials.gov</a></td>
</tr>
</tbody>
</table>
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer

Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Investigator Initiated Phase 1 Study of TBI-1201

Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma

A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

REO13 Melanoma With or Without GM-CSF Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma

Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML

https://ClinicalTrials.gov/show/NCT03196830
https://ClinicalTrials.gov/show/NCT02609386
https://ClinicalTrials.gov/show/NCT02619253
https://ClinicalTrials.gov/show/NCT02521870
https://ClinicalTrials.gov/show/NCT03027128
https://ClinicalTrials.gov/show/NCT01178281
https://ClinicalTrials.gov/show/NCT03086954
https://ClinicalTrials.gov/show/NCT02844699
https://ClinicalTrials.gov/show/NCT02933073
https://ClinicalTrials.gov/show/NCT02999646
https://ClinicalTrials.gov/show/NCT01625260
https://ClinicalTrials.gov/show/NCT02750995
https://ClinicalTrials.gov/show/NCT01625260
https://ClinicalTrials.gov/show/NCT03299309
https://ClinicalTrials.gov/show/NCT03277482
https://ClinicalTrials.gov/show/NCT03180034
https://ClinicalTrials.gov/show/NCT02950259
https://ClinicalTrials.gov/show/NCT02559024
https://ClinicalTrials.gov/show/NCT03828188
https://ClinicalTrials.gov/show/NCT02117024
https://ClinicalTrials.gov/show/NCT02172911
https://ClinicalTrials.gov/show/NCT00442130
https://ClinicalTrials.gov/show/NCT02117024
https://ClinicalTrials.gov/show/NCT02343211
https://ClinicalTrials.gov/show/NCT02750995
https://ClinicalTrials.gov/show/NCT02559024
https://ClinicalTrials.gov/show/NCT03088059
https://ClinicalTrials.gov/show/NCT02096614
https://ClinicalTrials.gov/show/NCT02366546
https://ClinicalTrials.gov/show/NCT02203825
https://ClinicalTrials.gov/show/NCT00788164
https://ClinicalTrials.gov/show/NCT02999646
https://ClinicalTrials.gov/show/NCT02933073
https://ClinicalTrials.gov/show/NCT02844699
https://ClinicalTrials.gov/show/NCT03086954
https://ClinicalTrials.gov/show/NCT01178281
https://ClinicalTrials.gov/show/NCT03027128
https://ClinicalTrials.gov/show/NCT03080974
https://ClinicalTrials.gov/show/NCT02521870
https://ClinicalTrials.gov/show/NCT02619253
https://ClinicalTrials.gov/show/NCT03029611
https://ClinicalTrials.gov/show/NCT02609386
https://ClinicalTrials.gov/show/NCT01995344
https://ClinicalTrials.gov/show/NCT02871115
https://ClinicalTrials.gov/show/NCT03196830
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Novel Autologous CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL)
FDG-PET/CT Imaging as Early Predictor of DP
The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma
A Study of GPC3-targeted T Cells by Intratumor Injection forAdvanced HCC (GPC3-CART)
µT for Advanced NSCLC
NY-ESO-1‡¶¥
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane in Patients With Advanced Solid Tumors
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
FASTER-Tlalpan Study
Selinexor Treatment of Refractory Myeloma
Multi-centric Study
to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
924 NCT03043594 Ipilimumab + 52 https://ClinicalTrials.gov/show/NCT03043599
925 NCT03123787 CD40 Agonist 99 https://ClinicalTrials.gov/show/NCT03123783
926 NCT02664363 EGFRvIII CAR 48 https://ClinicalTrials.gov/show/NCT02664363
927 NCT01183899 3F8/GM-CSF 31 https://ClinicalTrials.gov/show/NCT01183897
928 NCT02624250 Pilot Study of 10 https://ClinicalTrials.gov/show/NCT02624258
929 NCT01183888 3F8/GM-CSF 63 https://ClinicalTrials.gov/show/NCT01183884
930 NCT03029333 CD19 CAR T Cells 10 https://ClinicalTrials.gov/show/NCT03029338
931 NCT03296554 Valganciclovir 38 https://ClinicalTrials.gov/show/NCT03296553
932 NCT03326753 Phase 1b Dosing 80 https://ClinicalTrials.gov/show/NCT03326752
933 NCT02768555 Cisplatin and 660 https://ClinicalTrials.gov/show/NCT02768558
934 NCT03173951 Immune Checkpoint 180 https://ClinicalTrials.gov/show/NCT03173950
935 NCT02302333 A Study of Gl 120 https://ClinicalTrials.gov/show/NCT02302339
936 NCT02987164 HDCRT Plus F 21 https://ClinicalTrials.gov/show/NCT02987166
937 NCT03189181 Phase-I Trial 21 https://ClinicalTrials.gov/show/NCT03189186
938 NCT03042791 Vaccination 10 https://ClinicalTrials.gov/show/NCT03042793
939 NCT02844063 Pilot Study of 20 https://ClinicalTrials.gov/show/NCT02844062
940 NCT02030834 Phase Ila Stud 57 https://ClinicalTrials.gov/show/NCT02030834
941 NCT01856923 GI-6207 for A 37 https://ClinicalTrials.gov/show/NCT01856920
942 NCT03084389 Anti-GPC3 CA 20 https://ClinicalTrials.gov/show/NCT03084380
943 NCT02775291 Gene-Modified 12 https://ClinicalTrials.gov/show/NCT02775292
944 NCT02549833 Neo-adjuvant 30 https://ClinicalTrials.gov/show/NCT02549833
945 NCT02631448 Sequential Cs 230 https://ClinicalTrials.gov/show/NCT02631447
946 NCT02842131 Autologous C 25 https://ClinicalTrials.gov/show/NCT02842138
947 NCT02562754 Hepatocellular 600 https://ClinicalTrials.gov/show/NCT02562755
948 NCT03101709 The Safety ar 30 https://ClinicalTrials.gov/show/NCT03101709
949 NCT01588014 Vaccine Ther 36 https://ClinicalTrials.gov/show/NCT01588015
950 NCT02849146 Evaluation In 60 https://ClinicalTrials.gov/show/NCT02849145
951 NCT02396134 Vaccine Ther 96 https://ClinicalTrials.gov/show/NCT02396134
952 NCT03146533 CD19 CART C 20 https://ClinicalTrials.gov/show/NCT03146533
953 NCT01274626 Study of REO 32 https://ClinicalTrials.gov/show/NCT01274624
954 NCT01966800 Photodynamic 30 https://ClinicalTrials.gov/show/NCT01966809
955 NCT02709618 Personalized 20 https://ClinicalTrials.gov/show/NCT02709616
956 NCT03050554 Stereotactic I 56 https://ClinicalTrials.gov/show/NCT03050554
957 NCT03228666 QUILT-3.055: 105 https://ClinicalTrials.gov/show/NCT03228667
958 NCT02070404 Gene-Modified 12 https://ClinicalTrials.gov/show/NCT02070406
959 NCT02528682 MiHA-loaded 10 https://ClinicalTrials.gov/show/NCT02528682
960 NCT02982722 Evaluating Cc 44 https://ClinicalTrials.gov/show/NCT02982720
961 NCT00801320 Primary Tum 100 https://ClinicalTrials.gov/show/NCT00801320
962 NCT02432968 Vaccine Ther 19 https://ClinicalTrials.gov/show/NCT02432963
963 NCT0311333 A Study of DS 84 https://ClinicalTrials.gov/show/NCT03113334
964 NCT02944397 Study of Velip 192 https://ClinicalTrials.gov/show/NCT02944396
965 NCT03064854 PDR001 in Cc 170 https://ClinicalTrials.gov/show/NCT03064854
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Durvalumab in Pediatric and Adolescent Patients

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Nivolumab in Treatment of Bladder Cancer (MIBC) Undergoing Cystectomy

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Immunomonitoring of Children With Neuroblastoma

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Combination of Rituximab and NK Immunotherapy for B Lymphoma
1008 NCT0148294 A Rollover Pr 2 https://ClinicalTrials.gov/show/NCT01482949
1009 NCT0137021 NK Cell Basec 25 https://ClinicalTrials.gov/show/NCT01370213
1010 NCT0291777 Tailored Imm 200 https://ClinicalTrials.gov/show/NCT02917772
1011 NCT0270548 A Study to Ev 404 https://ClinicalTrials.gov/show/NCT02705482
1012 NCT0132687 A Study of Al 90 https://ClinicalTrials.gov/show/NCT01326871
1013 NCT0303693 Recombinant 180 https://ClinicalTrials.gov/show/NCT03036930
1014 NCT0283896 Preoperative 20 https://ClinicalTrials.gov/show/NCT02838966
1015 NCT0290518 Glypican 3-sp 14 https://ClinicalTrials.gov/show/NCT02905188
1016 NCT0316222 Safety and Ef 40 https://ClinicalTrials.gov/show/NCT03162224
1017 NCT0204558 A Phase I Do: 18 https://ClinicalTrials.gov/show/NCT02045589
1018 NCT0186290 Stereotactic I 14 https://ClinicalTrials.gov/show/NCT01862900
1019 NCT0320481 Tremelimum 27 https://ClinicalTrials.gov/show/NCT03204812
1020 NCT0268694 A Study to Ev 12 https://ClinicalTrials.gov/show/NCT02686944
1021 NCT0120932 Vaccine Ther 149 https://ClinicalTrials.gov/show/NCT01209325
1022 NCT0280784 Phase Ibl/Ill St 196 https://ClinicalTrials.gov/show/NCT02807844
1023 NCT0277162 Study CB-83S 242 https://ClinicalTrials.gov/show/NCT02771626
1024 NCT0290391 Arginase Inhi 236 https://ClinicalTrials.gov/show/NCT02903914
1025 NCT0331061 A Safety and 50 https://ClinicalTrials.gov/show/NCT03310619
1026 NCT0280566 Phase 1/2 St 119 https://ClinicalTrials.gov/show/NCT02805660
1027 NCT0252835 GSK3174998 264 https://ClinicalTrials.gov/show/NCT02528357
1028 NCT0264958 Adjuvant Der 20 https://ClinicalTrials.gov/show/NCT02649582
1029 NCT0278791 DC1s-CTL Cel 50 https://ClinicalTrials.gov/show/NCT02787915
1030 NCT0282058 A Phase I Stu 20 https://ClinicalTrials.gov/show/NCT02820584
1031 NCT0063423 A Phase I Stu 12 https://ClinicalTrials.gov/show/NCT00634231
1032 NCT0271064 "MIRO" Mole 110 https://ClinicalTrials.gov/show/NCT02710643
1033 NCT0196775 Phase I Study 11 https://ClinicalTrials.gov/show/NCT01967758
1034 NCT0236134 PK, PD, Safet 40 https://ClinicalTrials.gov/show/NCT02361346
1035 NCT0288108 Optimization 900 https://ClinicalTrials.gov/show/NCT02881086
1036 NCT0231506 Study Of OX4 210 https://ClinicalTrials.gov/show/NCT02315066
1037 NCT0163638 Allogeneic St 45 https://ClinicalTrials.gov/show/NCT01636388
1038 NCT0230161 Phase IIB TL 120 https://ClinicalTrials.gov/show/NCT02301611
1039 NCT0131614 Administratio 10 https://ClinicalTrials.gov/show/NCT01316146
1040 NCT0299908 Randomized 688 https://ClinicalTrials.gov/show/NCT02999087
1041 NCT0259603 An Investigati 150 https://ClinicalTrials.gov/show/NCT02596035
1042 NCT0135110 A Study of LG 170 https://ClinicalTrials.gov/show/NCT01351103
1043 NCT0237669 Safety Study 290 https://ClinicalTrials.gov/show/NCT02376699
1044 NCT0220937 Autologous T 12 https://ClinicalTrials.gov/show/NCT02209376
1045 NCT0311350 Brentuximab 40 https://ClinicalTrials.gov/show/NCT03113500
1046 NCT0302978 An Investigat 100 https://ClinicalTrials.gov/show/NCT03029780
1047 NCT0257650 An Investigat 726 https://ClinicalTrials.gov/show/NCT02576509
1048 NCT0205744 3rd Party LM 18 https://ClinicalTrials.gov/show/NCT02057445
1049 NCT0108729 Administrati 126 https://ClinicalTrials.gov/show/NCT01087294
<table>
<thead>
<tr>
<th>Trial Number</th>
<th>Study Title</th>
<th>Details/Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01530269</td>
<td>C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01530269" alt="link" /></td>
</tr>
<tr>
<td>NCT02498665</td>
<td>A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02498665" alt="link" /></td>
</tr>
<tr>
<td>NCT03167164</td>
<td>Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03167164" alt="link" /></td>
</tr>
<tr>
<td>NCT03169790</td>
<td>Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03169790" alt="link" /></td>
</tr>
<tr>
<td>NCT02728102</td>
<td>QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02728102" alt="link" /></td>
</tr>
<tr>
<td>NCT01209871</td>
<td>Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01209871" alt="link" /></td>
</tr>
<tr>
<td>NCT02900666</td>
<td>Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02900666" alt="link" /></td>
</tr>
<tr>
<td>NCT02531854</td>
<td>High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02531854" alt="link" /></td>
</tr>
<tr>
<td>NCT02122820</td>
<td>A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With Ipilimumab As a Monotherapy or in Combination With Ipilimumab in the First-line Treatment of Advanced HCC</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02122820" alt="link" /></td>
</tr>
<tr>
<td>NCT03175707</td>
<td>Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03175707" alt="link" /></td>
</tr>
<tr>
<td>NCT02523313</td>
<td>A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02523313" alt="link" /></td>
</tr>
<tr>
<td>NCT01902329</td>
<td>Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01902329" alt="link" /></td>
</tr>
<tr>
<td>NCT03071094</td>
<td>A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03071094" alt="link" /></td>
</tr>
<tr>
<td>NCT02506111</td>
<td>A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02506111" alt="link" /></td>
</tr>
<tr>
<td>NCT02079024</td>
<td>Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02079024" alt="link" /></td>
</tr>
<tr>
<td>NCT01183416</td>
<td>Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01183416" alt="link" /></td>
</tr>
<tr>
<td>NCT01530260</td>
<td>Integrating Primary &amp; Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01530260" alt="link" /></td>
</tr>
<tr>
<td>NCT03215810</td>
<td>QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03215810" alt="link" /></td>
</tr>
<tr>
<td>NCT01959760</td>
<td>Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01959760" alt="link" /></td>
</tr>
<tr>
<td>NCT02870244</td>
<td>Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ë-¿-glucan for High-Risk Neuroblastoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02870244" alt="link" /></td>
</tr>
<tr>
<td>NCT02902029</td>
<td>Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02902029" alt="link" /></td>
</tr>
<tr>
<td>NCT02122822</td>
<td>A Safety Study of SGN-CD33A in AML Patients</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02122822" alt="link" /></td>
</tr>
<tr>
<td>NCT00968760</td>
<td>TG4010 and Nivolumab in Patients With Lung Cancer</td>
<td><img src="https://ClinicalTrials.gov/show/NCT00968760" alt="link" /></td>
</tr>
<tr>
<td>NCT03208556</td>
<td>CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03208556" alt="link" /></td>
</tr>
<tr>
<td>NCT02424916</td>
<td>Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study</td>
<td><img src="https://ClinicalTrials.gov/show/NCT02424916" alt="link" /></td>
</tr>
<tr>
<td>NCT03325100</td>
<td>A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma</td>
<td><img src="https://ClinicalTrials.gov/show/NCT03325100" alt="link" /></td>
</tr>
<tr>
<td>NCT01902329</td>
<td>An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself</td>
<td><img src="https://ClinicalTrials.gov/show/NCT01902329" alt="link" /></td>
</tr>
<tr>
<td>Trial Title</td>
<td>Study ID</td>
<td>URL</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma</td>
<td>NCT02672527</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02672527">https://ClinicalTrials.gov/show/NCT02672527</a></td>
</tr>
<tr>
<td>A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma</td>
<td>NCT02916771</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02916771">https://ClinicalTrials.gov/show/NCT02916771</a></td>
</tr>
<tr>
<td>Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer</td>
<td>NCT03143985</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03143985">https://ClinicalTrials.gov/show/NCT03143985</a></td>
</tr>
<tr>
<td>Durvalumab in DLBCL After Autologous Transplant</td>
<td>NCT02808143</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02808143">https://ClinicalTrials.gov/show/NCT02808143</a></td>
</tr>
<tr>
<td>Expressing Personalized Tumor Antigens Study</td>
<td>NCT02650999</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02650999">https://ClinicalTrials.gov/show/NCT02650999</a></td>
</tr>
<tr>
<td>A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma</td>
<td>NCT02272855</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02272855">https://ClinicalTrials.gov/show/NCT02272855</a></td>
</tr>
<tr>
<td>CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma</td>
<td>NCT02149225</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02149225">https://ClinicalTrials.gov/show/NCT02149225</a></td>
</tr>
<tr>
<td>Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells</td>
<td>NCT02686372</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02686372">https://ClinicalTrials.gov/show/NCT02686372</a></td>
</tr>
<tr>
<td>Study of Anti-telomerase T CD4 Immunity in Melanoma</td>
<td>NCT00257738</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00257738">https://ClinicalTrials.gov/show/NCT00257738</a></td>
</tr>
<tr>
<td>Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)</td>
<td>NCT03181100</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03181100">https://ClinicalTrials.gov/show/NCT03181100</a></td>
</tr>
<tr>
<td>A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)</td>
<td>NCT02838433</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02838433">https://ClinicalTrials.gov/show/NCT02838433</a></td>
</tr>
<tr>
<td>Vemurafenib and TIL Therapy for Metastatic Melanoma</td>
<td>NCT03197025</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03197025">https://ClinicalTrials.gov/show/NCT03197025</a></td>
</tr>
<tr>
<td>A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma</td>
<td>NCT03241017</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03241017">https://ClinicalTrials.gov/show/NCT03241017</a></td>
</tr>
<tr>
<td>GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients</td>
<td>NCT03265080</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03265080">https://ClinicalTrials.gov/show/NCT03265080</a></td>
</tr>
<tr>
<td>Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma</td>
<td>NCT03153085</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03153085">https://ClinicalTrials.gov/show/NCT03153085</a></td>
</tr>
<tr>
<td>Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas</td>
<td>NCT03118180</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03118180">https://ClinicalTrials.gov/show/NCT03118180</a></td>
</tr>
<tr>
<td>Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma</td>
<td>NCT03149003</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03149003">https://ClinicalTrials.gov/show/NCT03149003</a></td>
</tr>
<tr>
<td>TEW-7197 in Combination w/Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma</td>
<td>NCT03242603</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03242603">https://ClinicalTrials.gov/show/NCT03242603</a></td>
</tr>
<tr>
<td>Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas</td>
<td>NCT03118180</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03118180">https://ClinicalTrials.gov/show/NCT03118180</a></td>
</tr>
<tr>
<td>CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma</td>
<td>NCT03294083</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03294083">https://ClinicalTrials.gov/show/NCT03294083</a></td>
</tr>
<tr>
<td>A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma</td>
<td>NCT0317751</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0317751">https://ClinicalTrials.gov/show/NCT0317751</a></td>
</tr>
</tbody>
</table>
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Racotumomab in Patients With High-risk Neuroblastoma

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Cytokine-induced Killer Study for Patients With Stage II Melanoma

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

_T Cells in Subjects With Advanced Myxoid/Round Cell Liposarcoma

A Pilot Study of NY-ESO-1‡‡§\_‰

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN

A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

PVSRIPO for Recurrent Glioblastoma (GBM)

A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma

Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma

Safety and Efficacy of Immune Therapy for Condyloma

TIL Therapy for Metastatic Renal Cell Carcinoma

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

T Cells in Subjects With Advanced Myxoid/Round Cell Liposarcoma

A Phase 1 Study of NCT02340975
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301 Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations MK-3475 and Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Small Cell Lung Cancer (NSCLC) Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer PD-1 Brain Collaboration for Patients With Melanoma Brain Metastases VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lines Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT) Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) Study of Safety and Efficacy of C-CAR011 in B-NHL Patients
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Local Definitive Radiotherapy in Synchronous Oligometastatic Non-small-cell Lung Cancer

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Response-based Treatment of High-risk Neuroblastoma

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy

Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Renal Adjuvant MultiPle Arm Randomised Trial

Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease

Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer

1259 NCT0259221 Treatment of 10 https://ClinicalTrials.gov/show/NCT02592213
1219 NCT0172516 Study Assesses 94 https://ClinicalTrials.gov/show/NCT01725165
1220 NCT0271627 Nivolumab N 125 https://ClinicalTrials.gov/show/NCT02716272
1221 NCT0278747 A Study of Pe 54 https://ClinicalTrials.gov/show/NCT02787473
1222 NCT0297685 A Phase 1 Stu 15 https://ClinicalTrials.gov/show/NCT02976857
1223 NCT0242496 CD8+ Memo 40 https://ClinicalTrials.gov/show/NCT02424968
1224 NCT0276347 NK Cells as Ci 35 https://ClinicalTrials.gov/show/NCT02763475
1225 NCT0204544 Maintenance 29 https://ClinicalTrials.gov/show/NCT02045446
1226 NCT0183562 Phase II Stud 24 https://ClinicalTrials.gov/show/NCT01835626
1227 NCT0213635 A Phase II Tri 40 https://ClinicalTrials.gov/show/NCT02136355
1228 NCT0046653 Treatment of 50 https://ClinicalTrials.gov/show/NCT00466531
1229 NCT0176061 Huaier Granu 1680 https://ClinicalTrials.gov/show/NCT01760616
1230 NCT0193271 A Feasibility ' 50 https://ClinicalTrials.gov/show/NCT01932710
1231 NCT0244609 Neoadjuvant 44 https://ClinicalTrials.gov/show/NCT02446093
1232 NCT0171060 Medico-econ 819 https://ClinicalTrials.gov/show/NCT01710605
1233 NCT0290154 Phase 2 Durv 34 https://ClinicalTrials.gov/show/NCT02901548
1234 NCT0270640 JCAR014 and 42 https://ClinicalTrials.gov/show/NCT02706405
1235 NCT0210093 Anti-GD2 3F8 125 https://ClinicalTrials.gov/show/NCT02100930
1236 NCT0316143 SX-682 Treat 77 https://ClinicalTrials.gov/show/NCT03161431
1237 NCT0251981 Continuous A 25 https://ClinicalTrials.gov/show/NCT02519816
1238 NCT0079041 Haploidenter 15 https://ClinicalTrials.gov/show/NCT00790413
1239 NCT0328853 Renal Adjuva 1750 https://ClinicalTrials.gov/show/NCT03288532
1240 NCT0057697 Intensity-Mo 87 https://ClinicalTrials.gov/show/NCT00576979
1241 NCT0055136 Stereotactic I 33 https://ClinicalTrials.gov/show/NCT00551369
1242 NCT0227403 Serial [18F]Tl 30 https://ClinicalTrials.gov/show/NCT02274038
1243 NCT0179908 Lower Dose I 100 https://ClinicalTrials.gov/show/NCT01799083
1244 NCT0264514 Molecular Pr 1000 https://ClinicalTrials.gov/show/NCT02645149
1245 NCT0266234 T Cell Mediat 6 https://ClinicalTrials.gov/show/NCT02662348
1246 NCT0313777 Maintenance 300 https://ClinicalTrials.gov/show/NCT03137771
1247 NCT0182265 3rd Generati 11 https://ClinicalTrials.gov/show/NCT01822652
1248 NCT0160266 Chemotherapy 247 https://ClinicalTrials.gov/show/NCT01602666
1249 NCT0161911 DETECT III - A 120 https://ClinicalTrials.gov/show/NCT01619111
1250 NCT0326783 Neoadjuvant 12 https://ClinicalTrials.gov/show/NCT03267836
1251 NCT0330544 Nivolumab/İp 13 https://ClinicalTrials.gov/show/NCT03305445
1252 NCT0120706 Adaptive Rad 40 https://ClinicalTrials.gov/show/NCT01207063
1253 NCT0163693 Minocycline ' 40 https://ClinicalTrials.gov/show/NCT01636934
1254 NCT0277174 Response-ba 54 https://ClinicalTrials.gov/show/NCT02771743
1255 NCT0262042 Study of Pem 9 https://ClinicalTrials.gov/show/NCT02620423
1256 NCT0178174 Stereotactic I 10 https://ClinicalTrials.gov/show/NCT01781741
1257 NCT0248426 Monitoring a 50 https://ClinicalTrials.gov/show/NCT02484261
1258 NCT0311951 Local Definiti 590 https://ClinicalTrials.gov/show/NCT03119519
1259 NCT0259945 Atezolizumab 33 https://ClinicalTrials.gov/show/NCT02599454
1260 NCT0065306 Combination
1261 NCT0056654 Ph 2 Intensifi
1262 NCT0228237 Cetuximab +
1263 NCT0154514 Chemokine-
1264 NCT0226232 Hypofraction
1265 NCT0267801 RFA+Highly-
1266 NCT0270907 Resection+Hi
1267 NCT0182687 Autologous E
1268 NCT0182453 Transmission
1269 NCT0170094 Therapy for F
1270 NCT0299518 Study of Apa'
1271 NCT0004310 Combination
1272 NCT0185468 Photodynam
1273 NCT0263380 Patritumab V
1274 NCT0189098 Phase II Stud
1275 NCT0114037 Adoptive Tra
1276 NCT0054099 Busulfan, Eto
1277 NCT0258952 VX-970 and V
1278 NCT0297655 The Influence
1279 NCT0293541 18F-FDG Met
1280 NCT0104923 Proton Beam
1281 NCT0269699 Trial of Nivol
1282 NCT0263104 Study Evaluat
1283 NCT0256874 Evaluation of
1284 NCT0214128 A Phase 2 Op
1285 NCT0329876 Targeted Ste
1286 NCT0203160 Intercalated 
1287 NCT0295033 Stereotactic I
1288 NCT0047528 "Geriatric As:
1289 NCT0280553 Radical Treat
1290 NCT0152322 Donor Periph
1291 NCT0321707 Pembrolizum
1292 NCT0271984 Additive Valu
1293 NCT0092081 Axitinib (AG-1
1294 NCT0265496 Cancer Stem
1295 NCT0195146 Gefitinib Wit
1296 NCT0342121 Trial of Thera
1297 NCT006871 Donor Lymph
1298 NCT0024870 Secondary Ac
1299 NCT0124675 Haematopoë
1300 NCT0191262 Trametinib, C
1301 NCT0303882 Study of Leul

https://ClinicalTrials.gov/show/NCT00653068
https://ClinicalTrials.gov/show/NCT00566540
https://ClinicalTrials.gov/show/NCT02282371
https://ClinicalTrials.gov/show/NCT01545141
https://ClinicalTrials.gov/show/NCT02262325
https://ClinicalTrials.gov/show/NCT02678013
https://ClinicalTrials.gov/show/NCT02709070
https://ClinicalTrials.gov/show/NCT01826877
https://ClinicalTrials.gov/show/NCT01824537
https://ClinicalTrials.gov/show/NCT01700946
https://ClinicalTrials.gov/show/NCT02995187
https://ClinicalTrials.gov/show/NCT00043108
https://ClinicalTrials.gov/show/NCT01854684
https://ClinicalTrials.gov/show/NCT02633800
https://ClinicalTrials.gov/show/NCT01890980
https://ClinicalTrials.gov/show/NCT01140373
https://ClinicalTrials.gov/show/NCT00540995
https://ClinicalTrials.gov/show/NCT02589522
https://ClinicalTrials.gov/show/NCT02976558
https://ClinicalTrials.gov/show/NCT02935416
https://ClinicalTrials.gov/show/NCT01049230
https://ClinicalTrials.gov/show/NCT02696993
https://ClinicalTrials.gov/show/NCT02631044
https://ClinicalTrials.gov/show/NCT02568748
https://ClinicalTrials.gov/show/NCT02141282
https://ClinicalTrials.gov/show/NCT03298763
https://ClinicalTrials.gov/show/NCT02031601
https://ClinicalTrials.gov/show/NCT02950337
https://ClinicalTrials.gov/show/NCT00475280
https://ClinicalTrials.gov/show/NCT02805530
https://ClinicalTrials.gov/show/NCT01523223
https://ClinicalTrials.gov/show/NCT03217071
https://ClinicalTrials.gov/show/NCT02719847
https://ClinicalTrials.gov/show/NCT00920816
https://ClinicalTrials.gov/show/NCT02654964
https://ClinicalTrials.gov/show/NCT01951469
https://ClinicalTrials.gov/show/NCT03042182
https://ClinicalTrials.gov/show/NCT0068718
https://ClinicalTrials.gov/show/NCT0248703
https://ClinicalTrials.gov/show/NCT01246752
https://ClinicalTrials.gov/show/NCT01912625
https://ClinicalTrials.gov/show/NCT03038828
1302 NCT0163113 Strategies for 932 https://ClinicalTrials.gov/show/NCT01631136
1303 NCT0296010 mHealth Inte 100 https://ClinicalTrials.gov/show/NCT02960100
1304 NCT0226874 Efficacy and 43 https://ClinicalTrials.gov/show/NCT02268747
1305 NCT0060184 Photodynam 9 https://ClinicalTrials.gov/show/NCT00601848
1306 NCT0055346 Carboplatin ε 78 https://ClinicalTrials.gov/show/NCT00553462
1307 NCT0273704 Belinostat Th 20 https://ClinicalTrials.gov/show/NCT02737046
1308 NCT0154243 Treatment W 66 https://ClinicalTrials.gov/show/NCT01542437
1309 NCT0203864 Phase 2 Stud 178 https://ClinicalTrials.gov/show/NCT02038647
1310 NCT0077799 Auto-Allo Tar 221 https://ClinicalTrials.gov/show/NCT00777998
1311 NCT0203581 DETECT IV - A 520 https://ClinicalTrials.gov/show/NCT02035813
1312 NCT0275983 Local Ablative 100 https://ClinicalTrials.gov/show/NCT02759835
1313 NCT0306881 Cytokine Indi 24 https://ClinicalTrials.gov/show/NCT03068819
1314 NCT0248799 The Study of 1200 https://ClinicalTrials.gov/show/NCT02487992
1315 NCT0296023 H3.3K27M Pe 29 https://ClinicalTrials.gov/show/NCT02960230
1316 NCT0063285 Radiation Th 729
1317 NCT0170471 High Risk Ne 2700 https://ClinicalTrials.gov/show/NCT01704716
1318 NCT0245463 Phase I Trial 39 https://ClinicalTrials.gov/show/NCT02454634
1319 NCT0301333 Nivolumab in 450 https://ClinicalTrials.gov/show/NCT03013335
1320 NCT0087590 Proton Thera 23 https://ClinicalTrials.gov/show/NCT00875901
1321 NCT0294613 Phase II Trial 44 https://ClinicalTrials.gov/show/NCT02946138
1322 NCT0134585 Image-Guide 45 https://ClinicalTrials.gov/show/NCT01345851
1323 NCT0292137 Tracking Peri 12 https://ClinicalTrials.gov/show/NCT02921373
1324 NCT0180185 Autologous N 300 https://ClinicalTrials.gov/show/NCT01801852
1325 NCT0299985 Safety and Ef 195 https://ClinicalTrials.gov/show/NCT02999854
1326 NCT0182249 Erlotinib Hyd 234 https://ClinicalTrials.gov/show/NCT01822496
1327 NCT0275679 Stereotactic I 54 https://ClinicalTrials.gov/show/NCT02756793
1328 NCT0248501 The Study of 80 https://ClinicalTrials.gov/show/NCT02485015
1329 NCT0231877 Radiation Th 40 https://ClinicalTrials.gov/show/NCT02318771
1330 NCT0278077 Apatinib Plus 20 https://ClinicalTrials.gov/show/NCT02780778
1331 NCT0248989 CIK in Treatin 1500 https://ClinicalTrials.gov/show/NCT02489890
1332 NCT0323586 Radiation Th 19 https://ClinicalTrials.gov/show/NCT03235869
1333 NCT0167844 Monoclonal 2 https://ClinicalTrials.gov/show/NCT01678443
1334 NCT0250435 Combination 24 https://ClinicalTrials.gov/show/NCT02504359
1335 NCT0183669 Isotoxic Inter 38 https://ClinicalTrials.gov/show/NCT01836692
1336 NCT0210126 Efficacy of M 156 https://ClinicalTrials.gov/show/NCT02101268
1337 NCT0238379 Immunodefici 5 https://ClinicalTrials.gov/show/NCT02383797
1338 NCT0292228 IL2 Imaging in 30 https://ClinicalTrials.gov/show/NCT02922283
1339 NCT0179913 Feasibility Stu 20 https://ClinicalTrials.gov/show/NCT01799135
1340 NCT0255444 Detection of 80 https://ClinicalTrials.gov/show/NCT02554448
1341 NCT0263846 Allogeneic St 20 https://ClinicalTrials.gov/show/NCT02638467
1342 NCT0175562 Effect of TTFi 18 https://ClinicalTrials.gov/show/NCT01755624
1343 NCT0217284 Hypofraction 23 https://ClinicalTrials.gov/show/NCT02172846
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma

Trial of CMB305 and Atezolizumab in Patients With Sarcoma

Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Aging Mammary Stem Cells and Breast Cancer Prevention

A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

Temozolomide as Maintenance Therapy in Small Cell Lung Cancer

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

13845 NCT01979211 Post-operative Therapy
13846 NCT0159506 Radiation Therapy
13847 NCT0244180 Allogeneic HSCT
13848 NCT0219277 UARK 2014-2
13849 NCT0322315 Evaluate Con
13850 NCT0250751 Role of PET Scans
13851 NCT0290615 Thymosin Alpha 1
13852 NCT0321904 The EXPLORE
13853 NCT0323382 Pre-Treatment
13854 NCT0149848 Therapeutic I
13855 NCT0195837 Radiation Therapy
13856 NCT0064331 CytokineR
13857 NCT0262359 A Study of SBRT
13858 NCT0049052 Phase 1-2 of
13859 NCT0148097 Stereotactic I
13860 NCT0287545 Apatinib as a standalone treatment
13861 NCT0149441 Concurrent N
13862 NCT0269640 Efficacy of Pr
13863 NCT0270140 Tremelimumum
13864 NCT0190095 Temozolomide
13865 NCT0074145 Chemotherapy
13866 NCT0185974 A Phase 1b/2
13867 NCT0070382 Clofarabine F
13868 NCT0264209 Aging Mammary
13869 NCT0304631 Local Therapy
13870 NCT0096497 Effectiveness
13871 NCT0260998 Trial of CMB305
13872 NCT0079495 Bacillus Calmette-Guerin
13873 NCT0190945 Study Comparison
13874 NCT0319686 the Study of
13875 NCT0104406 Precursor BC
13876 NCT0079214 Bortezomib,
13877 NCT0189229 CT Antigen Ti
13878 NCT0253532 Methoxyamoll
13879 NCT0279385 PD-1 Knockout
13880 NCT0329994 Feasibility an
13881 NCT0247812 Pilot Study of
13882 NCT0259287 Treatment St
13883 NCT0105955 Treatment of
13884 NCT0097921 Chemotherapy
13885 NCT0298844 Study of Safe
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin Lymphoma

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JS001 for Patients With Recurrent Malignant Lymphoma

Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

GRASPA Treatment for Patients With Acute Myeloblastic Leukemia

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin alone for Patients With Stage IV Non-Small Cell Lung Cancer Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE).

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
1428 NCT0240292 A Phase I Trial of Entavir & 80 https://ClinicalTrials.gov/show/NCT02402920
1429 NCT0231436 A Trial of Integra & 30 https://ClinicalTrials.gov/show/NCT02314364
1430 NCT0295189 Application of 120 https://ClinicalTrials.gov/show/NCT02951897
1431 NCT0177041 A Phase I/II S 61 https://ClinicalTrials.gov/show/NCT01770418
1432 NCT0138638 Veliparib Wint & 162 https://ClinicalTrials.gov/show/NCT01386385
1433 NCT0258200 Bupropion H 60 https://ClinicalTrials.gov/show/NCT02582008
1434 NCT0162535 A Study of CE 23 https://ClinicalTrials.gov/show/NCT01625351
1435 NCT0332728 C-CAR011 Tr 40 https://ClinicalTrials.gov/show/NCT03327285
1436 NCT0257522 Study of Neo 30 https://ClinicalTrials.gov/show/NCT02575222
1437 NCT0102053 Allogeneic St & 18 https://ClinicalTrials.gov/show/NCT01020539
1438 NCT0298073 A Study Evalu & 200 https://ClinicalTrials.gov/show/NCT02980731
1439 NCT0278254 Cytokine Indi 60 https://ClinicalTrials.gov/show/NCT02782546
1440 NCT0238495 QUILT-3.002: 86 https://ClinicalTrials.gov/show/NCT02384954
1441 NCT0154867 Efficacy Stud & 2175 https://ClinicalTrials.gov/show/NCT01548677
1442 NCT0267010 Autologous H 20 https://ClinicalTrials.gov/show/NCT02670109
1443 NCT0200418 Pemetrexed i 765 https://ClinicalTrials.gov/show/NCT02004184
1444 NCT0263500 Whole-Brain 304 https://ClinicalTrials.gov/show/NCT02635009
1445 NCT0309181 Dynamic Peri 7 https://ClinicalTrials.gov/show/NCT03091816
1446 NCT0308171 PD-1 Knocko 21 https://ClinicalTrials.gov/show/NCT03081715
1447 NCT0069666 O6-Benzylgu 24 https://ClinicalTrials.gov/show/NCT00696669
1448 NCT0233473 A Comparison 50 https://ClinicalTrials.gov/show/NCT02334735
1449 NCT0133663 Study of Sele 174 https://ClinicalTrials.gov/show/NCT01336634
1450 NCT0175028 Assess Efficac 212 https://ClinicalTrials.gov/show/NCT01750281
1451 NCT0240936 An Open-Lab 800 https://ClinicalTrials.gov/show/NCT02409368
1452 NCT0292403 A Study of Vâ 30 https://ClinicalTrials.gov/show/NCT02924038
1453 NCT0297378 Effect of Turn 512 https://ClinicalTrials.gov/show/NCT02973789
1454 NCT0052070 3-Dimension: 168 https://ClinicalTrials.gov/show/NCT00520702
1455 NCT0194652 Therapeutic â 24 https://ClinicalTrials.gov/show/NCT01946529
1456 NCT0267456 Study of Rovi 339 https://ClinicalTrials.gov/show/NCT02674568
1457 NCT0106492 Ph I Vorinost 38 https://ClinicalTrials.gov/show/NCT01064921
1458 NCT0183991 Donor T Cells 56 https://ClinicalTrials.gov/show/NCT01839916
1459 NCT0204948 A Study of IC 20 https://ClinicalTrials.gov/show/NCT02049489
1460 NCT0058905 Nelfinavir, Ra 55 https://ClinicalTrials.gov/show/NCT00589056
1461 NCT0222968 Mild-dose IM 40 https://ClinicalTrials.gov/show/NCT02229682
1462 NCT0308893 Evaluating Cr 18 https://ClinicalTrials.gov/show/NCT03088930
1463 NCT0219328 Erlotinib Hyd 450 https://ClinicalTrials.gov/show/NCT02193286
1464 NCT0207864 Safety and Ef 74 https://ClinicalTrials.gov/show/NCT02078648
1465 NCT0303351 A Study of Re 740 https://ClinicalTrials.gov/show/NCT03033511
1466 NCT0332254 Pembrolizum 588 https://ClinicalTrials.gov/show/NCT03322540
1467 NCT0164040 Study of 5-Fl 350 https://ClinicalTrials.gov/show/NCT01640405
1468 NCT0000304 Chemothera 60 https://ClinicalTrials.gov/show/NCT00003042
1469 NCT0310087 Melphalan, T 63 https://ClinicalTrials.gov/show/NCT03100877

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment to Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Effect of Tumor Treating Fields (TTFields) (150 kHz) as Second Line Treatment of Non-small Cell Lung Cancer in Combination With PD-1 Inhibitors or Docetaxel (LUNAR)

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non-Small Cell Lung Cancer Treatment.

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Have Lost a Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer

A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or ... eir Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor

Whole-body Radiation Therapy With or Without Intrathecal Methotrexate in Treating Patients With Metastatic Brain Cancer
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

A Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) Surgery for Non-Small Cell Lung Cancer (NSCLC) Following Definitive Surgical Resection

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

https://ClinicalTrials.gov/show/NCT03100955
https://ClinicalTrials.gov/show/NCT02862678
https://ClinicalTrials.gov/show/NCT01851200
https://ClinicalTrials.gov/show/NCT03138070
https://ClinicalTrials.gov/show/NCT02840994
https://ClinicalTrials.gov/show/NCT02445248
https://ClinicalTrials.gov/show/NCT01851200
https://ClinicalTrials.gov/show/NCT02862678
https://ClinicalTrials.gov/show/NCT01044745
https://ClinicalTrials.gov/show/NCT03100955
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment

A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy

Depletion of Myeloid DerivedSuppressor Cells to Enhance Anti-PD-1 Therapy

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

CIK in Treating Patients With Esophageal Cancer

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors

Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Interferon for the Therapy of Minimal Residual Disease

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-small Cell Lung Cancer Progressing After at Least One Prior Therapy for Metastatic Disease

Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-small Cell Lung Cancer

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL

A Phase I/II Trial of Stereotactic Body Radiation Therapy MPDL3280A-treatment-IST-UMCG

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

A Phase I/II Study of NEDAP-001 or 1068 in Combination With Pembrolizumab for Patients With Advanced Melanoma and Glioblastoma Multiforme Who Have Failed Current Standard Therapies (TITAN-002)

A Phase 2 Study of Protafin for the Treatment of Infection in anemic Critically Ill Patients (TITAN-001)

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-small Cell Lung Cancer Progressing After at Least One Prior Therapy for Metastatic Disease

Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-small Cell Lung Cancer

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL

A Phase I/II Trial of Stereotactic Body Radiation Therapy MPDL3280A-treatment-IST-UMCG

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

A Phase I/II Study of NEDAP-001 or 1068 in Combination With Pembrolizumab for Patients With Advanced Melanoma and Glioblastoma Multiforme Who Have Failed Current Standard Therapies (TITAN-002)

A Phase 2 Study of Protafin for the Treatment of Infection in anemic Critically Ill Patients (TITAN-001)

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-small Cell Lung Cancer Progressing After at Least One Prior Therapy for Metastatic Disease

Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-small Cell Lung Cancer

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL

A Phase I/II Trial of Stereotactic Body Radiation Therapy MPDL3280A-treatment-IST-UMCG

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

A Phase I/II Study of NEDAP-001 or 1068 in Combination With Pembrolizumab for Patients With Advanced Melanoma and Glioblastoma Multiforme Who Have Failed Current Standard Therapies (TITAN-002)

A Phase 2 Study of Protafin for the Treatment of Infection in anemic Critically Ill Patients (TITAN-001)

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-small Cell Lung Cancer Progressing After at Least One Prior Therapy for Metastatic Disease

Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-small Cell Lung Cancer

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
1596 NCT0257216 A Study of Br... 93 https://ClinicalTrials.gov/show/NCT02572167
1597 NCT0294204 Bevacizumab... 87 https://ClinicalTrials.gov/show/NCT02942043
1598 NCT0251934 A Study of M... 440 https://ClinicalTrials.gov/show/NCT02519348
1599 NCT0321570 A Study of Ni... 420 https://ClinicalTrials.gov/show/NCT03215706
1600 NCT0257010 Research anc... 100 https://ClinicalTrials.gov/show/NCT02570100
1601 NCT0268849 A CpG-methy... 300 https://ClinicalTrials.gov/show/NCT02688491
1602 NCT0296894 Avelumab W... 43 https://ClinicalTrials.gov/show/NCT02968940
1603 NCT0330463 Pembrolizum... 96 https://ClinicalTrials.gov/show/NCT03304639
1604 NCT0264109 Phase II Trial... 80 https://ClinicalTrials.gov/show/NCT02641093
1605 NCT0225279 Phase I Hypo... 18 https://ClinicalTrials.gov/show/NCT02252796
1606 NCT0211650 Anti-Biopharm... 156 https://ClinicalTrials.gov/show/NCT02116504
1607 NCT0309682 Extended An... 98 https://ClinicalTrials.gov/show/NCT03096821
1608 NCT0327017 A Dose-Findi... 61 https://ClinicalTrials.gov/show/NCT03270176
1609 NCT0305086 Cabazitaxel i... 100 https://ClinicalTrials.gov/show/NCT03050866
1610 NCT0250055 Safety and Ef... 15 https://ClinicalTrials.gov/show/NCT02500550
1611 NCT0251356 AZD1775 Plu... 60 https://ClinicalTrials.gov/show/NCT02513563
1612 NCT0301809 A Phase I Stu... 20 https://ClinicalTrials.gov/show/NCT03018093
1613 NCT0131235 Neoadjuvant... 40 https://ClinicalTrials.gov/show/NCT01312350
1614 NCT0077434 A Study to Ev... 317 https://ClinicalTrials.gov/show/NCT00774345
1615 NCT0260950 Pembrolizum... 29 https://ClinicalTrials.gov/show/NCT02609503
1616 NCT0128710 A Phase I Stu... 34 https://ClinicalTrials.gov/show/NCT01287104
1617 NCT0208742 A Global Stuc... 444 https://ClinicalTrials.gov/show/NCT02087423
1618 NCT0019376 Elective vs Th... 710 https://ClinicalTrials.gov/show/NCT00193765
1619 NCT0185647 LUX-Head&N... 340 https://ClinicalTrials.gov/show/NCT01856478
1620 NCT0249382 B7.1/IL-2 Leu... 10 https://ClinicalTrials.gov/show/NCT02493829
1621 NCT0130604 Molecular Pr... 600 https://ClinicalTrials.gov/show/NCT01306045
1622 NCT0190177 The Parents i... 624 https://ClinicalTrials.gov/show/NCT01901770
1623 NCT0319246 TAA Specific... 45 https://ClinicalTrials.gov/show/NCT03192462
1624 NCT0010717 Surgery With... 224 https://ClinicalTrials.gov/show/NCT00107172
1625 NCT0125639 Dasatinib Fol... 66 https://ClinicalTrials.gov/show/NCT01256398
1626 NCT0328887 A Study of Ef... 218 https://ClinicalTrials.gov/show/NCT03288870
1627 NCT0315252 CD3/CD19 De... 41 https://ClinicalTrials.gov/show/NCT03152526
1628 NCT0255564 A Study of Pr... 70 https://ClinicalTrials.gov/show/NCT02555644
1629 NCT0236076 Surgical Trea... 339 https://ClinicalTrials.gov/show/NCT02360761
1630 NCT0258826 A Study of A$... 530 https://ClinicalTrials.gov/show/NCT02588261
1631 NCT0332766 Utilising CTC... 1178 https://ClinicalTrials.gov/show/NCT03327662
1632 NCT0162949 Intensity-Mo... 100 https://ClinicalTrials.gov/show/NCT01629498
1633 NCT0150170 Caspofungin... 55 https://ClinicalTrials.gov/show/NCT01501708
1634 NCT0318475 Intervention... 100 https://ClinicalTrials.gov/show/NCT03184753
1635 NCT0318052 Topical Reme... 30 https://ClinicalTrials.gov/show/NCT03180528
1636 NCT0215198 AZD9291 Ver... 419 https://ClinicalTrials.gov/show/NCT02151981
1637 NCT0312507 Self-Manager... 2650 https://ClinicalTrials.gov/show/NCT03125070
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>ClinicalTrials.gov Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0171221</td>
<td>A Study of A1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01712217">https://ClinicalTrials.gov/show/NCT01712217</a></td>
</tr>
<tr>
<td>NCT0235372</td>
<td>Stem Cell Mc</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02353728">https://ClinicalTrials.gov/show/NCT02353728</a></td>
</tr>
<tr>
<td>NCT0308092</td>
<td>High Dose Dc</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03080922">https://ClinicalTrials.gov/show/NCT03080922</a></td>
</tr>
<tr>
<td>NCT0000817</td>
<td>Radiolabeled</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00008177">https://ClinicalTrials.gov/show/NCT00008177</a></td>
</tr>
<tr>
<td>NCT0210554</td>
<td>Genomic Seq</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02105545">https://ClinicalTrials.gov/show/NCT02105545</a></td>
</tr>
<tr>
<td>NCT0322422</td>
<td>Apatinib Cor</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03224221">https://ClinicalTrials.gov/show/NCT03224221</a></td>
</tr>
<tr>
<td>NCT0247850</td>
<td>Testis CAB: C</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02478502">https://ClinicalTrials.gov/show/NCT02478502</a></td>
</tr>
<tr>
<td>NCT0293450</td>
<td>Study of Pem</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02934503">https://ClinicalTrials.gov/show/NCT02934503</a></td>
</tr>
<tr>
<td>NCT0007885</td>
<td>Mycophenolic</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00078858">https://ClinicalTrials.gov/show/NCT00078858</a></td>
</tr>
<tr>
<td>NCT0055320</td>
<td>Donor Stem</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00553202">https://ClinicalTrials.gov/show/NCT00553202</a></td>
</tr>
<tr>
<td>NCT0229708</td>
<td>Next-generation</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02297087">https://ClinicalTrials.gov/show/NCT02297087</a></td>
</tr>
<tr>
<td>NCT0261944</td>
<td>Concurrent C</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02619448">https://ClinicalTrials.gov/show/NCT02619448</a></td>
</tr>
<tr>
<td>NCT0328541</td>
<td>CDK 4/6 Inh herein</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03285412">https://ClinicalTrials.gov/show/NCT03285412</a></td>
</tr>
<tr>
<td>NCT0246802</td>
<td>JolT-Ca Subl</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02468024">https://ClinicalTrials.gov/show/NCT02468024</a></td>
</tr>
<tr>
<td>NCT0185727</td>
<td>Erlotinib Hyd</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01857271">https://ClinicalTrials.gov/show/NCT01857271</a></td>
</tr>
<tr>
<td>NCT0278428</td>
<td>Phase II Treas</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02784288">https://ClinicalTrials.gov/show/NCT02784288</a></td>
</tr>
<tr>
<td>NCT0235901</td>
<td>Pembrolizum</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02359019">https://ClinicalTrials.gov/show/NCT02359019</a></td>
</tr>
<tr>
<td>NCT0217816</td>
<td>Comprehensive</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02178163">https://ClinicalTrials.gov/show/NCT02178163</a></td>
</tr>
<tr>
<td>NCT0033481</td>
<td>Combination</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00334815">https://ClinicalTrials.gov/show/NCT00334815</a></td>
</tr>
<tr>
<td>NCT0094545</td>
<td>Stereotactic I</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00945451">https://ClinicalTrials.gov/show/NCT00945451</a></td>
</tr>
<tr>
<td>NCT0310796</td>
<td>Treatment of</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03107962">https://ClinicalTrials.gov/show/NCT03107962</a></td>
</tr>
<tr>
<td>NCT0292663</td>
<td>S1400E Lung</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0292663">https://ClinicalTrials.gov/show/NCT0292663</a></td>
</tr>
<tr>
<td>NCT0324548</td>
<td>Pembrolizum</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03245489">https://ClinicalTrials.gov/show/NCT03245489</a></td>
</tr>
<tr>
<td>NCT0164225</td>
<td>Cisplatin and</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01642251">https://ClinicalTrials.gov/show/NCT01642251</a></td>
</tr>
<tr>
<td>NCT0305006</td>
<td>Image Guided</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03050060">https://ClinicalTrials.gov/show/NCT03050060</a></td>
</tr>
<tr>
<td>NCT0188462</td>
<td>Phase III Trial</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01884623">https://ClinicalTrials.gov/show/NCT01884623</a></td>
</tr>
<tr>
<td>NCT0197514</td>
<td>Validity of HE</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01975142">https://ClinicalTrials.gov/show/NCT01975142</a></td>
</tr>
<tr>
<td>NCT0262945</td>
<td>A Study to De</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02629458">https://ClinicalTrials.gov/show/NCT02629458</a></td>
</tr>
<tr>
<td>NCT0224038</td>
<td>Predicting De</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02240381">https://ClinicalTrials.gov/show/NCT02240381</a></td>
</tr>
<tr>
<td>NCT0080519</td>
<td>LUME-Lung 1</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00805194">https://ClinicalTrials.gov/show/NCT00805194</a></td>
</tr>
<tr>
<td>NCT0231600</td>
<td>Phase II Stud</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02316002">https://ClinicalTrials.gov/show/NCT02316002</a></td>
</tr>
<tr>
<td>NCT0308571</td>
<td>Targeting PD</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03085719">https://ClinicalTrials.gov/show/NCT03085719</a></td>
</tr>
<tr>
<td>NCT0263026</td>
<td>E10A for the</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02630264">https://ClinicalTrials.gov/show/NCT02630264</a></td>
</tr>
<tr>
<td>NCT0329396</td>
<td>Therapeutic</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03293966">https://ClinicalTrials.gov/show/NCT03293966</a></td>
</tr>
<tr>
<td>NCT0170895</td>
<td>Erlotinib Hyd</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01708954">https://ClinicalTrials.gov/show/NCT01708954</a></td>
</tr>
<tr>
<td>NCT0140782</td>
<td>Erlotinib Vers</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01407822">https://ClinicalTrials.gov/show/NCT01407822</a></td>
</tr>
<tr>
<td>NCT0324022</td>
<td>Bioinformatics</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03240224">https://ClinicalTrials.gov/show/NCT03240224</a></td>
</tr>
<tr>
<td>NCT0184172</td>
<td>Ibrutinib in T</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01841723">https://ClinicalTrials.gov/show/NCT01841723</a></td>
</tr>
<tr>
<td>NCT0303278</td>
<td>A Two Step A</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03032783">https://ClinicalTrials.gov/show/NCT03032783</a></td>
</tr>
<tr>
<td>NCT0215823</td>
<td>Stereotactic I</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02158234">https://ClinicalTrials.gov/show/NCT02158234</a></td>
</tr>
<tr>
<td>NCT0250335</td>
<td>Selumetinib</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02503358">https://ClinicalTrials.gov/show/NCT02503358</a></td>
</tr>
<tr>
<td>NCT0302987</td>
<td>Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03029871">https://ClinicalTrials.gov/show/NCT03029871</a></td>
</tr>
</tbody>
</table>
Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non-Small Cell Lung Cancer

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non-Small Cell Lung Cancer

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies.

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1-Expressing Malignancies

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non-squamous Non-small Cell Lung Cancer

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)


Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

Bioinformation Therapy for Pancreatic Cancer

Bioinformation Therapy for Liver Cancer

https://ClinicalTrials.gov/show/NCT02274337
https://ClinicalTrials.gov/show/NCT01451268
https://ClinicalTrials.gov/show/NCT03297593
https://ClinicalTrials.gov/show/NCT01640444
https://ClinicalTrials.gov/show/NCT02888743
https://ClinicalTrials.gov/show/NCT02566993
https://ClinicalTrials.gov/show/NCT00209209
https://ClinicalTrials.gov/show/NCT03169335
https://ClinicalTrials.gov/show/NCT02206334
https://ClinicalTrials.gov/show/NCT03048500
https://ClinicalTrials.gov/show/NCT02633188
https://ClinicalTrials.gov/show/NCT02540824
https://ClinicalTrials.gov/show/NCT02206333
https://ClinicalTrials.gov/show/NCT03169335
https://ClinicalTrials.gov/show/NCT0245765
https://ClinicalTrials.gov/show/NCT00209209
https://ClinicalTrials.gov/show/NCT03084471
https://ClinicalTrials.gov/show/NCT02566993
https://ClinicalTrials.gov/show/NCT00910910
https://ClinicalTrials.gov/show/NCT02888743
https://ClinicalTrials.gov/show/NCT01640444
https://ClinicalTrials.gov/show/NCT03262948
https://ClinicalTrials.gov/show/NCT01627379
https://ClinicalTrials.gov/show/NCT03297593
https://ClinicalTrials.gov/show/NCT01451268
https://ClinicalTrials.gov/show/NCT02274337
https://ClinicalTrials.gov/show/NCT01374841
https://ClinicalTrials.gov/show/NCT03146468
<table>
<thead>
<tr>
<th>NCT</th>
<th>Title</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00955942</td>
<td>Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00955942">https://ClinicalTrials.gov/show/NCT00955942</a></td>
</tr>
<tr>
<td>NCT02226861</td>
<td>NCT02456246 Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02226861">https://ClinicalTrials.gov/show/NCT02226861</a></td>
</tr>
<tr>
<td>NCT02843074</td>
<td>NCT03014648 Topical Itraconazole in Treating Patients With Basal Cell Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02843074">https://ClinicalTrials.gov/show/NCT02843074</a></td>
</tr>
<tr>
<td>NCT01059188</td>
<td>NCT01088802 A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01059188">https://ClinicalTrials.gov/show/NCT01059188</a></td>
</tr>
<tr>
<td>NCT02760667</td>
<td>NCT02446860 Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02760667">https://ClinicalTrials.gov/show/NCT02760667</a></td>
</tr>
<tr>
<td>NCT01119066</td>
<td>NCT01025453 Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01119066">https://ClinicalTrials.gov/show/NCT01119066</a></td>
</tr>
<tr>
<td>NCT02893189</td>
<td>NCT02295540 Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02893189">https://ClinicalTrials.gov/show/NCT02893189</a></td>
</tr>
<tr>
<td>NCT00867529</td>
<td>NCT0233616 Phase 2 Study of Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00867529">https://ClinicalTrials.gov/show/NCT00867529</a></td>
</tr>
<tr>
<td>NCT0283842</td>
<td>NCT0255115 Phase III Ope</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0283842">https://ClinicalTrials.gov/show/NCT0283842</a></td>
</tr>
<tr>
<td>NCT00619879</td>
<td>NCT01025453 Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00619879">https://ClinicalTrials.gov/show/NCT00619879</a></td>
</tr>
<tr>
<td>NCT01059188</td>
<td>NCT01088802 A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01059188">https://ClinicalTrials.gov/show/NCT01059188</a></td>
</tr>
<tr>
<td>NCT02760667</td>
<td>NCT02446860 Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02760667">https://ClinicalTrials.gov/show/NCT02760667</a></td>
</tr>
<tr>
<td>NCT01119066</td>
<td>NCT01025453 Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01119066">https://ClinicalTrials.gov/show/NCT01119066</a></td>
</tr>
<tr>
<td>NCT00867529</td>
<td>NCT0233616 Phase 2 Study of Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00867529">https://ClinicalTrials.gov/show/NCT00867529</a></td>
</tr>
</tbody>
</table>
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA (N2) Non-Small Cell Lung Cancer

A Phase III Trial of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma

VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma

S1400A Lung-Map: MEDI4736 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Phase I/II Study of Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

SABR for T1-2a N1 NSCLC

A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer

Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer

Nanoscale Artificial Nose in Monitoring Response and Detecting Recurrence After Surgery or Radiation Therapy in Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/Pomalidomide/Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

1764 NCT01745585 Autologous S 23 https://ClinicalTrials.gov/show/NCT01745588
1765 NCT02452464 Nintedanib C 99 https://ClinicalTrials.gov/show/NCT02452463
1766 NCT02535339 Erlotinib Hyd 46 https://ClinicalTrials.gov/show/NCT02535338
1767 NCT00856388 Fludarabine f 62 https://ClinicalTrials.gov/show/NCT00856388
1768 NCT0259096 A Clinical Tri 91 https://ClinicalTrials.gov/show/NCT02590965
1769 NCT03070000 Denosumab i 42 https://ClinicalTrials.gov/show/NCT03070002
1770 NCT00690964 Individual Bo 12 https://ClinicalTrials.gov/show/NCT00690963
1771 NCT01840159 Nanoscale Ar 35 https://ClinicalTrials.gov/show/NCT01840150
1772 NCT02405366 Front-line Th 46 https://ClinicalTrials.gov/show/NCT02405364
1773 NCT02410382 Dexamethas 80 https://ClinicalTrials.gov/show/NCT02410382
1774 NCT02616393 Study of Tes 60 https://ClinicalTrials.gov/show/NCT02616393
1775 NCT03289299 Aggressive Sr 80 https://ClinicalTrials.gov/show/NCT03289299
1776 NCT02722946 Panobinostat 30 https://ClinicalTrials.gov/show/NCT02722941
1777 NCT02741570 Study of Niv 700 https://ClinicalTrials.gov/show/NCT02741570
1778 NCT01198020 Study of Erl 33 https://ClinicalTrials.gov/show/NCT01198028
1779 NCT02709720 Locally Advar 67 https://ClinicalTrials.gov/show/NCT02709720
1780 NCT00053359 Surgery and l 302 https://ClinicalTrials.gov/show/NCT00053352
1781 NCT02073966 PET-Adjusted 39 https://ClinicalTrials.gov/show/NCT02073968
1782 NCT02027428 Safety and Ef 426 https://ClinicalTrials.gov/show/NCT02027428
1783 NCT03269344 Gabapentin f 60 https://ClinicalTrials.gov/show/NCT03269344
1784 NCT02119555 Circulating Ti 115 https://ClinicalTrials.gov/show/NCT02119559
1785 NCT02898116 A Study of Al 32 https://ClinicalTrials.gov/show/NCT02898116
1786 NCT01599750 Adjuvant Axil 700 https://ClinicalTrials.gov/show/NCT01599754
1787 NCT03321674 SABR for T1- 24 https://ClinicalTrials.gov/show/NCT03321670
1788 NCT00941720 Busulfan, Cyc 71 https://ClinicalTrials.gov/show/NCT00941720
1789 NCT00003145 Fludarabine f 18 https://ClinicalTrials.gov/show/NCT00003145
1790 NCT00003199 Low-Dose To 63 https://ClinicalTrials.gov/show/NCT00003196
1791 NCT02949700 Phase I/II Stu 32 https://ClinicalTrials.gov/show/NCT02949700
1792 NCT02507154 Reactivating 31 https://ClinicalTrials.gov/show/NCT02507154
1793 NCT01208661 Randomized 660 https://ClinicalTrials.gov/show/NCT01208662
1794 NCT00049517 Combination 657 https://ClinicalTrials.gov/show/NCT00049517
1795 NCT02766331 S1400A Lung 100 https://ClinicalTrials.gov/show/NCT02766331
1796 NCT02567422 VX-970, Cispl 45 https://ClinicalTrials.gov/show/NCT02567422
1797 NCT02570893 A Phase III Tr 366 https://ClinicalTrials.gov/show/NCT02570893
1798 NCT01235962 A Study to Ev 1540 https://ClinicalTrials.gov/show/NCT01235962
1799 NCT02085149 A Phase I Do 77 https://ClinicalTrials.gov/show/NCT02085149
1800 NCT00765973 Topotecan Li 50 https://ClinicalTrials.gov/show/NCT00765973
1801 NCT00856037 Topotecan HCl 30 https://ClinicalTrials.gov/show/NCT00856037
1802 NCT02638099 Pembrolizumab and 100 https://ClinicalTrials.gov/show/NCT02638099
1803 NCT02348001 Phase Ib and 61 https://ClinicalTrials.gov/show/NCT02348008
1804 NCT02974426 To Evaluate t 1094 https://ClinicalTrials.gov/show/NCT02974426
1805 NCT02223611 Clinical Obs 100 https://ClinicalTrials.gov/show/NCT02223611
1806 NCT0180297 Safety and Bl 20 https://ClinicalTrials.gov/show/NCT01802970
1807 NCT0264486 Autologous T 60 https://ClinicalTrials.gov/show/NCT02644863
1808 NCT0212470 Weekly Carbi 38 https://ClinicalTrials.gov/show/NCT02124707
1809 NCT0072179 F-18 Fluorode 33 https://ClinicalTrials.gov/show/NCT00721799
1810 NCT0004084 Alemtuzumab 60 https://ClinicalTrials.gov/show/NCT00040846
1811 NCT0290074 Clinical Study 100 https://ClinicalTrials.gov/show/NCT02900742
1812 NCT0075663 Prophylactic 30 https://ClinicalTrials.gov/show/NCT00756639
1813 NCT0158930 PCI-32765 (It 78 https://ClinicalTrials.gov/show/NCT01589302
1814 NCT0237520 Standard-Do: 420 https://ClinicalTrials.gov/show/NCT02375204
1815 NCT0233316 Intensity Mod 30 https://ClinicalTrials.gov/show/NCT02333162
1816 NCT0272870 Sirolimus anc 9 https://ClinicalTrials.gov/show/NCT02728700
1817 NCT0224023 Combination 182 https://ClinicalTrials.gov/show/NCT02240238
1818 NCT0270662 Trial of Brigal 40 https://ClinicalTrials.gov/show/NCT02706626
1819 NCT0222540 Induction Stu 45 https://ClinicalTrials.gov/show/NCT02225405
1820 NCT0035756 Hematopoiet 20 https://ClinicalTrials.gov/show/NCT00357565
1821 NCT0241159 A Study of Ne 70 https://ClinicalTrials.gov/show/NCT02411591
1822 NCT0260977 A Dose Escal 90 https://ClinicalTrials.gov/show/NCT02609776
1823 NCT0243785 Surgery in Tr 56 https://ClinicalTrials.gov/show/NCT02437851
1824 NCT0191310 HSV-tk + Val 25 https://ClinicalTrials.gov/show/NCT01913106
1825 NCT0178233 A Novel Singl 43 https://ClinicalTrials.gov/show/NCT01782339
1826 NCT0184213 Vaccine Ther 36 https://ClinicalTrials.gov/show/NCT01842139
1827 NCT0321816 MEDI-551 as 36 https://ClinicalTrials.gov/show/NCT03218163
1828 NCT0312906 Study to Eval 24 https://ClinicalTrials.gov/show/NCT03129061
1829 NCT0256779 BIO 300 Non- 36 https://ClinicalTrials.gov/show/NCT02567799
1830 NCT0324039 Study of Oral 192 https://ClinicalTrials.gov/show/NCT03240393
1831 NCT0224374 Palliative Car 385 https://ClinicalTrials.gov/show/NCT02243748
1832 NCT0315812 Study Of Indi 66 https://ClinicalTrials.gov/show/NCT03158129
1833 NCT0086017 Iodine I 131 I 16 https://ClinicalTrials.gov/show/NCT00860171
1834 NCT0254965 MEDI4736 Al 207 https://ClinicalTrials.gov/show/NCT02549651
1835 NCT0190993 Study of Brer 45 https://ClinicalTrials.gov/show/NCT01909934
1836 NCT0229612 AZD9291 Ver 674 https://ClinicalTrials.gov/show/NCT02296125
1837 NCT0085702 Beta-Glucan 20 https://ClinicalTrials.gov/show/NCT00857025
1838 NCT0268400 A Study of Av 830 https://ClinicalTrials.gov/show/NCT02684006
1839 NCT0105003 Autologous T 39 https://ClinicalTrials.gov/show/NCT01050036
1840 NCT0127072 Gemcitabine, 28 https://ClinicalTrials.gov/show/NCT01270724
1841 NCT0226200 Phase II Imag 40 https://ClinicalTrials.gov/show/NCT02262000
1842 NCT0273872 SBRT Compa 50 https://ClinicalTrials.gov/show/NCT02738723
1843 NCT0321066 Pembrolizum 70 https://ClinicalTrials.gov/show/NCT03210662
1844 NCT0279051 Provision of 18 https://ClinicalTrials.gov/show/NCT02790515
1845 NCT0198217 Phase II Clin i 120 https://ClinicalTrials.gov/show/NCT01982175
1846 NCT0273770 Paclitaxel De' 120 https://ClinicalTrials.gov/show/NCT02737709
1847 NCT0002782 Total-Body Ir 106 https://ClinicalTrials.gov/show/NCT00027820
1848  NCT0102871 Donor Periph  50 https://ClinicalTrials.gov/show/NCT01028716
1849  NCT0251046 Apatinib as N  48 https://ClinicalTrials.gov/show/NCT02510469
1850  NCT0184133 PF-04449913  28 https://ClinicalTrials.gov/show/NCT01841333
1851  NCT0318817 MUK Nine b:  95 https://ClinicalTrials.gov/show/NCT03188172
1852  NCT0313120 A Study of Al  78 https://ClinicalTrials.gov/show/NCT03131206
1853  NCT0181847 Phase I/II Stu  24 https://ClinicalTrials.gov/show/NCT01818479
1854  NCT0182319 Natural Killer  72 https://ClinicalTrials.gov/show/NCT01823198
1855  NCT0198295 Tepotinib Wi  70 https://ClinicalTrials.gov/show/NCT01982955
1856  NCT0249256 Pembrolizum  74 https://ClinicalTrials.gov/show/NCT02492568
1857  NCT0143039 In Vitro Expa  12 https://ClinicalTrials.gov/show/NCT01430390
1858  NCT0250422 DC-CIK In Cor  80 https://ClinicalTrials.gov/show/NCT02504229
1859  NCT0128837 Empirical Ver  556 https://ClinicalTrials.gov/show/NCT01288378
1860  NCT0269972 Arsenic Triox  5 https://ClinicalTrials.gov/show/NCT02699723
1861  NCT0258469 Study of Ster  40 https://ClinicalTrials.gov/show/NCT02584699
1862  NCT0205034 Activated T L:  40 https://ClinicalTrials.gov/show/NCT02050347
1863  NCT0040800 Combination  1895 https://ClinicalTrials.gov/show/NCT00408005
1864  NCT0324226 Measuremen  200 https://ClinicalTrials.gov/show/NCT03242265
1865  NCT0328829 Therapeutic I  4 https://ClinicalTrials.gov/show/NCT03288298
1866  NCT0304099 Study of Pem  780 https://ClinicalTrials.gov/show/NCT03040999
1867  NCT0119018 Safety Evaluat  600 https://ClinicalTrials.gov/show/NCT01190189
1868  NCT0287206 Treatment of  40 https://ClinicalTrials.gov/show/NCT02872064
1869  NCT0125157 Sirolimus, Cy  80 https://ClinicalTrials.gov/show/NCT01251575
1870  NCT0328653 Ruxolitinib +  64 https://ClinicalTrials.gov/show/NCT03286530
1871  NCT0285208 A Trial With I  86 https://ClinicalTrials.gov/show/NCT02852083
1872  NCT0192822 Randomized,  180 https://ClinicalTrials.gov/show/NCT01928225
1873  NCT0200822 A Study of At  1225 https://ClinicalTrials.gov/show/NCT02008227
1874  NCT0245801 Study of Blin:  40 https://ClinicalTrials.gov/show/NCT02458014
1875  NCT0218380 Chemothera:  30 https://ClinicalTrials.gov/show/NCT02183805
1876  NCT0105301 Open-Label F  60 https://ClinicalTrials.gov/show/NCT01053013
1877  NCT0198268 Allogeneic He  41 https://ClinicalTrials.gov/show/NCT01982682
1878  NCT0125266 Clofarabine a  44 https://ClinicalTrials.gov/show/NCT01252667
1879  NCT0204617 Nonrandomi:  120 https://ClinicalTrials.gov/show/NCT02046174
1880  NCT006042 Fludarabine I  40 https://ClinicalTrials.gov/show/NCT0060424
1881  NCT0286227 Atezolizumab  40 https://ClinicalTrials.gov/show/NCT02862275
1882  NCT0154417 A Study of IR  265 https://ClinicalTrials.gov/show/NCT01544179
1883  NCT0218684 Chemothera:  168 https://ClinicalTrials.gov/show/NCT02186847
1884  NCT0067523 Photodynamic  29 https://ClinicalTrials.gov/show/NCT00675233
1885  NCT0298476 Veterans Aff:  670 https://ClinicalTrials.gov/show/NCT02984761
1886  NCT0154564 Pilot Study tc  45 https://ClinicalTrials.gov/show/NCT01545648
1887  NCT0163073 A Multinatio:  700 https://ClinicalTrials.gov/show/NCT01630733
1888  NCT0091500 Trial of Imag  250 https://ClinicalTrials.gov/show/NCT00915005
1889  NCT0295258 Study To Con  640 https://ClinicalTrials.gov/show/NCT02952586
1990 NCT0191042 L-asparaginase 24 https://ClinicalTrials.gov/show/NCT01910428
1991 NCT0243899 Super-Selective 21 https://ClinicalTrials.gov/show/NCT02438995
1992 NCT0098339 Melphalan, C 55 https://ClinicalTrials.gov/show/NCT00983398
1993 NCT0327581 Trial of Nab- 61 https://ClinicalTrials.gov/show/NCT03275818
1994 NCT0289616 Microwave A 150 https://ClinicalTrials.gov/show/NCT02896166
1995 NCT0291762 ACTOpus Me 39 https://ClinicalTrials.gov/show/NCT02917629
1996 NCT0293819 Phase II Stud 50 https://ClinicalTrials.gov/show/NCT02938195
1997 NCT0209457 A Study to Ev 222 https://ClinicalTrials.gov/show/NCT02094573
1998 NCT0251078 A Study on N 200 https://ClinicalTrials.gov/show/NCT02510781
1999 NCT0209895 Erlotinib Con 40 https://ClinicalTrials.gov/show/NCT02098954
2000 NCT0320069 Neoadjuvant 21 https://ClinicalTrials.gov/show/NCT03200691
2001 NCT0215449 S1400 Lung- 10000
2002 NCT0102633 Magnetic Re: 40 https://ClinicalTrials.gov/show/NCT01026337
2003 NCT0245121 Laser Intersti 18 https://ClinicalTrials.gov/show/NCT02451215
2004 NCT0233753 Selumetinib i 62 https://ClinicalTrials.gov/show/NCT02337530
2005 NCT0139298 Post T-plant l 44 https://ClinicalTrials.gov/show/NCT01392989
2006 NCT0089943 Nonmyeloab 80 https://ClinicalTrials.gov/show/NCT00899431
2007 NCT0235374 Concurrent E 47 https://ClinicalTrials.gov/show/NCT02353741
2008 NCT0269308 CT Perfusion 20 https://ClinicalTrials.gov/show/NCT02693080
2009 NCT0088192 Kappa-CD28 54 https://ClinicalTrials.gov/show/NCT00881920
2010 NCT0302342 A Study of De 96 https://ClinicalTrials.gov/show/NCT03023423
2011 NCT0275657 Early Allogene 30 https://ClinicalTrials.gov/show/NCT02756572
2012 NCT0305260 A Study Of Lc 280 https://ClinicalTrials.gov/show/NCT03052608
2013 NCT0220390 Multi-institut 36 https://ClinicalTrials.gov/show/NCT02203903
2014 NCT0011410 Lenalidomide 460 https://ClinicalTrials.gov/show/NCT00114101
2015 NCT0227212 Study of Chei 100 https://ClinicalTrials.gov/show/NCT02272127
2016 NCT0184978 Autologous S 41 https://ClinicalTrials.gov/show/NCT01849783
2017 NCT0288966 Cisplatin, Car 500 https://ClinicalTrials.gov/show/NCT02889666
2018 NCT0080005 Total Marrow 27 https://ClinicalTrials.gov/show/NCT00800005
2019 NCT0263174 Nivolumab in 20 https://ClinicalTrials.gov/show/NCT02631746
2020 NCT0267235 Study of Effic 10 https://ClinicalTrials.gov/show/NCT02672358
2021 NCT0247781 Temozolomide 19 https://ClinicalTrials.gov/show/NCT02477813
2022 NCT0312969 The Efficacy i 52 https://ClinicalTrials.gov/show/NCT03129698
2023 NCT0099529 Taxotere (Do 240 https://ClinicalTrials.gov/show/NCT00995293
2024 NCT0257407 A Study of Ni 555 https://ClinicalTrials.gov/show/NCT02574078
2025 NCT0248701 DC-CKI Comb 60 https://ClinicalTrials.gov/show/NCT02487017
2026 NCT0098165 Radiation Ther 37 https://ClinicalTrials.gov/show/NCT00981656
2027 NCT0102700 Donor Stem I 68 https://ClinicalTrials.gov/show/NCT01027000
2028 NCT0242665 Pemetrexed 30 https://ClinicalTrials.gov/show/NCT02426658
2029 NCT0124770 Umbilical Cor 20 https://ClinicalTrials.gov/show/NCT01247701
2030 NCT0248300 Anti-CD20 Ra 3 https://ClinicalTrials.gov/show/NCT02483000
2031 NCT0191150 INC280 and E 44 https://ClinicalTrials.gov/show/NCT01911507
1932 NCT02276922 Diagnostic Rs 29 https://ClinicalTrials.gov/show/NCT02276924
1933 NCT0142747 Evaluation of 315 https://ClinicalTrials.gov/show/NCT01427478
1934 NCT0250437 Study of Pem 1380 https://ClinicalTrials.gov/show/NCT02504372
1935 NCT0182149 Study of DC( 100 https://ClinicalTrials.gov/show/NCT01821495
1936 NCT0245493 Study of AZD 29 https://ClinicalTrials.gov/show/NCT02454933
1937 NCT0260224 Clinical Safet 24 https://ClinicalTrials.gov/show/NCT02602249
1938 NCT0042351 Clofarabine, l 42 https://ClinicalTrials.gov/show/NCT00423514
1939 NCT0321471 Myeloid Deri 50 https://ClinicalTrials.gov/show/NCT03214718
1940 NCT0249912 Safety And El 120 https://ClinicalTrials.gov/show/NCT02499120
1941 NCT0275822 Prophylactic 30 https://ClinicalTrials.gov/show/NCT02758223
1942 NCT0222877 Phase I Study 28 https://ClinicalTrials.gov/show/NCT02228772
1943 NCT0301588 Alpha Radiati 35 https://ClinicalTrials.gov/show/NCT03015883
1944 NCT0180354 Stereotactic I 200 https://ClinicalTrials.gov/show/NCT01803542
1945 NCT0244696 Total Marrow 24 https://ClinicalTrials.gov/show/NCT02446964
1946 NCT0233298 Pembrolizum 68 https://ClinicalTrials.gov/show/NCT02332980
1947 NCT0327862 Immune Che 10 https://ClinicalTrials.gov/show/NCT03278626
1948 NCT0117143 "WB-DCE-MF 140 https://ClinicalTrials.gov/show/NCT01171430
1949 NCT0052843 Temozolomici 46 https://ClinicalTrials.gov/show/NCT00528437
1950 NCT0272599 By Using Ado 140 https://ClinicalTrials.gov/show/NCT02725996
1951 NCT0253437 Cellular Effec 70 https://ClinicalTrials.gov/show/NCT02534376
1952 NCT0181697 Carfilzomib, l 44 https://ClinicalTrials.gov/show/NCT01816971
1953 NCT0182971 Moxetumom 80 https://ClinicalTrials.gov/show/NCT01829711
1954 NCT0141222 Induction Ch 40 https://ClinicalTrials.gov/show/NCT01412229
1955 NCT0170132 Laboratory-T 15 https://ClinicalTrials.gov/show/NCT01701323
1956 NCT0320347 Study of Opti 58 https://ClinicalTrials.gov/show/NCT03203473
1957 NCT0269129 A Phase III Cl 521 https://ClinicalTrials.gov/show/NCT02691299
1958 NCT0093977 Crizotinib in 122 https://ClinicalTrials.gov/show/NCT00939770
1959 NCT0102722 Low Dose Ra 40 https://ClinicalTrials.gov/show/NCT01027221
1960 NCT0097498 Boron Neutr 32 https://ClinicalTrials.gov/show/NCT00974987
1961 NCT0072659 Hydroxychlor 64 https://ClinicalTrials.gov/show/NCT00726596
1962 NCT0041259 2CDA With R 150 https://ClinicalTrials.gov/show/NCT00412594
1963 NCT0178464 Pemetrexed l 13 https://ClinicalTrials.gov/show/NCT01784640
1964 NCT0330185 Long-term Sa 150 https://ClinicalTrials.gov/show/NCT03301857
1965 NCT0205777 Allogeneic or 75 https://ClinicalTrials.gov/show/NCT02057770
1966 NCT0288022 Pembrolizum 41 https://ClinicalTrials.gov/show/NCT02880228
1967 NCT0298357 AZD9150 Wit 75 https://ClinicalTrials.gov/show/NCT02983578
1968 NCT0181707 Chlorhexidini 177 https://ClinicalTrials.gov/show/NCT01817075
1969 NCT0218141 A Study of Or 652 https://ClinicalTrials.gov/show/NCT02181413
1970 NCT0236987 Study of MEL 736 https://ClinicalTrials.gov/show/NCT02369874
1971 NCT0277581 Cisplatin, Int 56 https://ClinicalTrials.gov/show/NCT02775812
1972 NCT0276983 Nab-Paclitaxi 32 https://ClinicalTrials.gov/show/NCT02769832
1973 NCT01853822 An Open Lab 481 https://ClinicalTrials.gov/show/NCT01853826
2015  NCT02503722  Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Recurrent and/or Metastatic Esophageal Squamous Cell Carcinoma
2014  NCT02976896  S1400C Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
2013  NCT03126708  S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
2012  NCT02785939  Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
2011  NCT02129582  Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
2010  NCT02920996  Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage II A-II A NSCLC With EGFR Mutation
2009  NCT00979992  Topical Itraconazole in the Treatment of Basal Cell Carcinoma
2008  NCT02785913  The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
2007  NCT01111058  Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
2006  NCT00792948  Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
2005  NCT03164616  Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy Using NGS
2004  NCT01993810  Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
2003  NCT01885689  Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
2002  NCT00301093  Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
2001  NCT00004088  2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
2000  NCT01996097  Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
1999  NCT02129582  Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
1998  NCT00302448  Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
1997  NCT00303719  Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
1995  NCT02225497  BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
1994  NCT01885689  Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
1993  NCT01993810  Phase II Anti-ALP Study of Denileukin Diftuximab in Patients With Relapsed &/or Refractory Cutaneous T-Cell Lymphoma
1992  NCT01885689  Radiofrequency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
1991  NCT01794299  Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os

Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer

Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers

Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer

A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone T... tWithout Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic ... ng Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic ... ng Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>NCT Number</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0214650</td>
<td>Endoscopic Percutaneous Multichannel Therapy for Eosinophilia</td>
<td>2058</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02146508">https://ClinicalTrials.gov/show/NCT02146508</a></td>
</tr>
<tr>
<td>NCT0152982</td>
<td>Fludarabine Infusion in Hematological Malignancies</td>
<td>2059</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01529827">https://ClinicalTrials.gov/show/NCT01529827</a></td>
</tr>
<tr>
<td>NCT0260461</td>
<td>The Role of Ceftriaxone in the Management of Sepsis</td>
<td>2060</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02604615">https://ClinicalTrials.gov/show/NCT02604615</a></td>
</tr>
<tr>
<td>NCT0309535</td>
<td>A Randomized Trial of Oral Fluorouracil</td>
<td>2061</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03095352">https://ClinicalTrials.gov/show/NCT03095352</a></td>
</tr>
<tr>
<td>NCT0278922</td>
<td>Research Study of Pembrolizumab Treatment</td>
<td>2062</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02789228">https://ClinicalTrials.gov/show/NCT02789228</a></td>
</tr>
<tr>
<td>NCT0326050</td>
<td>Aldesleukin alpha for the Treatment of Acute Myeloid Leukemia</td>
<td>2063</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03260504">https://ClinicalTrials.gov/show/NCT03260504</a></td>
</tr>
<tr>
<td>NCT0249666</td>
<td>Osimertinib in the Management of NSCLC</td>
<td>2064</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02496663">https://ClinicalTrials.gov/show/NCT02496663</a></td>
</tr>
<tr>
<td>NCT0000625</td>
<td>Fludarabine Infusion in Hematological Malignancies</td>
<td>2065</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00006251">https://ClinicalTrials.gov/show/NCT00006251</a></td>
</tr>
<tr>
<td>NCT0205354</td>
<td>Haplo-identical Hematopoietic Stem Cell Transplant</td>
<td>2066</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02053545">https://ClinicalTrials.gov/show/NCT02053545</a></td>
</tr>
<tr>
<td>NCT0118536</td>
<td>Everolimus V in the Management of NSCLC</td>
<td>2067</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01185366">https://ClinicalTrials.gov/show/NCT01185366</a></td>
</tr>
<tr>
<td>NCT0091872</td>
<td>Vorinostat, F Test</td>
<td>2068</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00918723">https://ClinicalTrials.gov/show/NCT00918723</a></td>
</tr>
<tr>
<td>NCT0077749</td>
<td>Chemotherapy in the Management of NSCLC</td>
<td>2069</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00777491">https://ClinicalTrials.gov/show/NCT00777491</a></td>
</tr>
<tr>
<td>NCT0308881</td>
<td>Study of Irinotecan in the Management of NSCLC</td>
<td>2070</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03088813">https://ClinicalTrials.gov/show/NCT03088813</a></td>
</tr>
<tr>
<td>NCT0175242</td>
<td>Pilot Study of Pembrolizumab Treatment</td>
<td>2071</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01752426">https://ClinicalTrials.gov/show/NCT01752426</a></td>
</tr>
<tr>
<td>NCT0000278</td>
<td>Vaccine Therapy in the Management of NSCLC</td>
<td>2072</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00002787">https://ClinicalTrials.gov/show/NCT00002787</a></td>
</tr>
<tr>
<td>NCT0039781</td>
<td>Fludarabine Infusion in Hematological Malignancies</td>
<td>2073</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00397813">https://ClinicalTrials.gov/show/NCT00397813</a></td>
</tr>
<tr>
<td>NCT0192138</td>
<td>Radiolabeled Monoclonal Antibody and Combination Chemotherapy</td>
<td>2074</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01921387">https://ClinicalTrials.gov/show/NCT01921387</a></td>
</tr>
<tr>
<td>NCT0207281</td>
<td>Role of the Transplantation in the Management of NSCLC</td>
<td>2075</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02072811">https://ClinicalTrials.gov/show/NCT02072811</a></td>
</tr>
<tr>
<td>NCT0140507</td>
<td>Gefitinib Versus Cetuximab in the Management of NSCLC</td>
<td>2076</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01405079">https://ClinicalTrials.gov/show/NCT01405079</a></td>
</tr>
<tr>
<td>NCT0308759</td>
<td>APN401 in the Management of NSCLC</td>
<td>2077</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03087591">https://ClinicalTrials.gov/show/NCT03087591</a></td>
</tr>
<tr>
<td>NCT0268416</td>
<td>SGI-110 With Radiation in the Management of NSCLC</td>
<td>2078</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02684162">https://ClinicalTrials.gov/show/NCT02684162</a></td>
</tr>
<tr>
<td>NCT0318598</td>
<td>Anti-HER2 Therapy in the Management of NSCLC</td>
<td>2079</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03185988">https://ClinicalTrials.gov/show/NCT03185988</a></td>
</tr>
<tr>
<td>NCT0182250</td>
<td>Ipilimumab in the Management of NSCLC</td>
<td>2080</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01822509">https://ClinicalTrials.gov/show/NCT01822509</a></td>
</tr>
<tr>
<td>NCT0306241</td>
<td>Quality of Life in the Management of NSCLC</td>
<td>2081</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03062410">https://ClinicalTrials.gov/show/NCT03062410</a></td>
</tr>
<tr>
<td>NCT0034231</td>
<td>Reduced Intensity Conditioning Transplant in the Management of NSCLC</td>
<td>2082</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00342316">https://ClinicalTrials.gov/show/NCT00342316</a></td>
</tr>
<tr>
<td>NCT0204802</td>
<td>Paclitaxel and Carboplatin in the Management of NSCLC</td>
<td>2083</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02048020">https://ClinicalTrials.gov/show/NCT02048020</a></td>
</tr>
<tr>
<td>NCT0216253</td>
<td>Therapeutic Radiation in the Management of NSCLC</td>
<td>2084</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02162537">https://ClinicalTrials.gov/show/NCT02162537</a></td>
</tr>
<tr>
<td>NCT0211729</td>
<td>SCT Plus Immuno Therapy in the Management of NSCLC</td>
<td>2085</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02117297">https://ClinicalTrials.gov/show/NCT02117297</a></td>
</tr>
<tr>
<td>NCT0203552</td>
<td>Sorafenib in the Management of NSCLC</td>
<td>2086</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02035527">https://ClinicalTrials.gov/show/NCT02035527</a></td>
</tr>
<tr>
<td>NCT0235294</td>
<td>A Global Staging of the Management of NSCLC</td>
<td>2087</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02352948">https://ClinicalTrials.gov/show/NCT02352948</a></td>
</tr>
<tr>
<td>NCT0320667</td>
<td>Treatment Protocol for NSCLC</td>
<td>2088</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03206671">https://ClinicalTrials.gov/show/NCT03206671</a></td>
</tr>
<tr>
<td>NCT0230951</td>
<td>Lenalidomide In the Management of NSCLC</td>
<td>2089</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02309515">https://ClinicalTrials.gov/show/NCT02309515</a></td>
</tr>
<tr>
<td>NCT0249375</td>
<td>A Study Of Avelumab in the Management of NSCLC</td>
<td>2090</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02493751">https://ClinicalTrials.gov/show/NCT02493751</a></td>
</tr>
<tr>
<td>NCT0057727</td>
<td>Yttrium Y 90 in the Management of NSCLC</td>
<td>2091</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00577278">https://ClinicalTrials.gov/show/NCT00577278</a></td>
</tr>
<tr>
<td>NCT0069949</td>
<td>Cixutumumab in the Management of NSCLC</td>
<td>2092</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00699491">https://ClinicalTrials.gov/show/NCT00699491</a></td>
</tr>
<tr>
<td>NCT0297232</td>
<td>Extensive Stage SCLC in the Management of NSCLC</td>
<td>2093</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02972320">https://ClinicalTrials.gov/show/NCT02972320</a></td>
</tr>
<tr>
<td>NCT0221011</td>
<td>Nivolumab vs Nivolumab + Bevacizan in the Management of NSCLC</td>
<td>2094</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02210117">https://ClinicalTrials.gov/show/NCT02210117</a></td>
</tr>
<tr>
<td>NCT0166140</td>
<td>Anti-Angiogenic Therapy in the Management of NSCLC</td>
<td>2095</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01661400">https://ClinicalTrials.gov/show/NCT01661400</a></td>
</tr>
<tr>
<td>NCT0232228</td>
<td>TIGER-3: Open-Label Randomized Phase III Study in the Management of NSCLC</td>
<td>2096</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02322281">https://ClinicalTrials.gov/show/NCT02322281</a></td>
</tr>
<tr>
<td>NCT0187644</td>
<td>Pegylated IgG in the Management of NSCLC</td>
<td>2097</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01876446">https://ClinicalTrials.gov/show/NCT01876446</a></td>
</tr>
<tr>
<td>NCT0000395</td>
<td>Melphalan and Prednisone in the Management of NSCLC</td>
<td>2098</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00003954">https://ClinicalTrials.gov/show/NCT00003954</a></td>
</tr>
<tr>
<td>NCT0298191</td>
<td>Pilot Study of Pembrolizumab Treatment</td>
<td>2099</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02981914">https://ClinicalTrials.gov/show/NCT02981914</a></td>
</tr>
</tbody>
</table>
2100 NCT0296309 Pembrolizum 98 https://ClinicalTrials.gov/show/NCT02963090
2101 NCT0211546 Advanced Lue 94 https://ClinicalTrials.gov/show/NCT02115464
2102 NCT0323732 DOM-INNATI 190 https://ClinicalTrials.gov/show/NCT03237325
2103 NCT0239454 Phase I Trial 20 https://ClinicalTrials.gov/show/NCT02394548
2104 NCT0302240 A Study to In 40 https://ClinicalTrials.gov/show/NCT03022409
2105 NCT0098441 Allo-Allo Tanc 15 https://ClinicalTrials.gov/show/NCT00984412
2106 NCT009616 Pentostatin a 36 https://ClinicalTrials.gov/show/NCT0096161
2107 NCT0184732 Paclitaxel Alb 61 https://ClinicalTrials.gov/show/NCT01847326
2108 NCT0082735 Biomarker Tr 40 https://ClinicalTrials.gov/show/NCT00827359
2109 NCT0304131 Carboplatin, 100 https://ClinicalTrials.gov/show/NCT03041311
2110 NCT0282583 BTK Inhibitor 60 https://ClinicalTrials.gov/show/NCT02825836
2111 NCT0331931 Combination 369 https://ClinicalTrials.gov/show/NCT03319316
2112 NCT0320262 Ixazomib Citr 25 https://ClinicalTrials.gov/show/NCT03202628
2113 NCT0327137 Adjuvant Ave 100 https://ClinicalTrials.gov/show/NCT03271372
2114 NCT0247435 Real World T 3515 https://ClinicalTrials.gov/show/NCT02474355
2115 NCT0131795 Oral Green Tr 15 https://ClinicalTrials.gov/show/NCT01317953
2116 NCT0321304 Pembrolizum 100 https://ClinicalTrials.gov/show/NCT03213041
2117 NCT0282783 Durvalumab 20 https://ClinicalTrials.gov/show/NCT02827838
2118 NCT0309041 Photodynam 114 https://ClinicalTrials.gov/show/NCT03090412
2119 NCT0229095 A Phase 1 Stu 150 https://ClinicalTrials.gov/show/NCT02290951
2120 NCT0292961 Study of Stan 50 https://ClinicalTrials.gov/show/NCT02929615
2121 NCT0175728 Phase I/II Nal 98 https://ClinicalTrials.gov/show/NCT01757288
2122 NCT0232030 MART-1 Anti 23 https://ClinicalTrials.gov/show/NCT02320305
2123 NCT0321725 Tazemetosta 48 https://ClinicalTrials.gov/show/NCT03217253
2124 NCT0325915 Characteristi 30 https://ClinicalTrials.gov/show/NCT03259152
2125 NCT0241541 Carfilzomib ir 90 https://ClinicalTrials.gov/show/NCT02415413
2126 NCT0251543 The Efficacy i 40 https://ClinicalTrials.gov/show/NCT02515435
2127 NCT0268154 Pembrolizum 53 https://ClinicalTrials.gov/show/NCT02681549
2128 NCT0253173 Nintedanib \ 59 https://ClinicalTrials.gov/show/NCT02531737
2129 NCT0079357 Autologous c 32 https://ClinicalTrials.gov/show/NCT00793572
2130 NCT0332256 Pembrolizum 1062 https://ClinicalTrials.gov/show/NCT03322566
2131 NCT0041635 Clofarabine ii 29 https://ClinicalTrials.gov/show/NCT00416351
2132 NCT0240025 Crenolanib MV 48 https://ClinicalTrials.gov/show/NCT02400255
2133 NCT0312803 211^At-BC8-I 30 https://ClinicalTrials.gov/show/NCT03128034
2134 NCT0254766 Pomalidomid 30 https://ClinicalTrials.gov/show/NCT02547662
2135 NCT0306677 A Study of Pe 430 https://ClinicalTrials.gov/show/NCT03066778
2136 NCT0173750 Sirolimus anc 47 https://ClinicalTrials.gov/show/NCT01737502
2137 NCT0315610 A Clinical Stu 24 https://ClinicalTrials.gov/show/NCT03156101
2138 NCT0143744 Weekly Doce 27 https://ClinicalTrials.gov/show/NCT01437449
2139 NCT0194165 ATOM_local . 34 https://ClinicalTrials.gov/show/NCT01941654
2140 NCT0168222 Myeloablative 100 https://ClinicalTrials.gov/show/NCT01682226
2141 NCT0190413 NK Cells to Pr 45 https://ClinicalTrials.gov/show/NCT01904136
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

the "Fuzzing" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/IV Melanoma

Study of CD133KDEL Toxin in the Treatment for Solid Tumors

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study of NCT01307272 A Study to Ev
2268 NCT0070248 Study of Nim	37 https://ClinicalTrials.gov/show/NCT00702481
2269 NCT0106239 Everolimus, I	279 https://ClinicalTrials.gov/show/NCT01062399
2270 NCT0041659 Decitabine as a single drug	546 https://ClinicalTrials.gov/show/NCT00416598
2271 NCT0033606 Vorinostat ar	18 https://ClinicalTrials.gov/show/NCT00336063
2272 NCT0322244 Combination	20 https://ClinicalTrials.gov/show/NCT03222440
2273 NCT0244679 Isoquercetin	104 https://ClinicalTrials.gov/show/NCT02446795
2274 NCT0201581 Genetically N	18 https://ClinicalTrials.gov/show/NCT02015819
2275 NCT0311849 Combination	12 https://ClinicalTrials.gov/show/NCT03118492
2276 NCT0121804 ERBITUX À¨ Fc	40 https://ClinicalTrials.gov/show/NCT01218048
2277 NCT0090434 Study of Radi	23 https://ClinicalTrials.gov/show/NCT00904345
2278 NCT0013711 Therapy for N	501 https://ClinicalTrials.gov/show/NCT00137111
2279 NCT0318047 Maintenance	24 https://ClinicalTrials.gov/show/NCT03180476
2280 NCT0228889 PV-10 vs Che	225 https://ClinicalTrials.gov/show/NCT02288897
2281 NCT0238730 A Study of rS	42 https://ClinicalTrials.gov/show/NCT02387307
2282 NCT0241468 First Line TIP	37 https://ClinicalTrials.gov/show/NCT02414685
2283 NCT0154068 MLN8237 in l	9 https://ClinicalTrials.gov/show/NCT01540682
2284 NCT0265743 A Study of At	568 https://ClinicalTrials.gov/show/NCT02657434
2285 NCT0113712 Improve the	122 https://ClinicalTrials.gov/show/NCT01137123
2286 NCT0240717 Evaluating th	60 https://ClinicalTrials.gov/show/NCT02407171
2287 NCT0147071 Neoadjuvant	26 https://ClinicalTrials.gov/show/NCT01470716
2288 NCT0163950 Cabozantinib	68 https://ClinicalTrials.gov/show/NCT01639508
2289 NCT0299590 FLT-PET/DW-CA	13 https://ClinicalTrials.gov/show/NCT02995902
2290 NCT0130283 Radiation Ther	987 https://ClinicalTrials.gov/show/NCT01302834
2291 NCT0181225 Chemotherap	60 https://ClinicalTrials.gov/show/NCT01812252
2292 NCT0168439 Pazopanib H	66 https://ClinicalTrials.gov/show/NCT01684397
2293 NCT0309488 Pulsed Low D	40 https://ClinicalTrials.gov/show/NCT03094884
2294 NCT0319437 Phase II Trial	40 https://ClinicalTrials.gov/show/NCT03194373
2295 NCT0249932 Study to Asse	147 https://ClinicalTrials.gov/show/NCT02499328
2296 NCT0311794 Modulation of th	70 https://ClinicalTrials.gov/show/NCT03117946
2297 NCT0307036 Stereotactic I	78 https://ClinicalTrials.gov/show/NCT03070366
2298 NCT0086940 Dasatinib or I	217 https://ClinicalTrials.gov/show/NCT00869401
2299 NCT0101377 Merkel Positi	43 https://ClinicalTrials.gov/show/NCT01013779
2300 NCT0297611 A Phase II Stu	20 https://ClinicalTrials.gov/show/NCT02976116
2301 NCT0323866 Robot-Assisted	20 https://ClinicalTrials.gov/show/NCT03238664
2302 NCT0278648 Study of Mat	24 https://ClinicalTrials.gov/show/NCT02786485
2303 NCT0250091 SC-002 in Sm	102 https://ClinicalTrials.gov/show/NCT02500914
2304 NCT0104546 Trial of Activat	32 https://ClinicalTrials.gov/show/NCT01045460
2305 NCT0318856 Comparison o	200 https://ClinicalTrials.gov/show/NCT03188562
2306 NCT0297376 Safety, Tolerat	30 https://ClinicalTrials.gov/show/NCT02973763
2307 NCT0322450 Monoclonal A	82 https://ClinicalTrials.gov/show/NCT03224507
2308 NCT0315500 A Study of th	73 https://ClinicalTrials.gov/show/NCT03155009
2309 NCT0315116 Intermittent I	118 https://ClinicalTrials.gov/show/NCT03151161
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01168219</td>
<td>Oral Navelbine and Cisplatin Followed by Metronomic Navelbine in Non-Small Cell Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01168219">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01352286</td>
<td>Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01352286">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02144077</td>
<td>A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02144077">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01854567</td>
<td>WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01854567">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02864251</td>
<td>LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02864251">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02760225</td>
<td>Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02760225">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03156790</td>
<td>A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03156790">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02300298</td>
<td>Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02300298">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT00430365</td>
<td>Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00430365">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02906384</td>
<td>Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02906384">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03107182</td>
<td>Maintenance Therapy Using Lenalidomide in Myeloma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03107182">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03207334</td>
<td>Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03207334">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01099423</td>
<td>Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01099423">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT02065362</td>
<td>Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02065362">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01099423</td>
<td>Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01099423">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT03093350</td>
<td>Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03093350">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>NCT01468896</td>
<td>Comparison of 25mg Versus 5mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01468896">ClinicalTrials.gov</a></td>
</tr>
</tbody>
</table>

**URLs:**
- [ClinicalTrials.gov](https://ClinicalTrials.gov)
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Title</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01891123</td>
<td>Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01891123">Link</a></td>
</tr>
<tr>
<td>NCT01038778</td>
<td>Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01038778">Link</a></td>
</tr>
<tr>
<td>NCT01693783</td>
<td>Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01693783">Link</a></td>
</tr>
<tr>
<td>NCT02913443</td>
<td>A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02913443">Link</a></td>
</tr>
<tr>
<td>NCT01031069</td>
<td>A Study of pembrolizumab in combination with very low-dose cytarabine in patients with AML relapse after allogeneic hematopoietic stem cell transplantation</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01031069">Link</a></td>
</tr>
<tr>
<td>NCT02957032</td>
<td>Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02957032">Link</a></td>
</tr>
<tr>
<td>NCT03067181</td>
<td>Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03067181">Link</a></td>
</tr>
<tr>
<td>NCT01512589</td>
<td>A Trial of CMNa Combined With Preoperative Concurrent Chemoradiotherapy for Locally Advanced ESCC</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01512589">Link</a></td>
</tr>
<tr>
<td>NCT00915694</td>
<td>Ruxolitinib for Adult T-cell Leukemia</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00915694">Link</a></td>
</tr>
<tr>
<td>NCT02016872</td>
<td>A Study of durvalumab versus standard of care in advanced non-small-cell lung cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02016872">Link</a></td>
</tr>
<tr>
<td>NCT02978404</td>
<td>Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02978404">Link</a></td>
</tr>
<tr>
<td>NCT03010358</td>
<td>A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compare ... in + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03010358">Link</a></td>
</tr>
<tr>
<td>NCT02447549</td>
<td>Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02447549">Link</a></td>
</tr>
<tr>
<td>NCT00070135</td>
<td>Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00070135">Link</a></td>
</tr>
<tr>
<td>NCT02718820</td>
<td>Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02718820">Link</a></td>
</tr>
<tr>
<td>NCT00714246</td>
<td>Phase III Randomized Trial: Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer•__Multicenter Controlled Study.(RadimiR-01)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00714246">Link</a></td>
</tr>
<tr>
<td>NCT02718826</td>
<td>Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02718826">Link</a></td>
</tr>
<tr>
<td>NCT01430850</td>
<td>Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01430850">Link</a></td>
</tr>
<tr>
<td>NCT02721550</td>
<td>Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02721550">Link</a></td>
</tr>
<tr>
<td>NCT02978404</td>
<td>A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Advanced ESCC</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02978404">Link</a></td>
</tr>
<tr>
<td>NCT03010358</td>
<td>Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion</td>
<td><a href="https://ClinicalTrials.gov/show/NCT03010358">Link</a></td>
</tr>
<tr>
<td>NCT02978404</td>
<td>Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02978404">Link</a></td>
</tr>
<tr>
<td>NCT01512589</td>
<td>Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01512589">Link</a></td>
</tr>
</tbody>
</table>
2394 NCT0180263 A AZD9291 Firs		975 https://ClinicalTrials.gov/show/NCT01802632
2395 NCT0329598 Local Bispho:	120 https://ClinicalTrials.gov/show/NCT03295981
2396 NCT0168274 Photodynam		24 https://ClinicalTrials.gov/show/NCT01682746
2397 NCT0184641 A Study of At	138 https://ClinicalTrials.gov/show/NCT01846416
2398 NCT0312141 Nivolumab in	35 https://ClinicalTrials.gov/show/NCT03121417
2399 NCT0160503 Busulfan, Me	42 https://ClinicalTrials.gov/show/NCT01605032
2400 NCT0153099 De-intensifici:	45 https://ClinicalTrials.gov/show/NCT01530997
2401 NCT0300372 2015-10: Exp	10 https://ClinicalTrials.gov/show/NCT03003728
2402 NCT0315069 Inotuzumab i	310 https://ClinicalTrials.gov/show/NCT03150693
2403 NCT0209918 Multidisciplin	25 https://ClinicalTrials.gov/show/NCT02099188
2404 NCT0229255 Study of Safe	27 https://ClinicalTrials.gov/show/NCT02292550
2405 NCT0128112 Azacitidine ir	1 https://ClinicalTrials.gov/show/NCT01281124
2406 NCT0166500 Personalized	200 https://ClinicalTrials.gov/show/NCT01665001
2407 NCT0308380 Phase II Trial	35 https://ClinicalTrials.gov/show/NCT03083808
2408 NCT0275696 Improving Ri:	43 https://ClinicalTrials.gov/show/NCT02756962
2409 NCT0245053 A Study of At	150 https://ClinicalTrials.gov/show/NCT02450539
2410 NCT0201957 Stereotactic I	68 https://ClinicalTrials.gov/show/NCT02019576
2411 NCT0146577 Freeze-Dried	38 https://ClinicalTrials.gov/show/NCT01465776
2412 NCT0332516 Pembrolizum	20 https://ClinicalTrials.gov/show/NCT03325166
2413 NCT0092173 Esophageal S	25 https://ClinicalTrials.gov/show/NCT00921739
2414 NCT0243408 Nivolumab C	78 https://ClinicalTrials.gov/show/NCT02434081
2415 NCT0033837 Lymphodepl	189 https://ClinicalTrials.gov/show/NCT00338377
2416 NCT0197086 A Study Of Pf	361 https://ClinicalTrials.gov/show/NCT01970865
2417 NCT0321456 Study of the i	56 https://ClinicalTrials.gov/show/NCT03214562
2418 NCT0276200 Neoadjuvant	54 https://ClinicalTrials.gov/show/NCT02762006
2419 NCT0176081 CETUXIMAB i	25 https://ClinicalTrials.gov/show/NCT01760811
2420 NCT0270002 A Phase I Stu	24 https://ClinicalTrials.gov/show/NCT02700022
2421 NCT0256426 Study of Pem	720 https://ClinicalTrials.gov/show/NCT02564263
2422 NCT0185874 Selective Deş	20 https://ClinicalTrials.gov/show/NCT01858740
2423 NCT032174 Five Fraction	24 https://ClinicalTrials.gov/show/NCT03217477
2424 NCT0331497 Myeloablative	40 https://ClinicalTrials.gov/show/NCT03314974
2425 NCT0182306 Vandetanib ii	17 https://ClinicalTrials.gov/show/NCT01823068
2426 NCT0308584 SGI-110 Plus	22 https://ClinicalTrials.gov/show/NCT03085849
2427 NCT0267888 Head and Ne	20 https://ClinicalTrials.gov/show/NCT02678884
2428 NCT0151517 Ofatumumab	37 https://ClinicalTrials.gov/show/NCT01515176
2429 NCT0217636 Maintenance	120 https://ClinicalTrials.gov/show/NCT02176369
2430 NCT0233645 A Phase II Stu	160 https://ClinicalTrials.gov/show/NCT02336451
2431 NCT0244790 Marker Guidi	15 https://ClinicalTrials.gov/show/NCT02447900
2432 NCT0237464 A Phase I Stu	64 https://ClinicalTrials.gov/show/NCT02374645
2433 NCT0072325 Bevacizumab	53 https://ClinicalTrials.gov/show/NCT00723255
2434 NCT0242086 Study of Elot	100 https://ClinicalTrials.gov/show/NCT02420860
2435 NCT0225331 Phase II Stud	240 https://ClinicalTrials.gov/show/NCT02253316
2436 NCT0242381 To Study the
2437 NCT0319114 Osimertinib i
2438 NCT0150556 Auto Transpl.
2439 NCT0308253 Pembrolizum
2440 NCT0289907 Ibrutinib and
2441 NCT0218147 Intra-Osseou
2442 NCT0319811 Huaier Granu
2443 NCT0240791 Cisplatin for I
2444 NCT0242391 Fucosylated f
2445 NCT0326899 Effects of Avi
2446 NCT0317995 Impact of Rib
2447 NCT0265482 Study With T
2448 NCT0261381 Focal Ablativ
2449 NCT0179073 First Line Tre
2450 NCT0245065 Afatinib and l
2451 NCT0317361 The Efficien
2452 NCT0320725 Compassion
2453 NCT0319965 Beating Lung
2454 NCT0212417 Vidaza and V
2455 NCT0181373 Ponatinib in a
2456 NCT0303026 Elotuzumab,
2457 NCT0225182 JAK Inhibitor
2458 NCT0145150 Infusion of C
2459 NCT0200528 Phase II MOR
2460 NCT0087721 Significance o
2461 NCT0238154 Phase I Trial o
2462 NCT0241494 Tumor-Infiltr
2463 NCT0232425 A Study of RC
2464 NCT0323226 HLA-mismatch
2465 NCT0332772 VL-2397 Comb
2466 NCT0232460 Cetuximab Br
2467 NCT0149912 Study of Effic
2468 NCT0221391 Lenalidomide
2469 NCT0189932 Desipramine
2470 NCT0146900 A Study of Pe
2471 NCT0245823 Donor Lymph
2472 NCT0319342 Apatinib Con
2473 NCT0266570 Endostar Con
2474 NCT0332062 A Study of Açı
2475 NCT0323836 Window of O
2476 NCT0267759 Cisplatin Con
2477 NCT0231904 Phase II Stud
120 https://ClinicalTrials.gov/show/NCT02423811
20 https://ClinicalTrials.gov/show/NCT03191149
20 https://ClinicalTrials.gov/show/NCT01505569
83 https://ClinicalTrials.gov/show/NCT03082534
30 https://ClinicalTrials.gov/show/NCT02899078
12 https://ClinicalTrials.gov/show/NCT02181478
978 https://ClinicalTrials.gov/show/NCT03198117
50 https://ClinicalTrials.gov/show/NCT02407912
47 https://ClinicalTrials.gov/show/NCT02423915
36 https://ClinicalTrials.gov/show/NCT03268993
29 https://ClinicalTrials.gov/show/NCT03179956
25 https://ClinicalTrials.gov/show/NCT02654821
70 https://ClinicalTrials.gov/show/NCT02613819
80 https://ClinicalTrials.gov/show/NCT01790737
320 https://ClinicalTrials.gov/show/NCT02450656
132 https://ClinicalTrials.gov/show/NCT03173612
50 https://ClinicalTrials.gov/show/NCT03207256
2994 https://ClinicalTrials.gov/show/NCT03199651
50 https://ClinicalTrials.gov/show/NCT02124174
20 https://ClinicalTrials.gov/show/NCT01813734
40 https://ClinicalTrials.gov/show/NCT03030261
33 https://ClinicalTrials.gov/show/NCT02251821
250 https://ClinicalTrials.gov/show/NCT01451502
40 https://ClinicalTrials.gov/show/NCT02005289
1272 https://ClinicalTrials.gov/show/NCT00877214
30 https://ClinicalTrials.gov/show/NCT02381548
10 https://ClinicalTrials.gov/show/NCT02414945
185 https://ClinicalTrials.gov/show/NCT02324257
32 https://ClinicalTrials.gov/show/NCT03232268
200 https://ClinicalTrials.gov/show/NCT03327727
20 https://ClinicalTrials.gov/show/NCT02324608
110 https://ClinicalTrials.gov/show/NCT01499121
46 https://ClinicalTrials.gov/show/NCT02213913
9 https://ClinicalTrials.gov/show/NCT01899326
195 https://ClinicalTrials.gov/show/NCT01469000
67 https://ClinicalTrials.gov/show/NCT02458235
120 https://ClinicalTrials.gov/show/NCT03193424
76 https://ClinicalTrials.gov/show/NCT02665702
80 https://ClinicalTrials.gov/show/NCT03320629
50 https://ClinicalTrials.gov/show/NCT03238365
268 https://ClinicalTrials.gov/show/NCT02677597
267 https://ClinicalTrials.gov/show/NCT02319044
Safety Study of Gene Modified Donor T-cells Following TCR + Alpha Beta Depleted Stem Cell Transplant

Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Hematopoetic Stem Cell Transplant and Physical Function

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Improving Resection Rates Among African Americans With NSCLC

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
2520 NCT0236778 A Study of At 724 https://ClinicalTrials.gov/show/NCT02367781
2521 NCT0247269 Azacitidine, L 50 https://ClinicalTrials.gov/show/NCT02472691
2522 NCT0200622 Stem Cell Ha 30 https://ClinicalTrials.gov/show/NCT02006225
2523 NCT0086717 Vorinostat Cc 62 https://ClinicalTrials.gov/show/NCT00867178
2524 NCT0091065 Study of Gen 22 https://ClinicalTrials.gov/show/NCT00910650
2525 NCT0185981 Treatment fo 24 https://ClinicalTrials.gov/show/NCT01859819
2526 NCT0330223 Study of Pem 548 https://ClinicalTrials.gov/show/NCT03302234
2527 NCT0107751 Ofatumumab 346 https://ClinicalTrials.gov/show/NCT01077518
2528 NCT0320071 Study of Effi 140 https://ClinicalTrials.gov/show/NCT03200717
2529 NCT0312101 Study of Inte 38 https://ClinicalTrials.gov/show/NCT03121014
2530 NCT0288355 Study of Pem 39 https://ClinicalTrials.gov/show/NCT02883556
2531 NCT0210698 Concurrent C 40 https://ClinicalTrials.gov/show/NCT02106988
2532 NCT0176763 Pazopanib H 39 https://ClinicalTrials.gov/show/NCT01767636
2533 NCT0325942 Neoadjuvant 20 https://ClinicalTrials.gov/show/NCT03259425
2534 NCT0249506 Mometasone 160 https://ClinicalTrials.gov/show/NCT02495064
2535 NCT0227081 Cisplatin, Nal 70 https://ClinicalTrials.gov/show/NCT02270814
2536 NCT0114223 Lenalidomide 60 https://ClinicalTrials.gov/show/NCT01142232
2537 NCT0059615 Rituximab, M 33 https://ClinicalTrials.gov/show/NCT00596154
2538 NCT0116335 Bortezomib, 27 https://ClinicalTrials.gov/show/NCT01163357
2539 NCT0037870 Bevacizumab 361 https://clinicaltrials.gov/ct2/show/NCT00378703
2540 NCT0288564 Enzalutamide 20 https://ClinicalTrials.gov/show/NCT02885649
2541 NCT0240507 Pilot Project 50 https://ClinicalTrials.gov/show/NCT02405078
2542 NCT0328276 Safety Study 24 https://ClinicalTrials.gov/show/NCT03282760
2543 NCT0317729 Pirfenidone C 66 https://ClinicalTrials.gov/show/NCT03177291
2544 NCT0071258 Therapy for F 101 https://ClinicalTrials.gov/show/NCT00712582
2545 NCT0299406 Cisplatin + R 80 https://ClinicalTrials.gov/show/NCT02994069
2546 NCT0199145 Fludarabine / 20 https://ClinicalTrials.gov/show/NCT01991457
2547 NCT0227064 Randomized 28 https://ClinicalTrials.gov/show/NCT02270645
2548 NCT0230304 Sonidegib an 11 https://ClinicalTrials.gov/show/NCT02303041
2549 NCT0071182 Rituximab, C 21 https://ClinicalTrials.gov/show/NCT00711828
2550 NCT0257054 Impact of CD 150 https://ClinicalTrials.gov/show/NCT02570542
2551 NCT0286963 Ibrutinib in T 75 https://ClinicalTrials.gov/show/NCT02869633
2552 NCT0259591 Nivolumab in 29 https://ClinicalTrials.gov/show/NCT02595918
2553 NCT0168581 Lenalidomide 406 https://ClinicalTrials.gov/show/NCT01685814
2554 NCT0292185 Detection of 40 https://ClinicalTrials.gov/show/NCT02921854
2555 NCT0304339 Phase 1b Stu 12 https://ClinicalTrials.gov/show/NCT03043391
2556 NCT0254092 AMG 319 in H 54 https://ClinicalTrials.gov/show/NCT02540928
2557 NCT0252695 Efficacy Stud 314 https://ClinicalTrials.gov/show/NCT02526953
2558 NCT0185793 Therapy for C 210 https://ClinicalTrials.gov/show/NCT01857934
2559 NCT0314866 Saliva-based 300 https://ClinicalTrials.gov/show/NCT03148665
2560 NCT0299283 Anti-CD19:TC 10 https://ClinicalTrials.gov/show/NCT02992834
2561 NCT0292168 Study of a Hl 18 https://ClinicalTrials.gov/show/NCT02921685
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Study Title</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT0156770</td>
<td>Alisertib in Crzrovax</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0156770">Link</a></td>
</tr>
<tr>
<td>NCT0126584</td>
<td>Efficacy and Safety of Lenvatin in Patients With Advanced or Metastatic NSCLC</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0126584">Link</a></td>
</tr>
<tr>
<td>NCT0284988</td>
<td>T Lymphocytes in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0284988">Link</a></td>
</tr>
<tr>
<td>NCT0249789</td>
<td>Treatment of High-Grade Gliomas With ICB + Temozolomide</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0249789">Link</a></td>
</tr>
<tr>
<td>NCT0253535</td>
<td>Targeted Therapy for B Cell Non-Hodgkin's Lymphoma Based on PET Scan Results</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0253535">Link</a></td>
</tr>
<tr>
<td>NCT0266103</td>
<td>Allo HSCT Using RIC for Hematological Diseases</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0266103">Link</a></td>
</tr>
<tr>
<td>NCT0081663</td>
<td>Efficacy of a New Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0081663">Link</a></td>
</tr>
<tr>
<td>NCT0278271</td>
<td>PI SBRT + MMF for Advanced Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0278271">Link</a></td>
</tr>
<tr>
<td>NCT0281975</td>
<td>Pembrolizumab for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0281975">Link</a></td>
</tr>
<tr>
<td>NCT0256824</td>
<td>Interferon-β for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0256824">Link</a></td>
</tr>
<tr>
<td>NCT0320986</td>
<td>Treatment of High-Grade Gliomas With ICB + Temozolomide</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0320986">Link</a></td>
</tr>
<tr>
<td>NCT0147683</td>
<td>Radiolabeled Labeled in Patients With Advanced Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0147683">Link</a></td>
</tr>
<tr>
<td>NCT0248769</td>
<td>Radiofrequency Ablation for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0248769">Link</a></td>
</tr>
<tr>
<td>NCT0219235</td>
<td>Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0219235">Link</a></td>
</tr>
<tr>
<td>NCT0254190</td>
<td>Trial Using GI Direct Combi for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0254190">Link</a></td>
</tr>
<tr>
<td>NCT0157266</td>
<td>Allogeneic Transplantation for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0157266">Link</a></td>
</tr>
<tr>
<td>NCT0180555</td>
<td>Phase II Ranc for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0180555">Link</a></td>
</tr>
<tr>
<td>NCT0196527</td>
<td>High-Dose Pts for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0196527">Link</a></td>
</tr>
<tr>
<td>NCT0329100</td>
<td>Study of Intraventricular Delivery of Alisertib in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0329100">Link</a></td>
</tr>
<tr>
<td>NCT0222381</td>
<td>Crizotinib in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0222381">Link</a></td>
</tr>
<tr>
<td>NCT0234395</td>
<td>Consolidation of Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0234395">Link</a></td>
</tr>
<tr>
<td>NCT0311428</td>
<td>Pembrolizumab for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0311428">Link</a></td>
</tr>
<tr>
<td>NCT0257656</td>
<td>Safety and Efficacy Study of Leukocyte Interleukin, Injection for Cancer of the Oral Cavity</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0257656">Link</a></td>
</tr>
<tr>
<td>NCT0196106</td>
<td>Gene Therapy for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0196106">Link</a></td>
</tr>
<tr>
<td>NCT0203704</td>
<td>FOLFOX-6 in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0203704">Link</a></td>
</tr>
<tr>
<td>NCT0217757</td>
<td>Subventricular Zone (SVZ) and Temozolomide for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0217757">Link</a></td>
</tr>
<tr>
<td>NCT0214383</td>
<td>HSCT for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0214383">Link</a></td>
</tr>
<tr>
<td>NCT0207810</td>
<td>A Phase II Trial for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0207810">Link</a></td>
</tr>
<tr>
<td>NCT0032446</td>
<td>Tailoring Treatment for B Cell Non-Hodgkin's Lymphoma Based on PET Scan Results</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0032446">Link</a></td>
</tr>
<tr>
<td>NCT0191961</td>
<td>Lenalidomide for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0191961">Link</a></td>
</tr>
<tr>
<td>NCT0300159</td>
<td>Comparison of CAR T-cell Therapy for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0300159">Link</a></td>
</tr>
<tr>
<td>NCT0147885</td>
<td>Neural Progenitor Cell Sparing Radiation Therapy for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0147885">Link</a></td>
</tr>
<tr>
<td>NCT0155103</td>
<td>Bupalisib in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0155103">Link</a></td>
</tr>
<tr>
<td>NCT0299621</td>
<td>Lipusu Advanced Squamous Cell Carcinoma Study</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0299621">Link</a></td>
</tr>
<tr>
<td>NCT0256127</td>
<td>Combination of Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0256127">Link</a></td>
</tr>
<tr>
<td>NCT0231571</td>
<td>Carfilzomib/Carboplatin for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0231571">Link</a></td>
</tr>
<tr>
<td>NCT0315087</td>
<td>A Study Comparing the Efficacy and Safety Between ICB and Docetaxel</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0315087">Link</a></td>
</tr>
<tr>
<td>NCT0248851</td>
<td>Peptide Receptor for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0248851">Link</a></td>
</tr>
<tr>
<td>NCT0220798</td>
<td>Allogeneic HSCT for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0220798">Link</a></td>
</tr>
<tr>
<td>NCT0178813</td>
<td>A Study of Intraventricular Delivery of Alisertib in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0178813">Link</a></td>
</tr>
<tr>
<td>NCT0291306</td>
<td>S-1 IMRT Version for Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0291306">Link</a></td>
</tr>
<tr>
<td>NCT0205926</td>
<td>Dasatinib in Patients With Metastatic Renal Cell Carcinoma</td>
<td><a href="https://ClinicalTrials.gov/show/NCT0205926">Link</a></td>
</tr>
</tbody>
</table>
2688 NCT03003545 Nab-paclitaxel 18 https://ClinicalTrials.gov/show/NCT03003546
2689 NCT0295504 Biobehavioral 48 https://ClinicalTrials.gov/show/NCT02955043
2690 NCT0238481 Phase II Stud 70 https://ClinicalTrials.gov/show/NCT02384811
2691 NCT0294379 Optimization 118 https://ClinicalTrials.gov/show/NCT02943798
2692 NCT0322226 Adjuvant Per 46 https://ClinicalTrials.gov/show/NCT03322267
2693 NCT0332371 Study of Prog 33 https://ClinicalTrials.gov/show/NCT03323710
2694 NCT0239250 A Study of N 50 https://ClinicalTrials.gov/show/NCT02392507
2695 NCT0262675 A Prospective 122 https://ClinicalTrials.gov/show/NCT02626754
2696 NCT0157669 Combination 34 https://ClinicalTrials.gov/show/NCT01576692
2697 NCT0258597 Dose-escalation 24 https://ClinicalTrials.gov/show/NCT02585973
2698 NCT0102550 Ph+/Bcr-Abl+ 40 https://ClinicalTrials.gov/show/NCT01025505
2699 NCT0326712 A Study of Ag 45 https://ClinicalTrials.gov/show/NCT03267121
2700 NCT0133432 Survival Bene 448 https://ClinicalTrials.gov/show/NCT01334320
2701 NCT0235645 Combination 73 https://ClinicalTrials.gov/show/NCT02356458
2702 NCT0260542 Myeloablative 12 https://ClinicalTrials.gov/show/NCT02605421
2703 NCT0219518 Efficacy and 141 https://ClinicalTrials.gov/show/NCT02195180
2704 NCT0074989 Neoadjuvant 42 https://ClinicalTrials.gov/show/NCT00749892
2705 NCT0173115 Sequential Th 100 https://ClinicalTrials.gov/show/NCT01731158
2706 NCT0285483 A Study of M 78 https://ClinicalTrials.gov/show/NCT02854839
2707 NCT0233798 Gene Therap 10 https://ClinicalTrials.gov/show/NCT02337985
2708 NCT0254212 NM-IL-12 in 10 https://ClinicalTrials.gov/show/NCT02542124
2709 NCT0299399 Pre-operative 12 https://ClinicalTrials.gov/show/NCT02993991
2710 NCT0214531 An Open Lab 51 https://ClinicalTrials.gov/show/NCT02145312
2711 NCT0207204 Phase II Stud 60 https://ClinicalTrials.gov/show/NCT02072044
2712 NCT0315060 A Pralatrexat 22 https://ClinicalTrials.gov/show/NCT03150602
2713 NCT0277130 Safety and Ef 30 https://ClinicalTrials.gov/show/NCT02771301
2714 NCT0306376 Study to Eval 190 https://ClinicalTrials.gov/show/NCT03063762
2715 NCT0193371 Rituximab M 328 https://ClinicalTrials.gov/show/NCT01933711
2716 NCT0048730 Vaccination f 40 https://ClinicalTrials.gov/show/NCT00487305
2717 NCT0114782 Pazopanib Ve 183 https://ClinicalTrials.gov/show/NCT01147822
2718 NCT0300157 Accelerated I 10 https://ClinicalTrials.gov/show/NCT03001570
2719 NCT0199686 Lenalidomide 500 https://ClinicalTrials.gov/show/NCT01996865
2720 NCT0310484 Evaluation iN 153 https://ClinicalTrials.gov/show/NCT03104842
2721 NCT0261696 A Study to As 27 https://ClinicalTrials.gov/show/NCT02616965
2722 NCT0135959 S1001 PET-Di 159 https://ClinicalTrials.gov/show/NCT01359592
2723 NCT0152609 Stem Cell Tra 30 https://ClinicalTrials.gov/show/NCT01526096
2724 NCT0239973 Safety Study 18 https://ClinicalTrials.gov/show/NCT02399735
2725 NCT0301966 Ph I Trial of N 24 https://ClinicalTrials.gov/show/NCT03019666
2726 NCT0318493 Research for 40 https://ClinicalTrials.gov/show/NCT03184935
2727 NCT0087711 Anti-GD2 3F8 71 https://ClinicalTrials.gov/show/NCT00877110
2728 NCT0274773 Study of Ibrut 72 https://ClinicalTrials.gov/show/NCT02747732
2729 NCT0185088 MIBG for Ref 100 https://ClinicalTrials.gov/show/NCT01850888
2730 NCT03321893 Chidamide C  
2731 NCT02836929 Sofosbuvir+L  
2732 NCT03297696 Minimal Resi  
2733 NCT00963533 Lenalidomide  
2734 NCT02837046 Trial of Pemb  
2735 NCT02607599 A Prospective  
2736 NCT00787960 Rituximab, Cl  
2737 NCT02388581 First-line Ant  
2738 NCT02867333 PD-1 Knocko  
2739 NCT02541566 Pembrolizumab  
2740 NCT03000812 A Study of SB  
2741 NCT02203641 Evaluation of  
2742 NCT01676838 Topical Resiq  
2743 NCT01622431 Valproate as  
2744 NCT02844361 Comparison  
2745 NCT03124499 A Study to Ev  
2746 NCT03092454  
2747 NCT02811860 Lenvatinib/Ev  
2748 NCT00720946 Pazopanib Vc  
2749 NCT02301494 Effectiveness  
2750 NCT01926495 Risk of Squan  
2751 NCT03254927 A Study of CI  
2752 NCT02678912 Ovarian Tissu  
2753 NCT00902044 Her2 Chimeri  
2754 NCT00961220 O6-Benzylgu  
2755 NCT02570786 Evaluation of  
2756 NCT01104921 Re-irradiatio  
2757 NCT01289222 A Trial to Inv  
2758 NCT01722141 Re-directed  
2759 NCT02892220 Pembrolizum  
2760 NCT00075585 Vincristine, D  
2761 NCT03108066 PT2385 for t  
2762 NCT03121455 18F-FDG PET  
2763 NCT03263094 Efficacy and  
2764 NCT01381695 Bortezomib,  
2765 NCT02853333 Study to Eval  
2766 NCT01526600 High Dose Ch  
2767 NCT00749320 Arterial Spin  
2768 NCT03018222 Calcineurin Ir  
2769 NCT01852433 R-CEOP-90/R  
2770 NCT03024999 A Study of At  
2771 NCT0229572 GEMHDM20:
2772 NCT0113673 A Study of E7 153 https://ClinicalTrials.gov/show/NCT01136733
2773 NCT0311730 Study of Fror 120 https://ClinicalTrials.gov/show/NCT03117309
2774 NCT0189059 A Phase II Stc 46 https://ClinicalTrials.gov/show/NCT01890590
2775 NCT0206515 Post Transpl 48 https://ClinicalTrials.gov/show/NCT02065154
2776 NCT022269 PNT2258 for 61 https://ClinicalTrials.gov/show/NCT02226965
2777 NCT0184639 Romidepsin, 21 https://ClinicalTrials.gov/show/NCT01846390
2778 NCT0295955 Study in Whi 244 https://ClinicalTrials.gov/show/NCT02959554
2779 NCT0172910 Phase I/II Car 18 https://ClinicalTrials.gov/show/NCT01729104
2780 NCT0242875 R-CHOP Vers 216 https://ClinicalTrials.gov/show/NCT02428751
2781 NCT0143447 High-Dose Y- 24 https://ClinicalTrials.gov/show/NCT01434472
2782 NCT0273661 Obinutuzumab 20 https://ClinicalTrials.gov/show/NCT02736617
2783 NCT0301687 Nivolamab, I 43 https://ClinicalTrials.gov/show/NCT03016871
2784 NCT0150113 Treatment of 200 https://ClinicalTrials.gov/show/NCT01501136
2785 NCT0177715 ECHELON-2 : 452 https://ClinicalTrials.gov/show/NCT01777152
2786 NCT0126683 Open Label, S 80 https://ClinicalTrials.gov/show/NCT01266837
2787 NCT0291543 The Study to 448 https://ClinicalTrials.gov/show/NCT02915432
2788 NCT0244838 FLASH [Fluores 120 https://ClinicalTrials.gov/show/NCT02448381
2789 NCT0312339 TAK-659 in P 82 https://ClinicalTrials.gov/show/NCT03123393
2790 NCT0278401 Response Bas 41 https://ClinicalTrials.gov/show/NCT02784015
2791 NCT0295558 Efficacy and 30 https://ClinicalTrials.gov/show/NCT02955589
2792 NCT0155554 Study of Inte 24 https://ClinicalTrials.gov/show/NCT01555541
2793 NCT0301057 Erythropoieti 70 https://ClinicalTrials.gov/show/NCT03010579
2794 NCT0243670 Novel Combi 320 https://ClinicalTrials.gov/show/NCT02436707
2795 NCT0272996 Ceritinib Wit 30 https://ClinicalTrials.gov/show/NCT02729961
2796 NCT0186574 A Study of Ca 658 https://ClinicalTrials.gov/show/NCT01865747
2797 NCT0132154 Comparison of 260 https://ClinicalTrials.gov/show/NCT01321541
2798 NCT0235431 STUDY WITH 300 https://ClinicalTrials.gov/show/NCT02354313
2799 NCT0234101 Combination 31 https://ClinicalTrials.gov/show/NCT02341014
2800 NCT0289825 Lenalidomide 42 https://ClinicalTrials.gov/show/NCT02898259
2801 NCT0139991 Everolimus a 55 https://ClinicalTrials.gov/show/NCT01399918
2802 NCT0174699 CTOP/ITE/M 200 https://ClinicalTrials.gov/show/NCT01746992
2803 NCT0183303 An Open Lab 163 https://ClinicalTrials.gov/show/NCT01833039
2804 NCT0266917 Capecitabine 12 https://ClinicalTrials.gov/show/NCT02669173
2805 NCT0143120 Ruxolitinib Pl 90 https://ClinicalTrials.gov/show/NCT01431209
2806 NCT0109705 Rituximab, C 20 https://ClinicalTrials.gov/show/NCT01097057
2807 NCT0073752 A Study to Dr 134 https://ClinicalTrials.gov/show/NCT00737529
2808 NCT0312982 Ibrutinib, B 60 https://ClinicalTrials.gov/show/NCT03129828
2809 NCT0263239 Ixazomib Aft 62 https://ClinicalTrials.gov/show/NCT02632396
2810 NCT0262840 R-ICE and Ler 63 https://ClinicalTrials.gov/show/NCT02628405
2811 NCT0086336 Bortezomib a 56 https://ClinicalTrials.gov/show/NCT00863369
2812 NCT0206302 Efficacy of Dr 220 https://ClinicalTrials.gov/show/NCT02063022
2813 NCT0222320 Ro Plus CHOF 110 https://ClinicalTrials.gov/show/NCT02223208
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02812654</td>
<td>Study of Venetoclax and Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Have Been Treated With One or More Prior Regimens Including BTK Inhibitors (2016)</td>
</tr>
<tr>
<td>NCT02120829</td>
<td>Study of Venetoclax in Combination With Obinutuzumab and Rituximab in Patients With Indolent Non-Hodgkin Lymphoma With progression on or disease progression After 6 months or more Following Prior Rituximab (2015)</td>
</tr>
<tr>
<td>NCT02356883</td>
<td>Study of the Effect of Venetoclax on the Proliferation of B-Cells and Plasma Cells in Patients With Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) After Treatment With One or More Prior Regimens Including BTK Inhibitors (2015)</td>
</tr>
<tr>
<td>NCT02042954</td>
<td>Study of Ibrutinib in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Have Been Treated With One or More Prior Regimens Including BTK Inhibitors (2015)</td>
</tr>
<tr>
<td>NCT01805066</td>
<td>Study of Venetoclax in Combination With Obinutuzumab in Patients With Indolent Non-Hodgkin Lymphoma Who Have Disease Progression Following Rituximab-Based Therapy (2015)</td>
</tr>
<tr>
<td>NCT02120826</td>
<td>Study of Venetoclax in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Have Been Treated With One or More Prior Regimens Including BTK Inhibitors (2015)</td>
</tr>
<tr>
<td>NCT02120824</td>
<td>Study of Venetoclax in Combination With Ofatumumab in Patients With Indolent Non-Hodgkin Lymphoma With Progression or Disease Progression After 6 months or more Following Prior Rituximab (2015)</td>
</tr>
<tr>
<td>NCT02120823</td>
<td>Study of Venetoclax Alone or in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Have Been Treated With One or More Prior Regimens Including BTK Inhibitors (2015)</td>
</tr>
<tr>
<td>NCT02120825</td>
<td>Study of Venetoclax Alone or in Combination With Ofatumumab in Patients With Indolent Non-Hodgkin Lymphoma With Progression or Disease Progression After 6 months or more Following Rituximab (2015)</td>
</tr>
</tbody>
</table>

**ClinicalTrials.gov**

https://ClinicalTrials.gov/show/NCT02356883
https://ClinicalTrials.gov/show/NCT02042954
https://ClinicalTrials.gov/show/NCT01805066
https://ClinicalTrials.gov/show/NCT02120826
https://ClinicalTrials.gov/show/NCT02120824
https://ClinicalTrials.gov/show/NCT02120823
https://ClinicalTrials.gov/show/NCT02120825
2856 NCT00345865 Autologous P 421 https://ClinicalTrials.gov/show/NCT00345865
2857 NCT01327053 A Phase II Stt 229 https://ClinicalTrials.gov/show/NCT01327053
2858 NCT01897012 Alisertib and 42 https://ClinicalTrials.gov/show/NCT01897012
2859 NCT03147885 Selinexor Plu 44 https://ClinicalTrials.gov/show/NCT03147885
2860 NCT00853377 AMG 386 Phí 85 https://ClinicalTrials.gov/show/NCT00853377
2861 NCT02974647 Study of Rux 52 https://ClinicalTrials.gov/show/NCT02974647
2862 NCT02992522 Obinutuzum 60 https://ClinicalTrials.gov/show/NCT02992522
2863 NCT02753543 Chidamide Pl 33 https://ClinicalTrials.gov/show/NCT02753543
2864 NCT02661284 Autologous C 54 https://ClinicalTrials.gov/show/NCT02661284
2865 NCT02631232 MESA Versus 256 https://ClinicalTrials.gov/show/NCT02631232
2866 NCT03022123 The Study of 270 https://ClinicalTrials.gov/show/NCT03022123
2867 NCT02219736 Ibrutinib and 24 https://ClinicalTrials.gov/show/NCT02219736
2868 NCT02371163 Phase II of Hi 135 https://ClinicalTrials.gov/show/NCT02371163
2869 NCT02530124 Pidilizumab ii 30 https://ClinicalTrials.gov/show/NCT02530124
2870 NCT01582777 Study of OBII 315 https://ClinicalTrials.gov/show/NCT01582777
2871 NCT02871869 Cinobufacini 316 https://ClinicalTrials.gov/show/NCT02871869
2872 NCT02733455 GELAD Chem 51 https://ClinicalTrials.gov/show/NCT02733455
2873 NCT01415752 Rituximab, Br 332 https://ClinicalTrials.gov/show/NCT01415752
2874 NCT01959699 Carfilzomib, I 73 https://ClinicalTrials.gov/show/NCT01959699
2875 NCT02520797 Anti-ICOS Mc 46 https://ClinicalTrials.gov/show/NCT02520797
2876 NCT03255011 Pembrolizum 52 https://ClinicalTrials.gov/show/NCT03255011
2877 NCT02918747 PEG-ASP+Geli 186 https://ClinicalTrials.gov/show/NCT02918747
2878 NCT03071822 Combination 50 https://ClinicalTrials.gov/show/NCT03071822
2879 NCT03217644 CHP-BV Follo 25 https://ClinicalTrials.gov/show/NCT03217644
2880 NCT01994855 A Phase I/II S 32 https://ClinicalTrials.gov/show/NCT01994855
2881 NCT01267812 Bortezomib, a 36 https://ClinicalTrials.gov/show/NCT01267812
2882 NCT03229386 Evaluation of 60 https://ClinicalTrials.gov/show/NCT03229386
2883 NCT00274924 Rituximab an 100 https://ClinicalTrials.gov/show/NCT00274924
2884 NCT01282422 Efficacy and & 125 https://ClinicalTrials.gov/show/NCT01282422
2885 NCT02956885 To Assess Th 42 https://ClinicalTrials.gov/show/NCT02956885
2886 NCT02542111 A Study of Bc 30 https://ClinicalTrials.gov/show/NCT02542111
2887 NCT01354433 BMS-936558 198 https://ClinicalTrials.gov/show/NCT01354433
2888 NCT03324373 Lenvatinib ar 13 https://ClinicalTrials.gov/show/NCT03324373
2889 NCT02443079 Ibrutinib Bef 302 https://ClinicalTrials.gov/show/NCT02443079
2890 NCT01821485 A Study of Dc 100 https://ClinicalTrials.gov/show/NCT01821485
2891 NCT01717924 Evaluation of 314 https://ClinicalTrials.gov/show/NCT01717924
2892 NCT02008000 BENdamustir 50 https://ClinicalTrials.gov/show/NCT02008000
2893 NCT03075423 Randomized 306 https://ClinicalTrials.gov/show/NCT03075423
2894 NCT02531842 High-dose Ch 250 https://ClinicalTrials.gov/show/NCT02531842
2895 NCT01513187 Pazopanib in 53 https://ClinicalTrials.gov/show/NCT01513187
2896 NCT01924154 DC Vaccine C 30 https://ClinicalTrials.gov/show/NCT01924156
2897 NCT0076675 Vaccination-I 22 https://ClinicalTrials.gov/show/NCT0076675
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

Thalidomide Maintenance Treatment in DLBCL

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial to Determine Dose, Security and Efficacy of Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone With or Without Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

CD34+ Selected ASCT for Aggressive Lymphomas

2898 NCT0264609 CD34+ Select
2899 NCT0294366 Deferasirox
2900 NCT0239918 MT-R Follow
2901 NCT0295582 A Phase II Stu
2902 NCT0322002 Ibrutinib, Ritux
t
2903 NCT0220706 Ibrutinib in T
2904 NCT0152714 Ofatumumab
2905 NCT0312691 lobenguane I
2906 NCT0177684 A Study of th
2907 NCT0060420 Stem Cell Tr
2908 NCT00047060 Stem Cell Tra
2909 NCT0234093 Clinical Trial t
2910 NCT0239111 Phase II Cop
2911 NCT0207801 Treatment of
2912 NCT0070366 Bortezomib a
2913 NCT0324590 Study of Chic
2914 NCT0181136 Zevalin Befor
2915 NCT0207309 Carfilzomib, I
2916 NCT0301600 Thalidomide
2917 NCT0245148 Neoadjuvant
2918 NCT0228731 Most Closely
2919 NCT0288112 Paclitaxel and
2920 NCT0165733 Brentuximab
2921 NCT0316105 Metronomic
2922 NCT0329712 30 Assessment of
2923 NCT0147854 OPTIMAL>60
2924 NCT02079327 A Safety and
2925 NCT0037696 S0601 Rituxir
2926 NCT0234266 Japanese Pha
2927 NCT0195549 Lenalidomide
2928 NCT0248722 Pentoxifylline
2929 NCT0327345 Chidamide W
2930 NCT0113505 Study to Cor
2931 NCT0151156 Combination
2932 NCT0326888 Chidamide W
2933 NCT0155036 Study of Hyd
2934 NCT0153588 Using Multi-
2935 NCT0165306 STORM: Tem
2936 NCT0156674 Second-line F
2937 NCT0248912 Enzalutamide
2938 NCT0246526 Vaccine Ther
2939 NCT0166878 Study of Nivc

1152 https://ClinicalTrials.gov/show/NCT01478542
96 https://ClinicalTrials.gov/show/NCT02703272
68 https://ClinicalTrials.gov/show/NCT00376961
26 https://ClinicalTrials.gov/show/NCT02342665
34 https://ClinicalTrials.gov/show/NCT01955499
150 https://ClinicalTrials.gov/show/NCT02487225
30 https://ClinicalTrials.gov/show/NCT03273452
360 https://ClinicalTrials.gov/show/NCT01135056
113 https://ClinicalTrials.gov/show/NCT01511562
39 https://ClinicalTrials.gov/show/NCT03268889
39 https://ClinicalTrials.gov/show/NCT01550367
18 https://ClinicalTrials.gov/show/NCT01535885
88 https://ClinicalTrials.gov/show/NCT01653067
43 https://ClinicalTrials.gov/show/NCT01566747
20 https://ClinicalTrials.gov/show/NCT02489123
150 https://ClinicalTrials.gov/show/NCT02465268
1068 https://ClinicalTrials.gov/show/NCT01668784
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non-Squamous Cell Carcinoma

Rezum FIM Optimization

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

ADAM17 Inhibitor/Rituximab After Auto HCT for DLBCL

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus...with Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Rezum I Pilot Study for BPH

Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Monitor Response to Treatment in Neuroblastoma Using 3'-Deoxy-3'-Fluorothymidine - Positron Emission Tomography (FLT-PET)

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Dendritic Cell Activating Scaffold in Melanoma

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSCHI 10-011)

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiation Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
3024 NCT0257245 Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma
3025 NCT0243198 Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
3026 NCT0158640 Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
3027 NCT0228235 Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
3028 NCT02953652 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
3029 NCT03109353 Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease
3030 NCT02323230 A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
3031 NCT01865110 R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
3032 NCT00118209 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
3033 NCT02856997 Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
3034 NCT02670616 Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
3035 NCT02679196 The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110δ_/δ« Inhibitor) In B Cell Lymphoma
3036 NCT01856192 Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
3037 NCT01193842 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
3038 NCT00058422 Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
3039 NCT03255096 A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and ... ax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
3040 NCT03206970 Study of Evaluate Efficacy and Safety of BGB-3111 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
3041 NCT02799888 Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation